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Studies directed toward the enantioselective preparation of dihydroagarofuran natural 
products are presented. The purpose of this project is to synthesize dihydroagarofuran natural 
products in order to study what structural features are required for inhibition of Phospho-
glycoprotein (P-gp) induced multidrug resistance in this family of molecules. Once an optimal 
synthetic route is established, analogs can be synthesized to probe P-gp function at the molecular 
level. Three synthetic routes to the dihydroagarofuran family of natural products were 
investigated. Each synthesis utilized (R)-(-)-carvone, an inexpensive terpene available in high 
enantiomeric purity, as the sole source of chirality. Our studies have shown that the 
dihydroagarofuran tricyclic skeleton can be prepared in as few as eight steps from (R)-(-)-
carvone. Each synthesis is substantially shorter than previously published routes to similar ring 
systems. 
In conjunction with our studies toward interesting multidrug resistance modulating 
natural products, a short and enantioselective route to the tetrahydropyran (THP) bryostatin B 
ring was developed. This new method utilizes a cyclic acetal to generate a reactive 
oxocarbenium ion, which was subsequently trapped with a tethered silyl enol ether. The resulting 
diastereoselective reaction gives exclusively 2,6-cis-tetrahydropyranone rings in excellent yield. 
Unlike previous routes to create oxocarbenium ions from acetals, our approach uses Ce(NO3)3 an 
exceptionally mild Lewis acid. Ce(NO3)3 is inexpensive, non-toxic, and easy to separate from 
reaction mixtures. The use of acetals as oxocarbenium ion precursors is an attractive method for 
complex molecule synthesis, since acetals can be constructed under extemely mild conditions. 
This new method can be easily extended to the enantioselective preparation of other complex 
THP ring containing macrolide natural products, such as (+) Phorboxazole A or (+) 
Leucascandrolide A. 
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1. Multidrug Resistance 
 
1.1. Introduction to Multidrug Resistance 
The efficacy of any drug is largely dependant upon the drug’s active lifetime in the 
human body, as well as the ability of the drug to reach its intended target. One of the greatest 
obstacles in the clinical treatment of cancer is due to the malignant cells’ ability to rapidly 
develop a resistance to a multitude of structurally diverse therapeutic agents.1 This phenomenon, 
by which a cell can withstand or resist a typically lethal dose of more than one type of drug, is 
known as multidrug resistance (MDR).1-4 
Only a small amount is known about what causes cells to become resistant. Presently, 
multidrug resistance has been identified in cells ranging from simple bacteria to human cancers 
and poses a major health concern.4,5 Although there is still very little known about the 
recognition process utilized by multidrug resistant cells, research has identified four principle 
mechanisms that most commonly give rise to MDR:3   
1. Deactivation or modification of drugs by enzymes produced in the target cell. 
2. Post-translational modifications and/or mutations that alter the target site. 
3. Decreased permeability of the cell wall and outer membrane in bacteria. 
4. Active removal by membrane bound multidrug efflux transporters. 
 
Of these four general modes by which cells become resistant, active transport by plasma 
membrane associated proteins has by far received the most attention.3 Currently, it is believed 
1 
 that resistance in multiple types of human cancers is largely due to the overexpression of one 
such transporter known as Phospho-glycoprotein (P-gp).1-2 
 
1.2. The Role of Phospho-glycoprotein in MDR 
P-gp is a membrane bound cellular pump which functions to prevent the accumulation of 
certain hydrophobic molecules within a cell (Figure 1). Normally, P-gp is highly expressed in  
 
Figure 1 Phospho-glycoprotein 
 
the cells lining the stomach and the intestines where it functions to inhibit the absorption of drugs 
and other toxic agents.6 It is also found in the endothelial cells of the blood brain barrier, where it 
plays a key role in preventing certain compounds from being absorbed into the brain through the 
blood supply.7 P-gp, therefore, has an important role in the body’s ability to both metabolize and 
excrete toxic substances.8,9 
P-gp becomes problematic when cancer cells overexpress this protein, which then leads 
to multidrug resistance. Certain types of cancer cells have acquired the ability to use P-gp as a 
defense mechanism against cytotoxic chemotherapeutic agents.1-2 Normally, a non-P-gp 
expressing cancer cell would die when exposed to a toxic drug. Cells that can overexpress P-gp 
2 
 prevent the uptake of certain drugs, making the cancer cells immune towards the effects of 
cytotoxic drugs used in conventional chemotherapy. The overexpression of P-gp by cancer cells 
is thought to be chiefly due to the exposure of cancerous cells to toxic chemotherapeutic agents. 
In fact, P-gp induced MDR can be triggered by only a single exposure of the cancer cells to a 
toxic species.1-2 Once a cancer cell has overexpressed P-gp it is not only resistant to the initial 
toxic species, but can become resistant to a variety of structurally unrelated drugs.2 The cancer 
can then become unresponsive to chemotherapy, leaving few remaining options for treatment. 
 
1.3. Disease Associated with P-gp 
P-gp overexpression is the main cause of MDR in human cancer cells.1-2,10 To date, it is 
estimated that over 90% of all research efforts aimed at understanding MDR have focused on the 
role of active drug efflux pumps like P-gp.11 Research has established that P-gp is encoded for by 
the mdr1 gene12 and drugs are not the only known cause of P-gp overexpression.  Many other 
types of stressors including physical stress, such as X-ray or UV light irradiation, as well as heat 
shock, can cause the mdr1 gene to express P-gp.13 
There is little doubt that P-gp represents a major hurdle for the effectiveness of new 
chemotherapeutic regimes. It has been estimated, based on examining several hundred different 
types of human cancers, that nearly 50% will overexpress the mrd1 gene at some time during 
drug therapy.14 Current research has discovered that P-gp is responsible for drug resistance in 
other diseases, such as parasitic disease13 and AIDS.13,15 In order to develop effective new drugs 
to combat disease, we need to improve our understanding of how the defense mechanisms 
associated with MDR operate. Using this knowledge, we can design drugs that do not induce 
MDR. 
3 
 1.4. Function of P-gp 
P-gp is a member of the large ATP binding cassette (ABC) superfamily of membrane 
transporters.1-2, 4 The members of the ABC superfamily play a major role in the transport of 
drugs, natural products, and peptides across the membranes of many different cell types. They 
differ from other transport proteins in their ability to couple ATP hydrolysis with drug transport. 
Many transport proteins, even some in the ABC superfamily, are substrate specific. However, P-
gp has the ability to recognize and transport a wide variety of substrates.1-2, 4 
ATP binding and hydrolysis are essential for the proper functioning of P-gp.5, 16-17 In fact, 
ATP hydrolysis occurs in P-gp even in the absence of a foreign drug or substrate.5 One theory is 
that this basal activity can be attributed to the transport of native lipid molecules.18 However, 
ATP hydrolysis is further stimulated by the presence of a P-gp substrate.5, 16-17 What is still 
unclear at the molecular level is how the energy from ATP hydrolysis is coupled with drug 
transport.  
Several models10 have been proposed to account for the observation that drug binding 
increases ATP hydrolysis activity. The most commonly accepted theory is known as the 
alternating catalytic site model (Figure 2).18 In this model, two drug binding sites act in a 
cooperative fashion to expel substrates. When a substrate is bound at one site, ATP binding at the 
other site triggers a conformational change. This leads to hydrolysis of ATP to ADP at the drug 
bound site. Relaxation of the drug bound site and release of ADP then stimulates dissociation of 
the drug to the outside of the cell wall. The key aspects of this model, which are supported by  
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Figure 2 Alternating catalytic site model 
 
experimental results, include:  the observation that both nucleotide binding sites are required for 
active drug transport,16-17 presentation of the drug seems to occur inside the lipid bilayer,17 and 
that drug binding produces a conformational change near the nucleotide binding domain.5, 16-18 
 
1.5. Recognition of Substrates by P-gp 
Given that such a large number of P-gp substrates have been reported to date, what 
remains to be discovered is how so many structurally dissimilar classes of molecules can all 
interact with a single drug transporter protein. One theory is that there are multiple specific 
binding sites within the drug binding region, allowing for dissimilar molecule to bind at different 
locations on the same protein.17 A second theory speculates the possibility for the existence of a 
single, conformationally flexible, binding site.13, 17, 19 Such a site presumably would have the 
ability to recognize substrates through less specific interactions.  Based upon current evidence, 
5 
 including X-ray structures of similar proteins, either possibility is valid.20 Ideally, a high-
resolution image of P-gp with a bound substrate would be useful in determining how substrates 
interact with P-gp. Once better techniques to reconstitute and image membrane-associated 
proteins are found, this type of study might be possible. 
Clearly, determining the factors that affect substrate specificity is crucial to rational drug 
design for inhibiting or modulating P-gp activity. Multiple researchers have attempted to 
generalize the similarities between various P-gp substrates and inhibitors.2, 13, 19-23 One of the first 
studies suggested that the minimal structural features were a basic nitrogen and two planar 
aromatic domains.21 After examining a broader range of P-gp substrates, it was later realized that 
molecules lacking a basic nitrogen could also interact with P-gp.22-23 In fact, one of the only 
common features observed in these early studies was the relatively hydrophobic nature of P-gp 
substrates. The Seelig research group has suggested that a key aspect of substrate recognition 
may be due to the existence of multiple hydrogen bond donating residues, as well as aromatic 
residues present in the postulated drug interaction sites.13,19  Hydrogen bonding and π-π stacking 
maybe very important for drug efflux by P-gp. This would account for the observation that in 
addition to being hydrophobic, most P-gp substrates contain both aromatic and hydrogen bond 
accepting groups. 
Seelig recently reported that even some hydrophilic substrates could function as weak P-
gp substrates.13,19 This work suggests that the minimal requirement for substrate recognition is 
dependant upon having two or three electron donor groups arranged in a specific spatial 
orientation. Unlike previous reports, Seelig’s present work13,19 shows that there are predictable 
trends for substrates that have a higher propensity to trigger P-gp overexpression. Seelig has also 
examined molecules which are known to reverse or inhibit MDR in certain cancer cells.13 The 
6 
 only drawback to Seelig’s approach is that the exact mechanisms for MDR reversal are not 
known for many of the compounds utilized in her study. Therefore, it cannot be assumed that 
they all interact at the same binding site or even with P-gp at all.  
 
1.6. Structure of P-gp 
P-gp is known to be a 170 kDa membrane bound protein comprised of 1280 amino acid 
residues.24 Although there is currently no high-resolution structure of P-gp, a low-resolution (2.5 
nm) electron microscopy image25 has provided some insight into the three dimensional 
architecture of P-gp (Figure 3).  From this image, it can be estimated that P-gp is approximately 
10 nm in diameter and has a large central pore measuring about 5 nm across. Upon examining 
 
 
Figure 3 Low-resolution image of P-gp 
 
Reprinted with permission from Rosenberg, M. F. et. al. J. Biol. Chem. 1997, 272, 10685. 
Copyright 1997 American Society for Biochemistry and Molecular Biology 
 
both the top (A) and side on (B) view, it can be seen that this pore connects the inner 
phospholipid bilayer to the outside of the cell wall. Additionally, two 3 nm in diameter lobes can 
also be seen exposed at the cytoplasmic face of the membrane. These lobes are postulated to be 
7 
 the nucleotide binding domains (NBD’s) of P-gp where nucleotides bind and ATP hydrolysis 
occurs.25 
 
 
Figure 4 Topology of P-gp 
 
Reprinted with permission from Hrycyna, C.A. Semin. Cell Dev. Biol. 2001, 12, 247. 
Copyright 2001 Elsevier 
 
Most of what is known about P-gp comes from site directed fluorescence5, 16-17 and site 
directed mutagenesis26-27 experiments. The most common topological model (Figure 4) depicts 
P-gp as a dimeric protein consisting of twelve transmembrane domains with two nucleotide 
binding sites localized in the cytosol.1-2, 28 Each half consists of six transmembrane domains 
connected by a flexible linker region. At least two confirmed drug binding sites have been 
identified near the transmembrane segments at the phospholipid bilayer.16-17 Although the 
number and nature of drug binding sites is poorly defined, site directed mutagenesis and 
photoaffinity labeling studies have found that the transmembrane domains (TMD’s) 5, 6, 11, and 
12 make up at least part of the drug binding domains.16-17, 26-27  
Biochemical analysis has demonstrated that expression of either half of P-gp alone does 
not provide a functional multidrug transporting protein.28 An additional experiment verified the 
protein could not function in the absence of the flexible linker region.3 All of this data seems to 
8 
 reinforce the idea of a concerted type mechanism for drug transport, rather than each half 
operating independently. 
 
1.7. Inhibition of P-gp 
To date, many small molecule inhibitors of P-gp have been reported (Figure 5).29 
However, due to the diversity of these molecules, it has been difficult to determine which 
structural elements are required for recognition by P-gp or inhibition of P-gp. Very little is 
known about how P-gp inhibitors function at the molecular level. Like other substrates, 
inhibitors seem to directly interact with P-gp and compete for binding sites.17 What distinguishes 
inhibitors from other substrates is not fully understood.  From examining the complex structures  
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Figure 5 Representative MDR reversing compounds 
 
in Figure 5, it becomes apparent why making any generalizations has proven difficult. We 
believe that a series of structurally similar analogues would be advantageous. This would enable 
us to compare and contrast structure versus activity in a meaningful way. One particular family 
9 
 of molecules, collective known as dihydroagarofurans, has been recognized to posses multiple 
features that might facilitate such a study. Recently, it was reported that multiple members of this 
family (Figure 6), many isolated from the root of Celastrus orbiculatus, were more potent than a 
leading clinical agent in reversing P-gp mediated MDR.30 Lee and coworkers have shown that 
celafolin A-1 (IC50 12.4 µM) was more potent than verapamil (IC50 39.2 µM) for reversing 
multidrug resistance in the KBV-1 cell line (human nasopharynx carcinoma) to vinblastine. 
Additionally, celafolin A-1 does not posses any intrinsic cytotoxicity unlike verapamil which is 
cardiotoxic.31 Other members of this family have IC50 values in the 7-70 µM 
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Figure 6 Dihydroagarofuran MDR reversing agents 
 
range and can also reverse resistance to adriamycin and paclitaxel in the KBV-1 cell line and the 
MCF7/ADR cell line (human breast cancer).31 
The most attractive aspect of this family of natural products is that they all possess a rigid 
trans-decalin core (Figure 5). This conformational rigidity imparts a well-defined spatial 
relationship of substituents on the ring system, making these natural products an ideal scaffold 
for studying the structural aspects of P-gp inhibition. Once a synthetic route for preparing the 
dihydroagarofuran ring system is developed analogs will be prepared. These analogs will be 
prepared to test the importance of lipophilicity, hydrogen bond accepting groups, and aromatic 
10 
 ring stacking interactions. These three elements are reported to be crucial features required for 
recognition by and binding with P-gp.13,19 Carefully designed analogs will be used to study 
which structural elements and chemical features are required for P-gp inhibition for this family 
of natural products. 
Once these analogs are prepared, their biological activity can be evaluated using a variety 
of techniques. The MAINS technique, a fluorescence quenching technique developed by 
Sharom,5,16 can be used to determine if these natural products are substrates for Pgp or if they 
interact at another location. This technique utilizes P-gp tagged with a maleimide fluorophore in 
the nucleotide binding domain (NBD). When substrates bind for transport a conformational 
change occurs in the NBD region producing fluorescence quenching. Since this technique is 
concentration dependent, it can be used to estimate equilibrium constants (Ka) for different 
substrates.  
An alternative to the MAINS labeling approach is available for substrates that fluoresce 
at the same wavelength as the maleimide fluorophore. This FRET (fluorescence resonance 
energy transfer) method (Figure 7) utilizes tryptophan residues present in the drug binding 
regions of P-gp.17 The principle behind the FRET technique is that if a P-gp substrate can π-stack 
with a tryptophan residue in the drug binding region, fluorescence quenching will be detectable. 
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Figure 7 The FRET technique 
 
Dihydroagarofuran natural products should also be investigated to determine if they are 
true inhibitors of P-gp or just competitive substrates. This can be explored by a simple assay that 
monitors ATP hydrolysis.32 This assay quantifies ATP hydrolysis by a fluorescence technique 
that detects the inorganic phosphate byproducts of hydrolysis. Determination of a substrate as an 
inhibitor or competitive substrate is quite straightforward. Suppression of ATP hydrolysis 
indicates the substrate is an inhibitor of P-gp while an increase in ATP hydrolysis indicates a 
competitive substrate. These simple tests can help reveal how dihydroagarofuran natural 
products are recognized by P-gp. They can also aid in our understanding of how 
dihydroagarofurans can reverse multidrug resistance.  
 
1.8. Cytochrome P450 and P-gp 
In principle, the idea of inhibiting P-gp to enhance the effectiveness of chemotherapeutic 
agents seems like a straightforward approach. A resistant cancer cell is exposed to a P-gp 
inhibitor and loses its drug resistance. A cytotoxic agent is then administered and the cancer cell 
12 
 is killed. This overly simplified model fails to take into account what affect P-gp inhibition could 
have on other systems inside the body. 
Clinically, the benefits of P-gp inhibition have yet to be established and are often 
complicated due to undesirable side effects produced by P-gp inhibiting agents. One important 
study demonstrated that some P-gp inhibitors could also inhibit essential drug metabolizing 
enzymes such as cytochrome P450 3A (CYP3A).33 Since CYP3A is responsible for the 
metabolic degradation of more than 50% of all known drugs,8-9 this type of interaction could 
cause normally safe doses of drugs to become toxic. Fortunately, this study established no strong 
correlation between good P-gp inhibitors and good CYP3A inhibitors. 
To further complicate this situation, research has established that certain P-gp substrates 
can induce, rather than inhibit, both P-gp and CYP3A expression.8 Recently, it was demonstrated 
that drugs which activate a transcription factor known as the substrate xenobiotic receptor (SXR)  
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Figure 8 Feed-forward / feed-back mechanism for SXR 
 
can trigger their own metabolism and efflux. For example paclitaxel, a well documented P-gp 
substrate, induces the expression of P-gp and CYP3A through binding to and activating SXR 
13 
 (Figure 8).9 These clearance pathways lower the concentration of paclitaxel and reduce 
activation of SXR in a feedback pathway. However, docetaxel, a structural analog of paclitaxel, 
does not activate SXR and does not induce P-gp or CYP3A expression.8-9 This study suggests 
that through knowledge of this pathway and manipulation of drug structure it is possible to 
design drugs invisible to SXR that may then prevent P-gp expression. 
One final concern that needs to be addressed is whether P-gp inhibition can be a 
clinically viable approach to preventing MDR. Since P-gp is also thought to play a crucial role in 
other parts of the body, inhibition may adversely affect other areas of the body. To test the 
importance of P-gp in a living system, genetically modified mice, known as knockout mice, were 
engineered to lack P-gp.34 The results of these knockout mice studies clearly demonstrated that 
mice were able to survive in the absence of P-gp. 
There are certainly many different ways to address the problem of multidrug resistance. 
Ultimately, the goal of all these approaches is to enable the design of agents to selectively target 
and inhibit P-gp. Despite advances on many different fronts, it has yet to be determined how P-
gp inhibition occurs at the molecular level.  
14 
  
2. Dihydroagarofuran Natural Products 
 
Dihydroagarofurans are terpene-based metabolites of the celastraceae family of plants.35 
Members of this sesquiterpenoid family all contain a characteristic tricyclic trans-decalin 
skeleton with varying degrees of oxygenation (Figure 9). The dihydroagarofuran family 
members are exclusively obtained from their natural sources as ester derivatives (Table 1).30,35 
Over 200 members of this family have been characterized based on over 40 different 
oxygenation patterns. Prior to the early 1980’s, the various members of the dihydroagarofuran 
family of molecules were not known to possess any novel chemical or biological activity.36 
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Figure 9 Dihydroagarofuran numbering 
 
Then, in the mid to late 1980’s, researchers began to discover these natural products contain a 
rich variety of bioactivity including anticancer, anti-bacterial, immunosuppressive, stimulant, 
and anti-HIV activity.35,37 In 1998, Lee and coworkers reported that several dihydroagarofuran 
natural products were able to reverse MDR in the vinblastine resistant KB-V1 cell line that over-
expresses P-gp.30 They also found that these natural products exhibited virtually no in vivo 
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 cytotoxicity. The following year, the same group reported six new dihydroagarofuran MDR 
modulators.31 The IC50 and MDR reversing properties of 1-12 are summarized in Table 1.  
 
Compounds
1
2
3
4
5
6
7
8
9
10
11
12
VRP
KB-3-1
268.0 ± 26.7
8.6 ± 0.1
16.8 ± 1.4
28.3 ± 2.3
32.4 ± 6.3
26.4 ± 1.5
41.3 ± 2.0
85.3 ± 6.2
27.3 ± 2.5
10.5 ± 0.4
12.4 ± 0.4
31.6 ± 0.8
45.2 ± 0.3
KB-V1
246.0 ± 32.3
9.6 ± 0.3
17.8 ± 0.9
33.1 ± 1.9
39.3 ± 3.2
28.6 ± 2.2
34.8 ± 1.2
79.4 ± 8.1
28.6 ± 2.2
12.3 ± 0.3
12.4 ± 0.2
32.0 ± 0.6
39.2 ± 0.5
KB-V1 (+VLB)
19.6 ± 0.7
1.0 ± 0.2
1.2 ± 0.2
0.5 ± 0.2
1.1 ± 0.1
4.8 ± 0.1
0.4 ± 0.0
1.0 ± 0.1
0.5 ± 0.0
1.9 ± 0.0
0.7 ± 0.0
0.4 ± 0.0
1.6 ± 0.0
EFb
12.5
9.6
14.8
66.2
35.7
5.9
87.0
79.4
57.2
6.4
17.7
80.0
24.5
IC50 (µΜ)a
a Data are a  mean ± S.D. from two separate experiments. b EF (cytotoxicity enhancement factor) of 
VLB (100 nM). Cytotoxicity by each compound was calculated as follows: IC50 of KB-V1 cells with-
out VLB / IC50 of KB-V1 cells with VLB. KB-3-1 is a drug sensitive cell line and KB-V1 is a drug 
resistant cell line.    VLB (vinblastine), VRP (verapamil)
OAc
O
R2O
OR1
OAc
O
R3O
OR2
OR1
OAc
O
R3O
OR2
R1
OAc
1      R1 = Fu
2      R1 = Bz    
3      R1 = Fu    
10    R1 = Bz    
11    R1 = Cin
R2 = Bz
R2 = Fu
R2 = Fu
R2 = Bz
R2 = Bz
4      R1 = Ac   R2 = Fu   R3 = Bz
5      R1 = Fu   R2 = Fu   R3 = Bz
6      R1 = Bz   R2 = Bz   R3 = Bz
7      R1 = Ac   R2 = Ac   R3 = Bz
12    R1 = Ac   R2 = Bz   R3 = Bz
8      R1 =  H      R2 = Ac   R3 = Bz
9      R1 = OBz   R2 = Ac   R3 = Bz
 
Table 1 MDR reversing dihydroagarofurans 
 
Reprinted with permission from Lee, J. J. et. al. J. Nat. Prod. 1999, 62, 697. 
Copyright 1999 American Chemical Society 
 
 From examination of Table 1, it can be seen that several trends appear. The tri-ester 
compounds 1-3, 10, and 11 all show weaker activity than the tetra-ester compounds, except 6, 
which contains a C-2 benzoate. The tetra-esters 4, 5, 7, 8, and 12, all having a C-2 acetate group, 
are exceptional in their ability to reverse MDR compared to other members of this family. Many 
have IC50 values lower than verapamil and half of the species 1-12 were more effective. 
Another recent study by Ravelo and coworkers has shown that dihydroagarofurans can 
reverse MDR in a P-gp-like transporter present in multidrug resistant Leishmania tropica, a 
protozoan parasite.38 The authors found that the Leishmania P-gp expressing cells, resistant to 
16 
 verapamil, responded to dihydroagarofuran inhibitors. In this work, the authors screened thirty 
dihydroagarofuran derivatives by in vivo assays and QSAR modeling. Their study concluded that 
electrostatic interactions, hydrogen-bonding donor and acceptor capability, and lipophilicity 
were essential requirements for good inhibitors. The authors also suggest that the C-2 and C-6 
esters are crucial hydrogen-bonding elements, similar to results found with human P-gp by Lee 
and coworkers.30-31 
 
2.1. A Model for the Structural Basis of MDR Modulation 
The purpose of this project is to develop a structural basis for P-gp inhibition. It is 
anticipated that this project will allow for the discovery of improved P-gp inhibitors. In addition 
to the discovery of new P-gp inhibitors, the results of this study will also aid in the design of new 
drugs that are not recognized by P-gp. In order to study the elements required for P-gp inhibition 
by dihydroagarofuran natural products, various analogs of celafolin A-1 (11) and orbiculin A  
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Figure 10 Representative dihydroagarofuran natural products 
 
(12) will be prepared and evaluated for both P-gp binding and inhibition. Celafolin A-1 and 
orbiculin A were chosen as initial targets because they represent the simplest members of the 
17 
 dihydroagarofuran family that have been shown to reverse MDR (Table 1).30-31 Accordingly, the 
first goal of this project will be to develop a versatile and enantioselective route to orbiculin A 
and celafolin A-1. 
 
2.2. Advantages of Using Dihydroagarofurans 
There are multiple attractive features associated with using the dihydroagarofuran ring 
system for studying P-gp inhibition. For example, the syntheses of celafolin A-1 (11) and 
orbiculin A (12) can begin from (R)-(-)-carvone, an inexpensive chiral terpene available in high  
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Figure 11 Comparison of carvone and the dihydroagarofuran skeleton 
 
enantiomeric excess. The core skeletal features of celafolin A-1 (11) (Figure 11) consist of 
fifteen carbon atoms and seven chiral centers. Carvone already contains ten of the required 
carbons and one of the chiral centers. 
The rigid tricyclic core of the dihydroagarofuran ring system represents an ideal system 
for studying P-gp inhibition. Unlike other inhibitors (Figure 12) such as verapamil39 and 
stipiamide40 whose solution structures are conformationally mobile, the rigid core of the 
dihydroagarofuran imparts a well-defined spatial relationship between the functional groups on 
18 
 the tricyclic ring system. This rigidity will allow for a predictable solution conformation, making 
the data obtained from structure activity studies easier to interpret.  
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Figure 12 Structurally diverse MDR reversing agents 
 
The syntheses of celafolin A-1 (11) and orbiculin A (12) should be relatively short, 
efficient, and capable of providing ample material for biological assays. The planned route 
should also be flexible enough to allow for the incorporation of new functional groups, this 
would facilitate the preparation of analogs with minimal synthetic changes. For example, an 
ideal synthetic scheme would allow for the multiple ester moieties present in Table 1 to be easily 
manipulated and selectively installed. This would provide access to other members of the 
dihydroagarofuran family of natural products. 
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 2.3. Previous Dihydroagarofuran Syntheses 
A survey of the literature shows there are only a few racemic syntheses of 
dihydroagarofuran ring systems that have been published. The first reported synthesis of a 
dihydroagarofuran was published by Büchi and Barret in 1967.41 One year later Marshall42 and 
then Deslongchamps43 published similar methods. In 1979, Büchi and Wüest reported the first 
stereocontrolled synthesis of a dihydroagarofuran.44 Although carvone seems to be an obvious 
starting material, it was not utilized until 1986 when Huffmann introduced the first synthesis of a 
dihydroagarofuran starting from (R)-carvone.36 It should be noted that even though Huffman 
used enantiomerically pure carvone, the synthesis was racemic due to an oxidation which 
transformed carvone into a C2 symmetrical molecule. 
Li and coworker have only recently reported the first asymmetric total synthesis of a 
dihydroagarofuran sesquiterpenoid in 2001.37 Li and coworkers’ approach utilized a modification 
of Huffmann’s method36 to synthesize (-)-isocelorbicol. To date, however, no one has prepared 
an enantiopure dihydroagarofuran capable of reversing P-gp induced multidrug resistance. Two 
particularly noteworthy syntheses, White and coworkers’ synthesis of (±)-euonyminol45 along 
with Li and coworkers’ enatioselective synthesis of (-)-isocelorbicol37 are briefly outlined below. 
White and coworkers have demonstrated that the dihydroagarofuran ring system can be 
constructed in a racemic fashion by utilizing a Diels-Alder reaction (Figures 13 and 14). In order 
to construct the decalin core of (±)-euonyminol, White and coworkers began their synthesis with 
the readily available dienophile (13) and diene (14). When the diene (14) and dienophile (13) 
were heated to reflux in toluene a single cycloadduct was formed. The stereochemistry of the 
fused ring system was established by examination of the C-4 to C-5 coupling constant in the 1H 
NMR spectrum, and was determined to be the desired endo product (15). The cycloadduct (15) 
was then subjected to an allylic bromination, followed by treatment with triethylamine to afford 
20 
 HBr elimination providing the desired diene (16). The stereocenter at C-6 was selectively 
installed by a Luche reduction to give the required enone (16). A directed m-CPBA epoxidation 
followed by a γ-alkoxy substituent directed Michael addition of isopropenyl-magnesium bromide 
generated the desired product (17) in good yield.   
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Reagents and conditions: a) benzene, heat, 88%. b) NBS, (PhCO)2O2, CCl4. c) Et3N, 95% over 2-steps. d) NaBH4, 
CeCl3-7H20, MeOH, 90%. e) m-CPBA, NaH2PO4, CH2Cl2, 88%. f) i. LDA, 15-crown-5, ii. isopropenylmagnesium 
bromide, THF, -78 oC to 25 oC, 63%. 
Figure 13 White and coworkers (±)-euonyminol synthesis 
 
 
The C-7 isopropenyl group was then selectively epoxidized using the Sharpless 
asymmetric epoxidation protocol, which set up an epoxide opening cascade cyclization (Figure 
14). Treatment of the epoxide derivative of the cyclic ketone (17) with trifluoroacetic acid 
resulted in an SN2’ epoxide opening to produce a trifluoroacetate ester at C-2 and the desired 
tetrahydrofuran ring system. Mild hydrolysis conditions were used to selectively cleave the C-2 
trifluoroacetate ester in the presence of a methyl ester. Treatment of this newly formed allylic 
alcohol with imidazole cleanly produced the C-2 to C-5 lactone. The C-1 axial silyl ether was 
converted to the required equatorial silyl ether by a retro aldol reaction and subsequent 
benzylidene acetal protection provided the desired product (19). The C-8 hydroxyl group was 
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 stereoselectively incorporated by oxidation of the kinetic enolate of the C-10 ketone (19) using 
Davis’ oxaziridine.  
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Reagents and conditions: g) t-BuOOH, VO(acac)2, 2,6-lutidine, 55%. h) TFA, CHCl3. i) pyridine, H2O, THF. j) 
imidazole, CH3CN, 76% over 3-steps. k) PhCH(OMe)2, PPTS, toluene, heat, 83%. l) TBAF, THF, 96%. m) 
KHMDS, THF, then Davis’ oxaziridine, 83%. n) AlMe3, THF, 100%. o) LiAlH4, THF, then 0.5 M HCl. p) TBSOTf, 
Et3N, CH2Cl2. q) OsO4, pyridine. r) HOAc, H2O, heat. s) Ac2O, pyridine, 30% over 5-steps. t) NaOMe, MeOH, then 
purification using amberlite IR 120 resin, 100%. 
Figure 14 Completion of (±)-euonyminol 
 
The newly formed hydroxy-ketone was then subjected to excess trimethylaluminum and 
undergoes a variant of the Lobry deBruyn-Alberda van Eckenstein transformation in which the 
C-8 ketone and C-9 alcohol groups are transposed. This rearrangement, which is believed to 
occur through an aluminum enediol species, gave the desired C-9 equatorial alcohol in 
22 
 quantitative yields. A simple lithium aluminum hydride reduction, followed by global silyl 
protection produced the fully protected poly-hydroxyl derivative (20). The required oxidation 
states at C-3 and C-4 were introduced using a facially biased osmylation. The poly-silyl ether 
(20) was then subjected to global deprotection using acetic acid in water and then transformed 
into an octa-acetate species to facilitate purification. The octa-acetate derivative of  (±)-
euonyminol (21) was cleanly saponified using sodium methoxide to provide (±)-euonyminol in 
20 steps with an overall yield of 3.5%. 
Li and coworkers have only recently reported the first enantioselective route to a 
dihydroagarofuran (Figures 15 and 16). Their route to (-)-isocelorbicol (27) utilizes a 
modification of Huffmann’s method36 using (R)-(-)-carvone (22) as a starting material. A House 
epoxidation procedure was used to oxidize the enone of carvone. Exposure of this epoxy-ketone 
to sodium hydroxide provided the achiral di-ketone tautomer (23) of carvone. An asymmetric 
Robinson annulation, using ethyl vinyl ketone and a catalytic amount of D-(+)-phenylalanine, 
gave the desired bicyclic enone in 51% yield with an enantiomeric excess of only 54%. 
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Reagents and conditions: a) 30% H2O2, KOH, MeOH, H2O, 0 oC. b) 1M NaOH, H2O, reflux, 25% over 2-steps. c) 
ethyl vinyl ketone, KOH, MeOH, reflux, 85%. d) D-(+)-phenylalanine, D-(+)-CSA, 70 oC, 6 days, 51%. e) NaBH4, 
MeOH, 0 oC, 75%. f) TsNHNH2, BF3.Et2O, 25 oC, 95%. g) n-BuLi, THF, -78 oC to 0 oC, 90%. h) O3, P(OPh)3, 
CH2Cl2, -78 oC to 0 oC, 81%. 
Figure 15 Li and coworkers (-)-isocelorbicol synthesis 
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Following the Robinson annulation, the C-9 carbonyl group was selectively reduced with 
sodium borohydride to give the C-9 equatorial alcohol derivative (24).  This intermediate was 
recrystallized twice, in an overall yield of 67%, from ether and hexane to increase the 
enantiomeric purity to greater than 98%. The C-3 to C-5 enone was converted to an α,β-
unsaturated tosyl hydrazone and then treated with n-butyl lithium to generate a cis-diene. 
Treatment of this diene at -78 oC with ozone and triphenylphosphite, a recipe for generating 
singlet oxygen, produced the endo-cycloadduct (25) and also generated the trans-decalin ring 
fusion in one step.  
When this cycloadduct (25) was exposed to potassium carbonate in tetrahydrofuran, the 
peroxide underwent a rearrangement to afford the enone precursor to (26). The C-1 acetate group  
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Reagents and conditions: i) K2CO3, THF, 40 oC, 78%. j) Mn(OAc)3, benzene, reflux, 53%. k) TfOH, THF, 25 oC, 5 
min., 95%. l) Dess-Martin periodinane, CH2Cl2, 25 oC, 90%. m) LiAlH4, Et2O, 0 oC, 62%. n) TBSOTf, Et3N, 
CH2Cl2, 25 oC, 68%. o) H2, 10% Pd-C, EtOH, 25 oC, 85%. p) TBAF, THF, H2O, 25 oC, 47%. 
Figure 16 Completion of (-)-isocelorbicol 
 
was installed by using a regioselective acetoxylation with Mn(OAc)3. The C-5 β-hydroxyl group 
and the C-7 isopropenyl group then underwent a facile etherification in the presence of TfOH to 
afford the tetrahydrofuran C ring (26) and complete the tricyclic core of (-)-isocelorbicol (27).  
24 
 The next transformation to address was the selective reduction of the C-9 and C-2 
ketones to provide the required axial hydroxyl groups at these two positions. Instead of using a 
step-wise procedure, the authors found that both ketones could be simultaneously reduced using 
LiAlH4. This reducing agent removed the C-1 acetate and provided the triol precursor to (-)-
isocelorbicol (27) in 62% yield as a 3:1 mixture of epimers at C-2. The authors did not report any 
attempts to optimize this process. The last remaining step to complete (-)-isocelorbicol (27) was 
to selectively reduce the endocyclic C-3 / C-4 olefin. When the authors tried to directly convert 
the LiAlH4 adduct to (-)-isocelorbicol (27) using H2 and palladium on carbon, the reaction 
produced the incorrect β-methyl isomer (Figure 16). To circumvent this selectivity problem, the 
triol was converted to the tri-TBS ether derivative. Hydrogenation of this silyl ether species 
using H2 and palladium on carbon gave the desired α-methyl stereocenter and a minor amount of 
the β-methyl epimer as a 10:1 mixture in 27% yield. Finally, global TBS ether deprotection gave 
(-)-isocelorbicol (27) in a total of 16 steps, 0.2% overall yield, from (R)-(-)-carvone. Although 
this route illustrates the first asymmetric synthesis of dihydroagarofuran, the overall yield is 
extremely low. Additionally, this sequence would not allow for the introduction of a C-6 ester, 
which has been shown to be a crucial moiety for P-gp inhibition.30 
While neither of these two syntheses are directly applicable to celafolin A-1 (11) or orbiculin 
A (12), they do establish precedent for multiple transformations on similar ring systems. In the 
chapters to follow, it will become apparent how our celafolin A-1 (11) and orbiculin A (12) 
syntheses have been designed to incorporate the particularly efficient transformations utilized by 
the Huffmann,36 White,45 and Li37 groups. 
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 3. Work Towards the Construction of the Dihydroagarofuran Ring System 
One of the most important aspects of our synthetic plan was to design a synthesis that 
would allow for the simple preparation of analogs. During the course of these investigations, 
three distinct routes emerged as promising strategies. These routes will be presented in this 
chapter. 
 
3.1. Orbiculin A as an Initial Target 
When this project was initiated, orbiculin A (12) was chosen as our first target molecule. 
This dihydroagarofuran family member was selected since it possessed the most potent activity 
towards reversing P-gp MDR in a previous study (Table 1).31 Our retrosynthetic analysis for 
orbiculin A is highlighted in Figure 17. We decided to construct the tetrahydrofuran C ring and 
to establish the C-4 methyl stereocenter at the end of our synthesis. The C ring would be formed 
by an oxidative etherification protocol and the C-4 methyl group could be generated by a 
directed hydrogenation using the C-6 ester group. A directed epoxidation would be used to 
introduce the C-5 oxygen and establish the trans-decalin ring fusion. The subsequent opening of 
this epoxide would be brought about by a cleverly designed SN2’ epoxide opening reaction 
utilizing the C-1 acetate group. This acetoxy-assisted epoxide opening would also generate the 
desired C-2 acetate group in the same step. Alkylation of the C-5 alcohol with para-
nitrobenzenesulfenyl chloride will induce a 2,3-sigmatropic rearrangement to create the allylic 
alcohol precursor for the C-4 to C-5 epoxide. The required bond connectivity for the trans-
decalin ring will be constructed using an intramolecular addition of a (Z)-vinyl iodide into the  
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Figure 17 Retrosynthesis for orbiculin A 
 
C-5 carbonyl group. We then planned to generate the C-1, C-9, and C-10 stereocenters and the 
C-1 to C-10 carbon-carbon bond in one step using a tandem conjugate addition-aldol reaction. 
Finally, the enone precursor to the aldol addition can be made from (R)-(-)-carvone in a three-
step process using an enolate oxidation to install the C-6 oxygen, then methoxymethyl ether 
(MOM) protection, and Wilkinson’s catalyst to selectively hydrogenate the C-7 isopropenyl 
group. 
One of our initial synthetic approaches to orbiculin A (12) (Figure 18) began with 
addressing the problematic introduction of oxygen at C-6. At the time this work began, there was 
no literature precedent for an efficient method to prepare the required enone derivative (31a) of 
carvone. Early work had shown that oxidation of the kinetic enolate of carvone, using Davis’ 
27 
 oxaziridine (28), resulted in an inseparable mixture of the desired products (31a and 31b) and 
oxaziridine byproducts. After chromatographic purification to separate the two diastereomeric 
products, analysis of the 1H NMR revealed that two major impurities were present. These 
impurities were determined to be benzaldehyde and the di-phenyl sulfonimine byproduct from 
oxaziridine. The benzaldehyde formed is the result of slow sulfonimine hydrolysis during silica 
gel chromatography.  
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Figure 18 Oxidation of (R)-(-)-carvone using Davis’ oxaziridine (28) 
 
Additionally, we determined that the oxaziridine oxidation yielded predominantly the 
incorrect trans-stereoisomer at C-6 (31b). The preferential formation of the incorrect isomer 
(31b) can be rationalized by examining the geometry of the kinetic enolate of  (R)-(-)-carvone 
(Figure 18). In the lowest energy conformation, the isopropenyl group will be in the pseudo-
equatorial position. In this conformation, the isopropenyl group projects slightly downward, 
partially blocking the α-face of the enolate.  When the oxaziridine reagent approaches the β-face 
28 
 of the enolate this interaction is avoided and results in the formation of the undesired 
diastereomer (31b).    
After a number of additional conditions were screened and we found that a Rubottom 
oxidation46 gave superior results (Figure 19). Exposure of the trimethylsilyl (TMS) enol ether of 
(R)-(-)-carvone (29) to m-CPBA selectively oxidized the electron rich TMS enol ether in the 
presence of a 1,1-disubstituted olefin and a trisubstituted olefin. The resulting TMS ethers (30a 
and 30b) could be cleaved using a number of reagents. We found that acetic acid, ammonium 
fluoride, and TBAF worked well for this purpose, but HF in methanol gave the best results. 
Using HF in methanol the desired products (31a) and (31b) were isolated as a 1:2.5 mixture in 
63% yield from carvone. While this process still favored the formation of the undesired 
stereochemistry at C-6, the diastereomers were easily separated. 
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Figure 19 Rubottom oxidation of (R)-(-)-carvone 
 
29 
 Fortunately, conditions were developed to convert the undesired C-6 (S) stereocenter 
(31b) into the desired (R) isomer by a simple epimerization process. The C-6 alcohol was first 
protected as a methoxymethyl ether (MOM) and then epimerizing with lithium diisopropylamide 
(LDA) followed by an acetic acid quench (Figure 20). Experimentally, the easiest route to the 
desired syn-alkoxy enone (32a) was to carry both isomers (31a and 31b) through as a mixture 
and then separate the two following MOM ether formation. This method minimized 
chromatographic separations and greatly facilitated the preparation of large quantities of 
material. We have found that this Rubottom oxidation procedure can be reproducibly performed 
on a 30-gram scale without any difficulties.  
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Figure 20 Epimerization at C-6 
 
Once a reliable route to the enone component (32a) was established, the next step was to 
synthesize the required aldehyde (34) for an aldol addition. The aldehyde coupling partner (34) 
was prepared by a Dess-Martin periodinane47 oxidation of the corresponding primary alcohol 
(33) (Figure 21). Several attempts were made to purify this aldehyde, however this species was 
found to be both acid and base sensitive. Column chromatography using silica gel, silica gel 
deactivated with 3% triethylamine, basic alumina, and neutral alumina each caused the β,γ-
30 
 unsaturated aldehyde to rearrange to the more stable α,β-unsaturated isomer. The only way to 
avoid this undesired isomerization was to use the aldehyde crude.  
At this point in the synthesis, we have established a reliable route to both the enone (32a) 
and the aldehyde (34) components. The next step was to evaluate the potential utility of a tandem 
conjugate addition-aldol reaction process (Figure 21). The tandem conjugate addition-aldol 
reaction procedure that we utilized was designed by adapting a method originally reported by 
Itoh and coworkers.48 Itoh’s method was an attractive alternative to a typical aldol addition, since 
the conjugate addition process introduces an oxygen atom precursor at C-9.  Additionally, we 
recognized the potential for this reaction to generate three new chiral centers, including two 
neopentyl centers and one quaternary center. This process would also generate the C-1 to C-10 
carbon-carbon bond.  
Initial experiments using this method were carried out as follows (Figure 21): The chloro-
methylaluminum benzenethiolate reagent was prepared in situ by adding thiophenol to 
dimethylaluminum chloride at 0 oC in methylene chloride. This mixture was then cooled to -78 
oC and a solution of the enone (32a) in tetrahydrofuran was added. The addition of the aldehyde 
(34) to the aluminum enolate resulted in the formation of two aldol diastereomers (35 and 36) in 
a 3:1 ratio and 25% overall yield. Even though the yield was low, it was encouraging to find that 
more than 70% of the enone (32a) could be recovered. A substantial amount of the aldehyde (34) 
was also present before aqueous work-up, but did not survive silica gel chromatography. 
After repeating this experiment multiple times, we found that the conjugate addition 
reaction step always appeared to proceed slowly. In an attempt to optimize this aldol process, 
several experiments were evaluated. Different solvents were tried. The use of only methylene 
chloride or only tetrahydrofuran did not seem to improve the conversion of the conjugate 
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 addition step. Different Lewis acids, such as trimethylaluminum, methylaluminum dichloride, 
and tetrakis(dimethylamino) titanium, were also screened.  
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Figure 21 A tandem conjugate addition-aldol reaction 
 
The use of trimethylaluminum lowered the yield, but the use of the stronger Lewis acid, 
methylaluminum dichloride, simply caused quantitative cleavage of the C-6 MOM ether group. 
We also found that the Lewis acid tetrakis(dimethylamino) titanium resulted in the formation of 
a thick black slurry when the enone (32a) was added, and no identifiable products were isolated. 
Experiments using excess dimethylaluminum chloride and thiophenol also failed to improve the 
conversion of the conjugate addition step.  
One important observation that was discovered during this process was that the use of 
two equivalents of a Lewis acid was usually necessary to obtain the best yields. This result is 
consistent with an open transition state. In our proposed open transition state model (Figure22) 
one equivalent of an aluminum species is utilized in forming the five-membered ring aluminum 
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 chelate with the C-6 MOM ether. This intramolecular chelate disfavors the intermolecular 
chelate required for a Zimmerman-Traxler type transition state. Unlike the Zimmerman-Traxler  
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Figure 22 Closed and open transition state models 
 
model, where the metal atom coordinated to the enolate activates the aldehyde carbonyl group, 
an open transition state requires the presence of a second equivalent of a Lewis acid to activate 
the aldehyde. This observation supports an open transition state model. 
We also evaluated the use of other nucleophiles. Reactions were screened using both 4-
methoxythiophenol and 4-nitrothiophenol, however these nucleophiles did not perform any 
better than thiophenol. Eventually longer reaction times, typically five to six hours at -50 oC, 
were found to be required for the conjugate addition process to reach an optimal conversion, 
however the conversions were still low. 
In order to determine if either of the aldol diastereomers (35) or (36) possessed the 
desired stereochemistry at C-1, C-9, or C-10, the rigid cyclic carbonate analogs (38) and (40) 
were prepared using a two-step sequence (Figure 23). The first step involved a directed reduction 
using sodium acetoxyborohydride. This reagent will only reduce a ketone if it is coordinated to 
an electron-rich group, such as a hydroxyl group.49 The stereochemical outcome of this reaction 
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 is controlled by the neopentyl C-1 alcohol group, which delivers the hydride to the α-face of the 
ketone. The diol species (37 and 39) were then converted into cyclic carbonates (38 and 40) 
using triphosgene and pyridine. The stereochemistry of both cyclic carbonates was determined 
based on analysis of H,H-COSY and 1D NOE experiments (Figures 24 and 25).  
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Figure 23 Cyclic carbonate NOE analogs 
 
In order to determine the stereochemistry of the cyclic carbonate derivative (38) from the 
major aldol product (35), each hydrogen atom was unambiguously assigned using a H,H-COSY 
experiment. 1D NOE experiments were then performed to determine the absolute 
stereochemistry. The first NOE experiment irradiated the C-1 methine. This produced NOE 
enhancements at the C-10 quaternary methyl group (4.2%). This confirmed that both of these 
groups were on the same face of the fused ring system. The next NOE experiment irradiated the 
34 
 C-6 methine, producing an enhancement at the neighboring C-7 methine (4.2%) and at the C-10 
methyl group (3.5%). Since the absolute configuration at C-7 is known, this experiment proved 
that the C-10 methyl, the C-1 methine, and the C-6 methine groups are all on the same face of 
the bicyclic ring system. 
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Figure 24 1D NOE results for carbonate (38) of the aldol reaction major product 
 
When the C-5 methine was irradiated there were two enhancements observed, one with 
the C-9 methine (2.6%) and one with the methylene group once removed from the C-1 position 
(3.9%). The last NOE experiment on this substrate was to irradiate the C-9 methine. This 
irradiation produced enhancements at the C-5 methine (2.6%) and also at the methylene group 
mentioned in the last experiment (4.5%). These last two NOE experiments suggest that the C-5 
and C-9 methine groups and the alkyl chain from the aldehyde are all positioned on the same 
face of the ring. These experiments support all of the stereochemical assignments for the cyclic 
carbonate (38) and show that the major product of the aldol addition is the isomer required for 
orbiculin A (12).  
35 
 The cyclic carbonate derivative (40) of the minor product (36) from the aldol addition 
was also subjected to a battery of NOE experiments. The first NOE experiment with the cyclic 
carbonate (40) irradiated the C-10 methyl group. This irradiation produced enhancements at the 
C-6 methine (2.5%) and at the methylene group once removed from the C-1 methine (1.0%). The 
second experiment irradiated the C-6 methine and enhancements were seen at the neighboring  
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Figure 25 1D NOE results for carbonate (40) of the aldol reaction minor product 
 
C-7 methine (3.8%) and also to the C-10 methyl group (2.5%). Since the absolute 
stereochemistry at C-7 is known, it can be assumed that all four of these groups are on the same 
face of the ring system. The final NOE experiment for this substrate irradiated the C-9 methine. 
This caused enhancements to appear at the C-1 methine (4.7%) and at the C-5 methine (2.9%). 
These three experiments confirm the configuration at all six stereocenters. The minor 
diastereomer (36) only differs from the major product (35) at the C-1 stereocenter. 
Our NMR analysis reveals that the major product’s (35) stereochemistry is not consistent 
with a closed Zimmerman-Traxler transition state model. This model predicts that the minor  
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Figure 26 Zimmermann-Traxler model 
 
product (36) should have been the major product. The major product is likely the result of an 
open transition state and the observed selectivity of this process can be attributed to several 
control elements. Conformational analysis reveals that prior to conjugate addition, the enone 
(32a) is most likely in a half chair conformation with the C-7 isopropenyl group in the pseudo- 
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Figure 27 Half-chair conformations for enone (32a) 
 
equatorial position (Figure 27). Axial addition of benzenethiolate into the enone (32a) gives the 
cyclic enolate (41) with the sulfide group in the pseudo-axial position, avoiding a potentially 
high energy A1,2 interaction with the C-10 methyl group. An open transition state (42) may be 
preferred to a closed, Zimmerman-Traxler type, transition state due to the formation of a stable 
five-membered ring aluminum chelate (41) with the C-6 MOM ether (Figure 28). 
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Figure 28 Aluminum chelate and open transition state models 
 
In the open transition state model (42), the selectivity observed for the major product (35) 
presumably arises from the preference of the aldehyde to approach the enolate with the oxygen 
atoms anti-periplanar and the smaller hydrogen atom substituent under the enolate ring. The 
minor product (36) may arise from a similar approach, but with the alkyl chain of the aldehyde 
under the enolate ring instead. Another possibility is that a syn-clinal approach with respect to 
the aldehyde and enolate oxygen atoms, placing the smaller hydrogen atom under the enolate 
ring, also would produce the minor diastereomer. Although no direct evidence supporting the 
formation of a chelate species (41) was obtained, alkyl aluminum reagents have previously been 
recognized for their exceptional chelating ability in asymmetric synthesis.50 
Continuing on with the synthesis of orbiculin A, the major product from the aldol 
addition (35) was protected as an acetate ester (43) using acetic anhydride and pyridine. The next 
step was to convert the (E)-vinyl silane (43) into the required (Z)-vinyl iodide (44). In the 
planning of this synthetic route, it was realized that a (Z)-vinyl iodide would be prone to 
elimination under basic conditions. Therefore it was decided to minimize the number of steps 
through which to carry this sensitive group. We chose to use an (E)-vinyl silane as a surrogate 
for a (Z)-vinyl iodide (Figure 29). When the (E)-vinyl silane (43) was exposed to iodine 
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 monochloride in DMF, followed by Al2O3, multiple products were found. Following an aqueous 
work-up, analysis of the crude 1H NMR showed no sign of the expected product (44).  
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Figure 29 Attempted (Z)-vinyl iodide synthesis 
 
In retrospect, this reaction probably failed because iodine monochloride is a potent oxidant. The 
C-9 phenyl sulfide most likely underwent oxidation to the sulfoxide or sulfone and this process 
consumed the iodine monochloride before it could react with the hindered tri-substituted vinyl 
silane. 
In an attempt to circumvent this problem, the β,γ-unsaturated aldehydes (45) and (46) 
were prepared from (34) using procedures analogous to the iodine monochloride method shown 
in Figure 29. However, the aldehydes (45) and (46) were discovered to be incompatible with the 
conditions of the aldol reaction. Exposure of either aldehyde to the conditions of the tandem 
conjugate addition-aldol reaction produced no aldol products. 
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 When we discovered that generating the (Z)-vinyl halide group was proving to be a 
difficult task, alternative routes were examined. One solution was to use a 1,1-disubstituted-vinyl 
iodide. This change would give an exocyclic olefin instead of an endocyclic olefin, but we were 
confident that conditions could be found to isomerize the exocyclic olefin (47) to the required 
endocyclic species (48). 
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Figure 30 A comparison of the original route (top) and the new route (bottom) 
 
In our revised route, the isopropenyl group of the carvone derivative (32a) was 
selectively reduced (Figure 32) by adapting the procedure of Ireland and coworkers using 
Wilkinson’s catalyst and H2.51 The isopropenyl group present in the enone (32a) was reduced at 
this stage simply due to a reordering of steps. The required aldehyde, 4-iodopent-4-enal (51), 
was synthesized in four steps from commercially available 4-pentyn-1-ol.  The first step was to 
protect the primary alcohol as an acetate ester. We found that if the free alcohol was not 
protected prior to exposure to HI in acetonitrile, the desired product was obtained in low yield.52 
40 
 Analysis of several byproducts from this failed reaction by 1H NMR revealed that a substantial 
amount of material underwent alkyne hydration, giving a methyl ketone species (Figure 31).  
Another byproduct isolated from this reaction was consistent with acetate incorporation 
at the primary alcohol. The discovery of an acetate derivative was surprising. We presume that 
the formation of this species can be attributed to nucleophilic attack at the nitrile group of 
acetonitrile by the alcohol, followed by hydrolysis. To circumvent this problem, we discovered 
that protection of the primary alcohol as an acetate ester (49) before treatment with HI 
dramatically improved the yield.  
The procedure for generating HI in situ involved the slow addition of water to a solution 
of trimethylsilyl chloride and sodium iodide in acetonitrile (Figure 31).52 Following HI addition, 
the crude vinyl iodide was subjected to potassium carbonate in methanol, providing 4-iodopent-
4-enol (50) in 83% yield. The final step utilized a Dess-Martin periodinane oxidation47 that 
provided 4-iodopent-4-enal (51) in 93% yield.  
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Figure 31 An improved preparation of 4-iodopent-4-enal 
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 When our new enone derivative (52) was subjected to the benzenethiolate aldol reaction 
conditions, the conjugate addition process was still quite slow (Figure 32). After stirring for five 
hours at -50 oC, 4-iodopent-4-enal (51) was added. This produced the desired products (53 and 
54) in 28 % yield as a 6:1 ratio of diastereomers, presumably at C-1. 
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Figure 32 A selective tandem conjugate addition-aldol reaction 
 
Although the yield was low, the reaction seemed to favor the formation of the correct 
diastereomer (53). This was determined empirically by examining two diagnostic peaks in the 1H 
NMR spectra. We had discovered that a fairly reliable way to differentiate the two C-1 
diastereomers from this aldol reaction involved simply examining the coupling constants of the 
MOM ether methylene protons and the chemical shift values of the C-1 methine protons. This 
method suited or needs for exploratory work, since it did not involve the time consuming process 
of preparing analogs and acquiring NOE data. The assignments based on this method were never 
considered conclusive, only suggestive.  
Examination of the data in Table 2 illustrates this trend. The first four entries in Table 2 
are from diastereomers whose relative configurations were established using the aid of H,H-
COSY and 1D NOE experiments. The stereochemistry in the last two entries, aldol adducts (53 
42 
 and 54), were tentatively assigned by comparison to the first four entries. Although this 
assignment was not rigorously tested with 1D NOE experiments, we were confident that the 
open transition state model (Figure 28) was still operative in this system and our assignment was 
reliable for the aldol adducts (53 and 54).  
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Table 2 A comparison of the 1H NMR data from six aldol diastereomers 
 
Table 2 shows that when the desired (S) stereocenter (left-hand side of Table 2) is present 
at the C-1 center, the C-1 methine signal is always shifted upfield compared to the opposite C-1 
(R) isomer (right-hand side of Table 2). This indicates that the C-1 hydrogen in the undesired C-
1 (R) isomer is in a slightly more electron deficient environment. The second diagnostic signal is 
the peak shape and splitting pattern observed at the MOM ether methylene group. The 1H NMR 
peak(s) associated with this methylene group always show up as a slightly broadened singlet 
when the desired C-1 (S) isomer is present. When the opposite C-1 (R) isomer is present this 
methylene group shows up as two doublets in the 1H NMR spectrum. This apparent broadened 
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 singlet is the result of incidental chemical shift equivalence of the two diastereotopic MOM ether 
methylene protons in the desired product (53). 
 Before the cis-decalin ring system could be constructed, the C-1 hydroxy group required 
protection. Protection of the C-1 alcohol was necessary for two reasons. First, it would be 
difficult to avoid quenching the vinyl lithium precursor to the decalin ring (55) in the presence of 
an alcohol. Secondly, we suspected that strongly basic conditions might cause a retro-aldol 
reaction to occur. The major aldol isomer (53) was protected as a trimethylsilylethylmethoxy 
(SEM) ether (55) in good yield (Figure 33). Treatment of this vinyl iodide with one equivalent of 
sec-butyl lithium gave the desired cis-decalin ring system (56). This reaction represents our first 
successful synthesis of a decalin ring system.  
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Figure 33 A successful cis-decalin synthesis 
 
In order to convert the cis-decalin ring (56) to the desired trans-decalin ring, the di-
substituted exocyclic olefin would require isomerization to an endocyclic tri-substituted olefin 
(58). This conversion was first attempted using potassium aminopropyl amide (KAPA), a reagent 
designed for olefin isomerization.53 Exposure of the exocyclic olefin (56) to KAPA gave the diol 
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 derivative of the starting material (57) as the sole product. The strongly basic reagent had simply 
cleaved the SEM ether and no olefin isomerization was detected. We then recognized that in the 
absence of the SEM ether this isomerization process would need to generate three anions in one 
molecule (Figure 34). The formation of two anions in one molecule is reasonable, but forming 
three anions would give a fairly high-energy species and would be quite difficult. The KAPA 
reagent was a poor choice for our application due to our protecting group selection. 
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Figure 34 The KAPA mediated olefin isomerization 
 
Olefin isomerization was also attempted using Wilkinson’s catalyst.54 We found that 
these conditions also failed to isomerize the exocyclic olefin. This result was not surprising since 
rhodium catalysts normally exhibit a higher affinity for sulfide groups than olefins. Coordination 
of the catalyst to the olefin pi system was likely disfavored due to the soft nature of the sulfide 
group.  
Although these two synthetic routes did not yield a natural product, they did succeed in 
providing us with a substantial amount of information for planning future routes. We had found 
optimal conditions for the conjugate addition initiated aldol reaction and had determined a 
reliable method for establishing the stereochemistry of the aldol products. We had also 
constructed a transition state model for predicting the stereochemical outcome of this process 
45 
 and discovered the chemical incompatibility and limitations associated with the phenyl sulfide 
group. Using this knowledge, we designed a new system that would avoid the problems 
encountered in the first two attempts. 
 
3.2. A Ring Closing Metathesis Route to Celafolin A-1 
Celafolin A-1 (11) is one of the simplest members of the dihydroagarofuran family of 
natural products that is known to reverse MDR in cancers over-expressing P-gp.30-31 Since the 
chemistry developed to synthesize celafolin A-1 would be directly applicable to orbiculin A, we 
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Figure 35 Retrosynthesis of celafolin A-1 
 
46 
 decided to pursue this simpler natural product first. The selected disconnections for celafolin A-1 
(Figure 35) closely resemble our initial route to orbiculin A. The major change in our new route 
was the use of a ring closing metathesis (RCM) reaction to generate the trans-decalin ring. 
In an earlier experiment, we discovered that Grignard reagents could add easily into the 
hindered C-5 carvone carbonyl group. Our idea for using a ring closing metathesis approach for 
constructing the dihydroagarofuran ring system originated from the experiment shown in Figure 
36. While investigating a model system for orbiculin A, it was discovered that isopropenyl 
magnesium bromide readily added to the neopentyl C-5 carbonyl group. Although the model 
system in Figure 36 exhibited no facial selectivity, this result was encouraging since many of our 
attempts to add alkyl lithium nucleophiles, during intramolecular reactions, into the C-5 carbonyl 
group had previously failed. The success of this addition initiated our investigation of a ring 
closing metathesis route to celafolin A-1 (11). 
 
O
PhS O
O
OTHP
Br
O
PhS OH
O
OTHP
BrMgBr THF
-78 to 25 oC
56% Yield 
1:1 ratio of 2 diastereomers
at C-55 5
 
Figure 36 Grignard addition into a neopentyl ketone 
 
The first transformation to address was the selection of a coupling partner for the C-5 
isopropenyl group. We reasoned that this group could be installed using a tandem conjugate 
addition-aldol reaction (Figure 35) with an aldehyde similar to 3-butenal.55 Following protection 
of the resulting aldol adduct, isopropenyl-magnesium bromide could be added into the C-5 
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 ketone, giving the second coupling partner for the ring closing metathesis.56 This plan would 
yield a trans-decalin ring system in fewer steps than initially proposed for orbiculin A (12) 
(Figure 17). 
Our initial attempts using 3-butenal gave discouraging results. This aldehyde was 
difficult to prepare, gave poor yields, and produced mixtures of undesired products when 
subjected to the conditions of our aldol reaction. The major problems seemed to be due to the 
propensity of 3-butenal to isomerize to the more stable α,β-unsaturated isomer, crotonaldehyde. 
Fortunately, we found that 4-phenylselenobutanal (59) 57-58 could be used as a substitute for 3-
butenal since selenium oxidation and elimination59 affords the required terminal olefin.   
When 4-phenylselenobutanal (59), a known species prepared in one step from 4-
phenylselenyl-butyric acid methyl ester, was subjected to the conjugate addition initiated aldol 
with the enone (32a), it was found to be both reactive toward the aluminum enolate and 
remarkably robust. This aldehyde reacted with the aluminum enolate to give the desired aldol 
products as two diastereomers.  Following purification of these two C-1 diastereomers (60 and 
61), the yield for the reaction, based solely on product obtained, was found to be 22% in a 6.3:1 
ratio of diastereomers favoring the desired isomer (60). An additional 58% of the enone (32a) 
and 78% of the aldehyde (59) were also recovered. The major aldol diastereomer (60), which we 
believed contained the required stereochemistry for celafolin A-1, was then carried through the 
remaining synthesis and the stereochemistry was determined at a later point. 
Before isopropenylmagnesium bromide could be added into the C-5 carbonyl group, the 
neopentyl C-1 alcohol of the aldol adduct (60) required protection to prevent a possible retro-
aldol reaction. The MOM ether protecting group was selected based on the high, reproducible 
yields during its formation and the simplicity of its removal. We also elected to perform the 
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 selenoxide elimination prior to the Grignard addition. Oxidative elimination of the 
phenylselenide group (62) was accomplished by a chemoselective m-CPBA oxidation to 
generate the selenoxide in the presence of a phenyl sulfide.60 Oxidation of the sulfide was 
avoided by slowly adding one equivalent of m-CPBA to the phenylselenide substrate (62) in 
methylene chloride at -78 oC. The crude selenoxide was allowed to slowly warm to room 
temperature and then pyridine and dihydropyran were added. Dihydropyran was added since 
elimination of the selenoxide produces phenylselenenic acid, a potent electrophile. In the absence  
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Reagents and conditions: a) PhSAlMeCl, CH2Cl2, then 59, -50 oC, 6.3:1 ratio, 22%. b) MOMCl, DMAP, DIPEA, 
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bromide, THF, 25 oC, 20%, (80% based on recovered SM). e) Grubb’s catalyst (A), CH2Cl2, reflux, 94%. 
Figure 37 Construction of the A and B ring of celafolin A-1 
 
49 
 of the electrophile scavenger dihydropyran, the phenylselenenic acid would react with either the 
newly formed terminal olefin or the C-7 isopropenyl group. The desired elimination was 
achieved by gently refluxing the selenoxide, pyridine, and dihydropyran solution giving the 
desired olefin (63) in good yield.  
The first conditions that were evaluated for the addition of isopropenyl magnesium 
bromide into the C-5 carbonyl group involved exposure of the ketone substrate (63) to excess 
isopropenyl magnesium bromide in THF at -78 oC, followed by slow warming to ambient 
temperature. These conditions gave the RCM substrate (64) as a single isomer in 20% yield. The 
isolation of a single isomer was a surprising result, considering that no facial selectivity was 
observed in the model substrate in Figure 36.  Although the yield was low, most of the starting 
material (63) was recovered. The stereochemical outcome of this addition can be explained by 
examining the chair conformation of the starting material (63) (Figure 38).  From this 
conformation, the Felkin-Ahn model accounts for the observed selectivity and formation of the 
desired isomer for celafolin A-1 (11). 
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Figure 38 Substrate controlled addition into the C-5 ketone (63) 
 
Although selectivity for this Grignard addition process was excellent, the yield needed to 
be further optimized. The first experiment tried was to replace the solvent tetrahydrofuran with 
diethyl ether. This solvent change produced no increase in yield. Since this Grignard addition 
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 seemed to be a slow reaction, other competing processes, such as a Wurtz coupling, could be 
consuming the Grignard reagent before it could react with the hindered ketone (63). In an 
attempt to circumvent this competing reaction, an experiment was evaluated were fresh Grignard 
reagent was periodically added. This experiment failed to improve the yield. Since periodic 
addition of fresh Grignard reagent did not improve product conversion, perhaps the sluggish 
reactivity can be attributed to the ketone.  
Grignard reagents are both inherently nucleophilic and basic. We speculated that rather 
than adding into the ketone carbonyl group, the Grignard reagent may be acting as a base to 
deprotonate at C-6 giving a magnesium enolate. Formation of a magnesium enolate would 
certainly prevent Grignard addition.  
Enolate formation was initially a concern, but since no epimerized ketone starting 
materials (63) were recovered, it was presumed to not occur. In order to verify this conclusion 
the Grignard addition reaction was quenched with deuterium oxide instead of dilute HCl. To our 
surprise, a deuterium label was incorporated at the C-6 carbon (Figure 39). Even more surprising 
was that the deuterium incorporation occurred with a high degree of facial selectivity causing no 
epimerization at C-6. This result showed that nucleophilic addition and enolate formation were 
two competing processes. Furthermore, selective protonation of the enolate during an aqueous 
quench does not allow for enolate formation to be detected under normal reaction conditions.  
In an attempt to prevent enolate formation the cerium derived reagent, isopropenylcerium 
dichloride, was prepared using 2-lithiopropene and anhydrous CeCl3. The use of this 
nucleophilic cerium reagent, which is a substantially weaker base than a Grignard reagent, also 
failed to improve product conversion. We speculate that the sterically demanding neopentyl 
ketone may be too hindered to react with the larger cerium reagent. Since our initial attempts to 
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 optimize this reaction were not improving the yield of product, a temporary solution was to 
continually re-subject recovered starting material in order to explore new chemistry in 
subsequent steps. 
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Figure 39 Deuterium labeling experiment 
 
 The next step in our sequence was the anticipated ring closing metathesis reaction to 
construct the trans-decalin ring system (Figure 37). The outcome of the ring closing metathesis 
reaction in the presence of a phenyl sulfide was dependent largely upon the catalyst’s affinity for 
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 sulfur. Our previous experience with transition metal catalysts and sulfides taught us that sulfides 
are typically better ligands for transition metal complexes than olefins. Literature precedent has 
previously demonstrated that the first generation Grubbs’ catalyst is inactive in the presence of 
sulfide groups.56, 61 However, in a recent paper by Danishefsky and coworkers, it was reported 
that the 2nd generation Grubbs’ catalyst56 was able to function in the presence of a thioacetal 
protecting group.62 Encouraged by this result, we opted to try this procedure in the presence of 
the phenyl sulfide (64). The reaction that ensued was very fast, even at 0.04 M concentration, 
with a catalyst loading of 2.5 mol%. After a silica gel filtration to remove the catalyst, the crude 
1H NMR revealed the presence of a single product (65).   
 Prior to the ring closing metathesis reaction, the stereochemistry at C-5 and the 
stereochemistry of the ring fusion for the newly formed bicyclic ring were unknown. 
Examination of the coupling constants in the 1H NMR of the RCM product (65) suggested a 
trans-ring fusion with the molecule in a half chair-boat conformation (Figure 40). To provide  
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Figure 40 1H NMR coupling constant analysis for the RCM product (65) 
 
additional evidence supporting the assigned ring system, a 1D NOE experiment was performed. 
The result of this experiment showed that when the C-10 quaternary methyl group was 
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 irradiated, an enhancement was seen at the C-2 methylene (1.0%) and the C-7 methine (1.2%) 
positions. Unfortunately, additional NOE experiments were not possible since many of the 
diagnostic hydrogen signals could not be irradiated without also irradiating nearby signals. 
Furthermore, this experiment did not provide additional support for the assigned stereochemistry 
at C-1, but we were confident in our assignment based on results from similar substrates using 
the thiophenol tandem conjugate addition-aldol reaction. 
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Figure 41 C-10 NOE enhancements 
 
With the trans-decalin bicyclic substrate (65) in hand, the conversion of the C-9 phenyl 
sulfide into a carbonyl group was attempted via a Pummerer rearrangement63 (Figure 42). Clean 
oxidation of the phenyl sulfide (65) to the corresponding sulfoxide (66) was achieved using m-
CPBA at -78 oC. The sulfoxide (66) was then treated with trifluoroacetic anhydride (TFAA) and 
pyridine, which led to the exclusive formation of a vinyl sulfide (67) in 87% yield.  
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Reagents and conditions: a) m-CPBA, CH2Cl2, -78 to 25 oC, 100%. b) TFAA, Pyridine, CH2Cl2, 25 oC, 87%. 
Figure 42 Attempted Pummerer rearrangement 
 
In order for a successful Pummerer rearrangement to occur, trifluoroacetate has to attack 
the C-9 carbon center of the activated sulfide (Figure 43). Since the sulfide is attached to a 
neopentyl carbon, nucleophilic attack is slow. A competing reaction, elimination, can then occur 
which explains the formation of observed vinyl sulfide (67). This Pummerer rearrangement  
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Figure 43 The Pummerer rearrangement and a competing elimination process 
 
55 
 strategy was tested on other celafolin A-1 intermediates, (64) and (68), but these also failed to 
give the desired C-9 ketones. These initial results prompted a change in the synthetic scheme that 
would address this conversion at a later point. 
 Our attention then turned to the construction of the tetrahydrofuran C ring. The tricyclic 
tetrahydrofuran ring system (68) was constructed using a trifluoromethanesulfonic acid (TfOH) 
mediated etherification protocol. This method has been successfully used to close the C ring of 
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Reagents and conditions: a) TfOH, THF, 25 oC, 30%. b) Ac2O, pyridine, DMAP, CH2Cl2, 25 oC, 56%. c) 
[Ir(cod)py(PCy3)]PF6, H2, CH2Cl2, 65% based on recovered SM. 
Figure 44 Completion of the celafolin A-1 ring system 
 
similar natural products.37,45  The TfOH cyclization proceeded with the loss of both MOM ether 
protecting groups to give a diol (68) in modest yield (Figure 44). The success of this cyclization 
confirmed stereochemistry of the trans-ring junction, since the incorrect isomer at C-5 would 
have not undergone cyclization. NMR analysis, including H,H-COSY and 1D NOE experiments, 
were utilized to assign all of stereocenters in the tricyclic ring system (68). The data from the 1D 
NOE experiments for this diol (68) provided additional evidence supporting the trans-ring 
junction and previous stereochemical assignments (Figure 45). When the C-6 methine was 
irradiated, NOE enhancements were observed at the neighboring C-7 methine (5.5%) and also at 
the C-10 quaternary methyl group (5.7%). Even more satisfying, irradiation of the C-9 sulfide 
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 methine provided a NOE enhancement to the C-1 methine (2.0%) suggesting the stereochemistry 
at C-1 is the desired (S) configuration required for celafolin A-1. Irradiation of the C-9 methine 
also produced an enhancement at one of the tetrahydrofuran ring quaternary methyl groups 
(3.7%), providing additional evidence for our assignments. 
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Figure 45 NOE results for diol (68) 
 
 The next challenge was to determine if the C-1 and C-6 hydroxyl groups could be 
selectively manipulated. Our analysis of the tricyclic ring system in Figure 45 shows that both 
alcohols are equatorial and adjacent to quaternary centers. The C-1 alcohol may be slightly more 
accessible since the C-2 carbon is di-substituted, whereas the C-7 carbon is tri-substituted. When 
the diol (68) was treated with acetic anhydride, pyridine, and DMAP in methylene chloride two 
products were isolated. One product was consistent with mono-acylation at the C-1 hydroxyl 
group (69) and was isolated in 56% yield (Figure 44). This was determined by the downfield 
shift observed at the C-1 methine in the 1H NMR. The second product was consistent with 
acylation at both C-1 and C-6 hydroxyl groups. This bis-acylated byproduct was isolated in 11% 
yield and the starting material (68) was recovered in 33% yield. An interesting observation was 
that no product with mono-acylation at C-6 was found. This result indicates that the selectivity 
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 for acylation at C-1 could be improved if a less-reactive acylating reagent was employed. For 
example, by excluding DMAP in the above reaction conditions the selectivity might improve. 
The C-6 hydroxyl group was then utilized to perform a directed reduction of the C-3 
olefin. This step involved using a directed hydrogenation to set the C-4 methyl stereocenter. 
Treatment of the homoallylic alcohol (69) with Crabtree’s catalyst64 under 1 atm of H2 gave the 
desired product (70) in 65% yield based on recovered starting material. Examination of the 1H 
NMR revealed a single diastereomer and the absolute configuration of this product (70) was 
assigned by a 1D NOE experiment (Figure 46). Irradiation of the C-6 methine showed a strong 
enhancement at the C-4 methyl group (3.1%). This enhancement would not be observed if the 
opposite stereocenter was formed. The presence of additional NOE enhancements at the C-7 
methine (3.8%) and the C-10 methyl group (6.4%) provided further evidence supporting our 
stereochemical assignments. 
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Figure 46 Acetate (70) NOE experiment 
  
At this point, the skeleton of the dihydroagarofuran ring system was complete. Additional 
experiments showed that the C-6 hydroxyl group could be acylated with benzoyl triflate,65 
however insufficient quantities of the starting material (70) made complete characterization of 
this advanced intermediate difficult. Conversion of the C-9 phenyl sulfide into a carbonyl group 
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 also proved difficult, as multiple Pummerer reaction conditions were explored but the neopentyl 
sulfide proved resistant to the desired reactivity. Overall, this synthesis represents a concise route 
to the trans-decalin core of the dihydroagarofuran natural products. Although this RCM route did 
not allow us to complete celafolin A-1, we were closer than ever to our goal.  
The RCM sequence allowed us to test four new transformations, a ring closing metathesis 
reaction for constructing the trans-decalin core, a TfOH mediated etherification, C-1 and C-6 
ester formation and differentiation, and a directed hydrogenation to set the C-4 stereocenter 
selectively. When we began to run out of options at the end of this sequence, we decided to 
evaluate how to improve the troublesome steps in this route. 
Despite multiple attempts to optimize the tandem conjugate addition-aldol reaction, the 
isopropenyl Grignard addition, and the TfOH mediated etherification steps, no efficient 
conditions were found. These problems prevented the preparation of larger quantities of material 
and ultimately lead us to investigate alternative routes that would avoid these bottleneck steps.  
 
3.3. A Revised Route to Celafolin A-1 
Due to the difficulty encountered in multiple steps of the previous route, a completely 
new approach was designed. The ring closing metathesis route to celafolin A-1 (11) contained 
three troublesome elements that needed to be addressed. First, the yield of the aldol addition to 
construct the C-1 to C-10 carbon-carbon bond was low. Designing a system that will undergo an 
intramolecular aldol addition instead of a tandem conjugate addition-aldol process should 
improve the efficiency of the aldol reaction. Secondly, this new route would avoid the difficulties 
associated with nucleophilic additions at neopentyl centers, since the required C-1 and C-9 
oxygen atoms are installed earlier in the synthesis. The conversion of the C-9 sulfide into a 
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 ketone was a major problem encountered in earlier routes utilizing Pummerer63 rearrangements. 
Finally, a better method for constructing the tetrahydrofuran C ring of the dihydroagarofuran 
skeleton needed to be found. Acid catalyzed etherification37, 45 was an impractical route, as 
demonstrated earlier, due to the presence of multiple acid labile groups incorporated as 
intermediates during the planned synthesis.  
Our planned disconnections for a new aldol-based route to celafolin A-1 (11) are outlined 
in Figure 47. In a substantial change from our previous syntheses, we decided to investigate 
whether an intramolecular aldol addition could be used to generate the thermodynamically 
preferred trans-decalin ring junction. The C-5 stereocenter of the aldol precursor can be 
selectively constructed by an organolithium addition into the C-5 carbonyl group. This addition, 
as shown previously (Figure 36), should proceed through a Felkin-Ahn type process to give the 
desired C-5 stereoisomer for celafolin A-1. The required epoxide for this addition can be 
stereoselectively constructed from the known enone (32a) by treatment with alkaline hydrogen 
peroxide. This analysis then leads back to (R)-(-)-carvone as the preferred chiral starting 
material. 
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Figure 47 Revised retrosynthesis of celafolin A-1 
 
Our intramolecular aldol addition route to celafolin A-1 (11) began with the known enone 
(32a) that was used in the three previous routes. The first new step in this sequence was to 
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 epoxidize the enone using the conditions developed by House and coworkers.66 We found that 
subjection of the enone (32a) to hydrogen peroxide and sodium hydroxide in methanol and water 
caused C-6 epimerization and extensive decomposition. Using a modification of the House 
epoxidation method, the enone (32a) was cleanly epoxidized with hydrogen peroxide and 
potassium carbonate in a mixture of methanol, water, and tetrahydrofuran.67 These conditions 
provided the desired epoxy ketone (71) in good yield with no C-6 epimerization (Figure 48).  
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Reagents and conditions: a) K2CO3, H2O2, H2O, THF, 25 oC, 77%. b) (4-bromo-pent-4-enyloxy)-
triisopropylsilane (72), t-BuLi, THF, -78 oC, β:α= 12:1, 58%. c) i. I2, pyridine, CH2Cl2, 25 oC, ii. AIBN, 
Bu3SnH, toluene, reflux, 87% (2 steps), d) Cp2TiCl2, 1,4-cyclohexadiene, Mn, collidine-HCl, THF, 25 oC. 
Figure 48 Construction of the tetrahydrofuran C ring  
 
The next step required the addition of a vinyl lithium reagent into the C-5 carbonyl to 
construct the C-4 to C-5 carbon-carbon bond and generate the required (R)-stereocenter at C-5 
61 
 for celafolin A-1 (11). The known vinyl bromide (72) was constructed by alkylation of the 
lithium enolate of t-butyl acetate with 2,3-dibromopropene, followed by a LiAlH4 reduction and 
protection of the primary alcohol as a triisopropylsilyl (TIPS) ether. The vinyl bromide (72) was 
then treated with two equivalents of t-butyl lithium at -78 oC to cleanly generate the required 
vinyl lithium reagent. This vinyl lithium derivative of (72) was then added to a solution of the 
epoxy-ketone (71) in tetrahydrofuran at -78 oC. The resulting regioselective addition into the C-5 
carbonyl group gave the expected allylic alcohol as a 12:1 ratio of diastereomers at C-5 in 58% 
yield, favoring the desired diastereomer (73).  
Initially, the next step was to utilize an iodoetherification-dehalogenation procedure to 
close the tetrahydrofuran C ring (Figure 48). Exposure of the epoxy-alcohol (73) to iodine and 
pyridine in methylene chloride, followed by treatment with tributyltin hydride and AIBN gave 
the desired [3.2.1] bicyclic ring system (74) in 87% yield over two steps. However, we later 
found that this substrate would not undergo epoxide opening. Reagents that failed to open this 
epoxide include titanocene chloride, Red-Al, and sodium cyanoborohydride in the presence of 
boron trifluoride diethyl etherate.  
The failure encountered in opening the epoxide at this stage led us to investigate this 
transformation at other points in this sequence. The silyl ether substrate (73) was subjected to the 
titanocene chloride and cyclohexadiene reductive epoxide opening conditions, but also failed to 
react. Eventually, a solution was found to this problem. When the TIPS ether in the epoxy-
alcohol (73) was removed, the diol species (75) underwent reductive epoxide opening mediated 
by titanocene chloride68 to give the triol product (76) in excellent yield. A second, minor product, 
isolated from this reaction was determined to be an allylic alcohol formed due to radical 
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Figure 49 A successful epoxide-opening route 
 
disproportionation. The formation of this byproduct can be explained by examining the 
mechanism for this reductive epoxide opening process (Figure 50). The desired product is 
formed when the tertiary carbon radical abstracts a hydrogen atom from 1,4-cyclohexadiene or 
from 1,4-cyclohexadiene radical. The undesired allylic alcohol byproduct results from radical 
disproportionation. This disproportionation process occurs when the tertiary radical encounters 
another radical species before it can abstract a hydrogen atom from 1,4-cyclohexadiene. This 
process can be minimized, but not eliminated, by using excess 1,4-cyclohexadiene.  
In order for this reductive epoxide opening to be catalytic, the titanocene chloride must 
be regenerated during the reaction. To complete the catalytic cycle in Figure 50, two steps need 
to occur before the titanium (IV) alkoxide can be converted back to the catalytically active 
titanium (III) species. One of the two steps requires protonation of the titanium bound oxygen 
atom and the second step requires manganese metal to reduce the titanium (IV) to titanium (III).  
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Figure 50 Titanocene chloride reductive epoxide opening 
 
The titanium oxygen bond is a comparatively strong bond and therefore requires a relatively 
strong acid to facilitate cleavage. However, if a strong Bronsted acid were used, the manganese 
metal would oxidize when exposed to the acid and would not be able to regenerate the titanocene 
(III) chloride. To successfully complete the catalytic cycle, this reaction requires an acid that is 
strong enough to facilitate cleavage of the titanium oxygen bond, but weak enough to prevent 
manganese metal oxidation. This is the reason for the use of the fairly uncommon reagent, 
collidine hydrochloride, during this epoxide opening reaction.  
In order to close the tetrahydrofuran ring, the primary and secondary hydroxyl groups in 
the triol substrate (76) required protection. Both hydroxyl groups were protected as triethylsilyl 
(TES) ethers using TESCl, DMAP, and pyridine to afford the bis-silyl ether (77) in an acceptable 
yield. A two-step iodoetherification-dehalogenation procedure (Figure 51) gave the expected 
tetrahydrofuran product (78) in 55% yield. After carefully analyzing the 1H NMR data for the 
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 tetrahydrofuran product (78), an interesting observation was made. We noticed that the 
stereochemistry at the C-9 TES ether had been partially epimerized. The presence of two  
 
O
O
O
OTES
OTES
O
O
O
OH
OH
O
OH
O
OTES
OTES
O
O
O
O
O
a b c
77 78 79 80
 
Reagents and conditions: a) i. I2, pyridine, CH2Cl2, 25 oC, ii. AIBN, Bu3SnH, toluene, reflux, 55% (2 steps). b) 
TBAF, THF, 25 oC, 92%. c) DMPI, NaHCO3, CH2Cl2, 25 oC, 80%.  
Figure 51 Formation of the tetrahydrofuran C ring 
 
diastereomers was particularly noticeable in the region of the MOM ether proton signals. A 
probable mechanism for the epimerization that occurred during the dehalogenation process is 
shown in Figure 52.  
The primary alkyl iodide precursor of the [3.2.1] bicyclic ring containing substrate (78) 
contains a mixture of four diastereomers resulting from the previous epoxide opening and the 
stereo-random etherification. When the primary alkyl iodide reacts with the tributyltin radical, a 
primary carbon radical is produced. If given the opportunity, this high-energy primary radical 
can abstract a hydrogen atom to form a lower energy radical. Figure 52 shows one of the two 
radical intermediates is within close proximity to the C-9 hydrogen atom. Hydrogen atom 
transfer results in the formation of an oxygen stabilized tertiary radical. Eventually this new 
radical is reduced with tributyltin hydride and during this process the C-9 center is epimerized. 
Fortunately, this process is inconsequential since the C-9 stereocenter will be oxidized to a 
ketone after the TES ethers are removed. 
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Figure 52 Mechanism for C-9 epimerization 
 
This two-step iodoetherification-dehalogenation procedure (Figure 51) yields the desired 
tetrahydrofuran ring system in an overall yield of 55%. This represents a substantial 
improvement compared to a 30% yield from the previous TfOH catalyzed etherification method 
(Figure 44).69 The TES ethers groups present in (78) were then removed by treatment with TBAF 
to give the desired diol (79). Dess-Martin periodinane (DMPI) oxidation47 afforded the keto-
aldehyde (80) as a single isomer. 
In order to generate the required trans-decalin ring fusion, conditions for thermodynamic 
equilibrium needed to be determined. The cis-decalin ring system is the kinetically favored 
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 product when an intramolecular aldol addition is utilized to construct a [4.4.0] fused bicyclic 
ring. The trans-decalin ring system, which is the thermodynamically favored product, can only 
be obtained if the conditions employed allow for equilibration to occur. For comparison 
purposes, the difference in energy between a cis-decalin and a trans-decalin ring is 
approximately 3 kcal/mol. The difference in energy between the cis- and trans-decalin ring 
junctions in the tricyclic ring systems of the potential aldol adducts in Figure 53 is unknown. In 
order to estimate the energy differences between the possible aldol products, molecular 
mechanics calculations were performed. Macromodel (v. 5.5) was utilized to perform a Monte 
Carlo conformational search using the MM2* force field.70  
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Figure 53 Macromodel Monte Carlo calculations 
 
After minima for each of the possible products were found, it became apparent (Figure 
53) that the trans-decalin products were the thermodynamically favored species. Both of the cis-
decalin adducts were found to be at least 3-6 kcal/mol higher in energy than the corresponding 
trans-decalin isomers. This energy difference is in agreement with the energy difference between 
cis- and trans-decalin rings. Figure 53 shows that both cis-decalin aldol adducts are practically 
identical in energy. The cis-decalin adduct with the equatorial C-1 alcohol may be slightly lower 
in energy due to a hydrogen bonding interaction with the C-9 carbonyl group. The second cis-
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 decalin adduct has an axial C-1 alcohol that cannot participate in a hydrogen bond since it points 
away from the C-9 carbonyl group (see NOE Figure 56). 
The interactions responsible for the larger energy difference between the two trans-
decalin isomers cannot be attributed to only hydrogen bonding with the C-9 carbonyl group. In 
the trans-decalin ring system, each isomer has a hydroxyl group that is equally likely to 
participate in a hydrogen bond with the C-9 ketone (Figure 54). However, the axial isomer can 
participate with a second hydrogen bond acceptor group, the oxygen atom in the tetrahydrofuran 
ring. This interaction alone can still not explain the greater than 3 kcal/mol energy difference. 
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Figure 54 Hydrogen bonding interactions in the trans-decalin ring system 
 
Further examination shows the equatorial alcohol in the trans-decalin ring has a higher energy 
interaction with the neighboring quaternary center methyl group. The axial alcohol isomer does 
not experience this gauche interaction with the C-10 quaternary center.  
The results from our Macromodel calculations led to the conclusion that equilibration of 
the cis-decalin ring to the trans-decalin ring should be thermodynamically favorable, but the 
activation barrier for this conversion was still unknown. The Curtin-Hammet principle states that 
the product distribution is not dependent upon the energy difference of the products, but rather 
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 the energy difference between the two transition states leading to the products. We anticipated 
that the use of non-equilibrating enolization conditions, such as LDA, would give the kinetically 
preferred cis-decalin ring fusion. The use of equilibrating conditions during the aldol addition 
should result in equilibration and favor formation of the trans-decalin products. 
In order to test this theory, the amine base DBU was initially investigated (Figure 55). 
Treatment of keto-aldehyde (80) with DBU in methylene chloride at high dilution for 5 hours  
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Figure 55 DBU intramolecular aldol additions 
 
resulted in clean conversion to the aldol adduct (81). The 1H NMR was consistent with the 
desired product and the C-1 methine hydrogen appeared as a doublet with a coupling constant of 
2.9 Hz. The multiplicity and coupling constant for this hydrogen suggested that the C-1 hydroxyl 
group was in the axial position. To verify the stereochemistry, H,H-COSY and 2D NOESY 
experiments were performed. The most noticeable cross peak in the NOESY spectrum (Figure 
56) was between the C-10 methyl group and the C-1 methine hydrogen. Since we had established 
that the C-1 hydroxyl group was in an axial position, this NOESY result suggests a cis-decalin 
bicyclic ring with the B ring in a chair-like conformation. A second cross peak was observed 
between the C-6 methine and the axial hydrogen of the C-8 methylene group. This suggests that 
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 the A ring is in a chair conformation. A third NOESY cross peak was also found between the C-
10 methyl group and one of the C-4 olefin hydrogens, providing additional evidence for a 
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Figure 56 NOESY for cis-decalin (81)  
 
chair-like conformation in the B ring. These results (Figure 56) clearly showed this species (81) 
was the undesired cis-decalin adduct.  
In an identical experiment using DBU, the reaction duration was increased to 18 hours. 
These conditions produced two products, the initially isolated cis-decalin species (81) and a new 
isomer (82). Analysis of the 1H NMR coupling constants revealed that the new product (82) 
contained an equatorial C-1 hydroxyl group. Our assignment was based on the appearance of the 
C-1 hydrogen as a doublet of doublet of doublets (ddd) with coupling constants of 12.4, 4.9, and 
1.1 Hz. The unusual multiplicity of a ddd at this position can be attributed to long-range coupling 
to possibly the C-4 methylene group. After utilizing a H,H-COSY experiment to verify the 
identity of each proton, a 2D NOESY experiment was used to determine the stereochemistry 
(Figure 57). Four important cross peaks were observed in this experiment. The C-1 and C-6 
methine groups and the C-8 axial methylene hydrogen each possessed cross peaks to one 
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 another. The fourth cross peak found was between the C-10 methyl group and one of the C-4 
olefin hydrogens. Since this identical cross peak was observed in the NOESY spectrum of other  
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Figure 57 NOESY for cis-decalin (82) 
 
aldol isomer (81), it can be reasoned that this new species (82) is also not a trans-decalin adduct. 
All four of these cross peaks are consistent with another cis-decalin ring system. 
Isomerization of the cis-decalin ring to the trans-decalin ring was proving to be a difficult 
conversion. The equilibration of the cis-axial isomer (81) to the cis-equatorial isomer (82) 
corresponds to Macromodel calculations and experimental observations, but cis- to trans-decalin 
conversion does not. Thermodynamic equilibration of the cis-decalin kinetic product to the 
trans-decalin product may require longer reaction times. We tested this theory by subjecting the 
keto-aldehyde (80) to DBU in methylene chloride for 72 hours. When this reaction was checked 
using 1H NMR analysis, only cis-decalin products were observed. The keto-aldehyde (80) was 
also exposed to potassium carbonate in methanol, since a protic solvent may disrupt the hydrogen 
bonding network in the aldol products (81 and 82) and possibly promote cis- to trans-decalin 
conversion. After stirring for 72 hours, the crude 1H NMR spectrum still showed only cis-decalin 
aldol adducts (81) and (82).  
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 Figure 58 illustrates why isomerization of the cis-decalin ring to the trans-decalin ring is 
not occurring. Analysis of either the chair or the boat transition state leading to the cis-decalin 
ring system shows that the exocyclic C-4 olefin is in a staggered conformation with respect to the 
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Figure 58 Transition states for cis- and trans-decalin ring forming aldol reactions 
 
C-5 tetrahydrofuran oxygen and the C-6 MOM ether. In order to achieve a conformation that will 
access the transition states required for the trans-decalin product, the C-4 olefin has to either 
eclipse the C-6 MOM ether (chair) or rotate counterclockwise moving closer to the C-6 MOM 
ether (boat). The methyl groups on the THF C-ring also partially block the approach of the 
aldehyde in the trans-decalin transition states. Although the experiment was not attempted, 
heating this reaction may provide enough energy to allow rotation around the C-4 / C-5 bond and 
could provide access to the transition states leading to the trans-decalin products.  
The principle of least motion can also be invoked to explain our inability to convert the 
cis-decalin products (81 and 82) to the desired trans-decalin species. Even if the aldol reaction is 
reversible, and we have shown that it is, the formation of the trans-decalin ring requires the 
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 aldehyde to wrap around to the opposite face of the ring. If bond rotation is somewhat slow, this 
reorganization process is difficult during an intramolecular reaction. 
Although initial experiments failed to obtain the desired trans-decalin ring system, this 
method has successfully circumvented three problems encountered in the previous routes. The 
yield of the intramolecular aldol reaction utilized to construct the C-1 to C-10 bond is 
substantially higher than the conjugate addition aldol. The incorporation of oxygen was achieved 
at C-9 prior to the formation of the quaternary C-10 stereocenter. This early transformation 
eliminates the need for a Pummerer rearrangement, which is a difficult transformation at a 
neopentyl carbon with β-hydrogens present. This route has also demonstrated that the use of an 
iodoetherification reaction to close the tetrahydrofuran C ring gives a better yield than the 
corresponding triflic acid procedure used in earlier routes. Additionally, the intramolecular aldol 
route can quickly build up a complex ring system and is flexible enough to allow for the 
preparation of analogs with no changes other than ester groups at the end of the synthesis. 
Further experimentation should allow for a means to obtain the desired trans-decalin ring fusion.  
When conditions are found which generate the trans-decalin ring system this route will 
be an exceptionally facile route to the dihydroagarofuran tricyclic ring system. The remaining 
steps for the total synthesis consist of a directed reduction of the C-9 ketone and removal of the 
C-6 MOM ether. This sequence gives the triol analog of celafolin A-1. The remaining ester 
groups can be selectively installed, similar to previous work, since each hydroxyl group is in a 
unique steric environment.69 
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 3.4. Summary  
This body of work has shown that the trans-decalin skeleton (68) of the dihydro-
agarofuran natural products can be quickly synthesized from (R)-carvone in eight steps.69 A key 
aspect of the RCM route to the celafolin A-1 intermediate (68) is the tandem conjugate addition-
aldol reaction. This reaction creates the C-1 to C-10 bond and sets the C-1, C-9, and C-10 
stereocenters with excellent control. Although the overall yield is low, 7% for eight steps, this 
route is substantially shorter than previously published routes. In fact only two of the eight steps, 
the aldol addition and TfOH catalyzed etherification, are problematic. 
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Figure 59 RCM route to celafolin A-1 
 
In order to improve these two steps an intramolecular aldol route was designed. A four-
step sequence was used to construct the tetrahydrofuran precursor (77) in an acceptable 24% 
yield. There are two advantages associated with avoiding the thiophenol conjugate addition 
process. First, the oxygen at C-9 was already installed using this new route, since Pummerer 
reactions failed to provide this functional group previously. Secondly, an iodoetherification 
method was used to close the tetrahydrofuran C-ring. This reaction is milder than TfOH, but  
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Figure 60 The intramolecular aldol addition route 
 
could not be used in the two earlier routes due to the presence of the phenyl sulfide group. The 
phenyl sulfide group would readily oxidize in the presence of iodine. This two-step procedure 
utilized iodine and pyridine to close the tetrahydrofuran ring, then tributyltin hydride and AIBN 
to reduce the primary alkyl iodide. This sequence produced the desired [3.2.1] bicyclic ring 
system (78) in superior yield.  
The last challenge to address was how to improve the C1 to C10 bond forming aldol 
process. Our results have demonstrated that an intramolecular aldol reaction can substantially 
improve this process. The chemical efficiency of the intramolecular aldol process was excellent. 
Macromodel calculations (Figure 53) show that the trans-ring junction should be the 
thermodynamically preferred product, but initial experiments gave exclusively the kinetically 
preferred cis-decalin adducts. More conditions need to be explored for this step. If this 
conversion is possible, this may be the preferred route to the dihydroagarofuran natural products. 
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 4. Studies Directed Toward Bryostatin 1: A MDR Modulating Natural Product 
 
Tetrahydropyran (THP) rings are common structural elements present in numerous 
biologically active molecules such as: polyether antibiotics, marine toxins, pheromones, C-
glycosides71 and anti-tumor species such as bryostatin72 and phorboxazole73 (Figure 61). A 
variety of methods have emerged recently74-89 for the non-racemic construction of 2,6-cis-THP 
rings contained in these natural products.  
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Figure 61 Bioactive THP ring containing natural products 
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 A survey of recent publications shows that there are at least five common routes to 2,6-
cis-THP ring systems: hetero Diels-Alder reactions,74 SN2 type cyclizations,75 Claisen 
rearrangements,76 ring closing metathesis,77 and Prins cyclizations.78-84 Prins reactions have 
become a popular method for this transformation. However, many of these recent Prins methods 
require the use of strong acids to generate oxocarbenium ions via condensation of an alcohol and 
an aldehyde.80-84 Few examples exist where non-racemic THP ring systems are formed under 
mild conditions using relatively weak Lewis acids. 
A selection of recent methods for constructing non-racemic THP rings is shown in Figure 
62. The first method in Figure 62 is from Evans and coworkers synthesis of bryostatin 2.85 
Evans’ route to the bryostatin THP B ring utilized a sequence of aldol reactions to construct a 
β,δ-dihydroxy ester. When this substrate was exposed to trifluoroacetic acid (TFA), the desired 
lactone was formed in high yield. Evans then used a two-step sequence, organolithium addition 
and elimination, to convert this lactone into a 2,6-cis-THP ring. One year after Evans method 
was disclosed, Smith86 reported that the Petasis-Ferrier rearrangement87 could be used to 
synthesize chiral 2,6-cis-THP rings. Smith’s method utilizes dimethylaluminum chloride to 
ionize a vinyl acetal into an oxocarbenium ion and an aluminum enolate. The recombination of 
these two groups, via a chair transition state, results in the selective formation of a 2,6-cis-THP 
ring. Rychnovsky has also demonstrated that α-acetoxy ethers can be used to regioselctively 
generate oxocarbenium ions for Prins reactions.88 The major drawback associated with these 
three methods is that a strong Lewis acid is required to initiate THP ring formation.  
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Figure 62 Five routes to non-racemic 2,6-cis-THP rings  
 
In 2002, Keck reported a new catalytic asymmetric method for constructing allyl silane 
substrates for intramolecular Prins reactions.80 Keck’s method is attractive since it utilizes achiral 
starting materials and a chiral titanium binol catalyst (BITIP) to generate hydroxy-allyl silanes 
with high enantioselectivity. Finally, the hetero Diels-Alder reaction is also an important method 
for synthesizing chiral THP rings. A recent example is from Paterson’s total synthesis of (+)-
leucascandrolide A.74 Paterson was able to construct the C-1 to C-10 subunit of  (+)-
leucascandrolide A in greater than 95% enantiomeric purity using a hetero Diels-Alder reaction 
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 with a Jacobsen’s catalyst. This method is perhaps the mildest of the reactions shown in Figure 
62. 
 
4.1. A Mild Method for Constructing 2,6-cis-THP Rings 
During the course of our studies toward the synthesis of MDR modulating natural 
products, a new and exceptionally mild method for constructing 2,6-cis-THP rings was 
developed. Previous work in our laboratory (Figure 63) has shown that an intramolecular Prins 
reaction between an acetal and an allylic silane can be used to synthesize 2,6-cis-THP rings in 
high yield.79, 89 While it is well known that allylic silanes are excellent nucleophiles for trapping 
oxocarbenium ions,90-94 we have found that Prins reactions with allylic silanes can be carried out 
in aqueous media utilizing the Lewis acid surfactant catalysts Sc(SDS)3 95 or Ce(NO3)3 / SDS.79 
Our new method utilizes a cyclic acetal as an oxocarbenium ion precursor. This unique process 
generates a highly reactive oxocarbenium ion in an aqueous system under very mild conditions. 
  While we were developing new substrates for this method, we observed that silyl enol 
ethers were not as reactive towards cyclization compared to allylic silanes. Silyl enol ethers, 
under identical reaction conditions, routinely produced low yields of the desired Mukaiyama 
aldol96 products (Figure 63). Several experiments were attempted in order to optimize this 
reaction. Our observation was that conversion of tert-butyldimethylsilyl enol ethers to 
tetrahydropyranones was slow. Since prolonging the reaction time resulted in slow hydrolysis of 
the tert-butyldimethylsilyl enol ether, we predicted that a triisopropylsilyl enol ether might 
prevent hydrolysis. The triisopropylsilyl enol ethers were effective in preventing hydrolysis, but 
were now not reactive toward cyclization. The addition of more Lewis acid or more SDS also 
failed to improve conversions. Eventually, we discovered that simply replacing the aqueous  
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Figure 63 Aqueous Prins and Mukaiyama aldol conditions 
 
media with acetonitrile produced superior results. The desired Mukaiyama aldol reaction96 now 
proceeded to full conversion in one hour at ambient temperature using Ce(NO3)3, a very mild 
Lewis acid.  
Before Ce(NO3)3 was evaluated, we had previously screened other Lewis acids, including 
TiCl4 and TMSOTf, for this reaction but the lanthanide species Ce(NO3)3 produced the best 
results. There were also several other features associated with Ce(NO3)3 that made it a desirable 
Lewis acid. First, lanthanide metal complexes are known to undergo fast inner-sphere ligand 
exchange.97 This aspect of Ce(NO3)3 promotes turnover and prevents product inhibition at the 
catalytic metal center. Secondly, Ce(NO3)3 is non-corrosive, non-toxic and easy to handle, unlike 
TiCl4, TMSOTf, or BF3 etherate. Lastly, Ce(NO3)3 is easy to separate from the organic products 
and will not form troublesome emulsions. 
An interesting aspect of our cyclization reaction was the observation that regardless of 
nucleophile and acetal structure, 2,6-trans-THP or tetrahydropyranone rings were never isolated. 
The exclusive selectivity for 2,6-cis-THP or tetrahydropyranone products can be explained by 
examining a chair transition state model (Figure 64). In the initial oxocarbenium ion 
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 intermediate, and then in the Prins or Mukaiyama aldol reaction transition state, both substituents 
are preferentially in the pseudo-equatorial position. We believe this transition state produces the 
observed 2,6-cis stereochemical selectivity. 
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More importantly, side chain scrambling, which normally occurs during Prins reactions 
due to the troublesome oxonia-Cope rearrangement,82, 98 was not observed under our conditions 
(Figure 65). The oxonia-Cope rearrangement is less favorable in our substrates due to the 
stabilizing effect of the α,β-unsaturated acetal. Fragmentation of the acetal generates an 
oxocarbenium ion that will not easily undergo a [3,3] sigmatropic rearrangement. The 
rearrangement would produce a higher-energy oxocarbenium ion, preventing the formation 
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Figure 65 The oxonia-Cope rearrangement produces side chain scrambling 
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of the oxonia-Cope product (Figure 66). Encouraged by these results and our success with model 
systems (Figure 71), a new asymmetric route to the B-ring fragment (C-9 to C-19) of bryostatin 
1 was pursued. 
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Figure 66 An unfavorable [3,3]-rearrangement 
 
4.2. The Bryostatins: Isolation and Biological Activity 
In 1968 the first bryostatin, bryostatin 1, was isolated from the marine bryozoa Bugula 
neritina linnaeus.99 The structure of bryostatin 1 was first determined by Petit in 1982 using a 
combination of single crystal X-ray diffraction analysis, NMR, and high-resolution mass 
spectroscopy.100 Since then, over twenty new bryostatins have been discovered and fully 
characterized.101 
The bryostatins (Figure 67) are a family of potent anti-tumor agents. Bryostatin 1 exhibits 
powerful antineoplastic activity against murine P388 lymphocytic leukemia, B-cell lymphoma, 
reticulum cell sarcoma, ovarian carcinoma, and melanoma.101-103 Bryostatins have also been 
shown to promote T-cell production, stimulate the immune system, and activate protein kinase C 
(PKC).104 Bryostatin 1 has a remarkable affinity, in the picomolar range, for the phorbol ester 
binding site of PKC.105 
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Figure 67 Bryostatin family members 
 
Bryostatin 1 is capable of reversing P-gp dependent MDR in several human cancer cell 
lines.72 The exact mode of action for MDR reversal by bryostatin 1 is still unknown. Initially, 
bryostatin 1 was thought to reverse MDR by activating PKC. Researchers speculated that PKC 
activation reduces phosphorylation at P-gp, preventing P-gp pumping activity. However, recent 
studies have shown that bryostatin 1 does reduce phosphorylation of P-gp, but this does not 
cause MDR reversal.105 The currently accepted theory is that bryostatin 1 directly interacts with 
P-gp and prevents its pumping activity.72 
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 4.3. Previous Bryostatin Syntheses 
The first total synthesis of a bryostatin family member was reported in 1990 by 
Masamune and coworkers.107 Their synthesis of bryostatin 7 was the only total synthesis 
published until eight years later when Evans and coworkers85 reported their synthesis of 
bryostatin 2. Shortly thereafter, Nishiyama and Yamamura108 completed another family member, 
bryostatin 3, in 2000. Each of these three syntheses are extraordinarily long. The shortest route is 
Evans bryostatin 2 synthesis, which is over 40 steps counting only the longest linear sequence.85 
Due to the complexity of these natural products, other groups have begun to synthesize 
simplified analogs of the bryostatin family. Most notable is the work of Wender and coworkers 
(Figure 68).109-115 Their studies have led to the discovery of two simplified bryostatin-like 
macrolides. The activity of analog 1 is comparable to bryostatin 1 and analog 2 is significantly 
more potent than bryostatin 1 in binding to PKC and in inhibiting human cancer cell growth.113-
115 These fully synthetic analogs are currently in pre-clinical trials.114  
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Figure 68 Wender and coworkers bryostatin analogs 
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 4.4. A Model System for the Bryostatin B Ring 
In preparation for our synthesis of the bryostatin 1 B-ring, two model systems (90 and 91) 
were created to study and optimize the Mukaiyama aldol process shown in Figure 69. These two 
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Figure 69 An intramolecular Mukaiyama aldol reaction 
 
model systems (90 and 91) were utilized to investigate the role of the acetal group, the reactivity 
of the silyl enol ether, and also to test the effects of different solvents and additives. The 
syntheses of these two substrates are shown in Figure 70. 
 The first step in the preparation of our test substrates (90 and 91) was to construct the 
acetal portion of the model. The required 1,3-diol (85) was synthesized by an acetate aldol 
addition using the Weinreb amide116 of acetic acid (83). Treatment of the Weinreb amide at low 
temperature with LDA, followed by the addition of 3-(tert-butyldiphenylsilyl)-hydroxy 
propionaldehyde gave the β-hydroxy amide (84) in acceptable yield.79 Subsequent removal of 
the tert-butyldiphenylsilyl (TBDPS) ether gave the expected diol (85) in excellent yield. Initially, 
we attempted to synthesize the cyclic acetals (86 and 87) using anisaldehyde and trans-2-
heptenal. We found that when the diol (85), PPTS, and either of the two aldehydes were heated 
to reflux using a Dean-Stark trap, only a small amount of the desired products (86 and 87) were 
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 formed. A similar experiment was attempted using the diethyl acetals of anisaldehyde and trans-
2-heptenal. These experiments yielded only slightly better results. We suspect that the low 
reactivity of this diol (85) is due to the presence of the neighboring Weinreb amide group. There 
may be two strong hydrogen bonding interactions between the C-3 secondary alcohol and the 
Weinreb amide carbonyl oxygen, and also between the C-5 alcohol and the C-3 alcohol oxygen 
(Figure 70). This interaction may explain the difficulty encountered during cyclic acetal 
formation. 
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Figure 70 Mukaiyama aldol substrates 
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Ultimately, we found the best way to synthesize the cyclic acetals (86 and 87) was to dissolve the 
diol (85), PPTS, and the corresponding diethylacetal in benzene, and then heat the mixture until 
no further liquids distilled. We did not attempt to heat the diol (85) and a diethylacetal of an 
aldehyde in the absence of a solvent, since azeotropic distillation with benzene gave good results.  
A two-step process was then used to introduce the second element of our model, the silyl 
enol ether groups. Treatment of the Weinreb amides (86 and 87) with methyl lithium at low 
temperature provided the methyl ketones (88 and 89) in high yield.116 The remaining step was to 
convert the methyl ketones (88 and 89) to the desired silyl enol ethers (90 and 91). Exposure of 
the methyl ketones to tert-butyldimethylsilyl triflate (TBSOTf) and triethylamine gave the 
desired silyl enol ethers (90 and 91) in acceptable yield. The undesired tri-substituted 
regioisomers (90b and 91b), resulting from trapping the thermodynamically more stable enol 
ethers, were also isolated as major byproducts. There was no attempt was made to optimize this 
process since we were only interest in testing the Mukaiyama aldol reaction. 
The first cyclization conditions which we explored with the Mukaiyama aldol substrate 
(91) utilized two equivalents of Ce(NO3)3 and acetonitrile as solvent (conditions C in Figure 71). 
These conditions produced a white biphasic mixture due to the partial insolubility of Ce(NO3)3 in 
acetonitrile. We observed that this method produced very slow product conversion. After 16 
hours at 25 oC the reaction was quenched with a small amount of water and the desired product 
(93) was isolated in 53% yield. A trace amount of starting material (91), 8%, was recovered, but 
the remaining 39% of material could not be accounted for. We presumed that this missing 
material had undergone acetal cleavage and silyl enol ether hydrolysis to give the water-soluble 
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 byproduct, 4,6-dihydroxy-2-hexanone. This byproduct could have been easily lost during an 
aqueous workup.  
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Figure 71 Mukaiyama aldol optimization 
 
We suspected that during the Mukaiyama aldol cyclization there were competing 
processes occurring. One likely decomposition pathway could certainly be due to hydrolysis. 
This undesired process was likely due to the presence of trace amounts of water or nitric acid and 
prolonged reaction times. In an attempt to prevent hydrolysis, two additives were evaluated. 
First, an identical reaction was run using the heptenal acetal model (91) and solid NaHCO3 as a 
buffer. This additive had little affect on the conversion rate and the yield did not change 
appreciably. The second experiment was to try molecular sieves as an additive (conditions B in 
Figure 71). The use of molecular sieves resulted in an increase in yield, but the reaction 
conversion was still relatively slow. Next, we tried replacing the solvent acetonitrile with 
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 methylene chloride. This change completely inhibited all reactivity and only the starting material 
(91) was recovered after stirring for sixteen hours. This result suggested that a solvent with a 
high dielectric constant might be required to facilitate oxocarbenium ion formation.  
The second anisaldehyde acetal test substrate (90) was also subjected to a similar series 
of experiments. We found that when this aromatic acetal (90) was treated with Ce(NO3)3 in 
acetonitrile only 23% of the desired product was isolated. The addition of NaHCO3 had little 
effect. When molecular sieves were added, the yield increased to 44% and a small amount of 
starting material was recovered using these conditions. The low yields observed during both of 
these experiments with the anisaldehyde acetal (91) were definitely caused by acetal hydrolysis. 
In this case, acetal hydrolysis was confirmed by the presence of anisaldehyde during TLC 
analysis.  
It became apparent to us that using additives to slow hydrolysis was probably not the 
most effective way to improve the yield of the Mukaiyama aldol reaction. We realized that if 
hydrolysis could not be slowed, we needed to find conditions that would increase the rate of the 
desired reaction instead. The simplest way to increase the rate of the Mukaiyama aldol addition 
was to use more Ce(NO3)3. This change produced excellent results (conditions A in Figure 71).  
When four equivalents of Ce(NO3)3 were used, the Mukaiyama aldol addition proceeded to 
100% conversion in under one hour at room temperature. These conditions (Figure 71) gave the 
expected product (93) in 93 % yield, a substantial improvement. In a subsequent reaction, the 
less reactive anisaldehyde acetal substrate (90) was evaluated with these new conditions. When 
four equivalents of Ce(NO3)3 were used with the aromatic acetal (90), a dramatic increase in 
yield was also observed. The desired Mukaiyama aldol reaction now proceeded to 100% 
conversion, and the product (92) was isolated in 81% yield. This slightly lower yield was 
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 acceptable considering the improvement from 44% yield using two equivalents of Ce(NO3)3 and 
molecular sieves.  
Overall, we were quite satisfied with these results. Our optimized conditions substantially 
improved product conversions in both model systems (90 and 91) and dramatically decreased the 
reaction times as well, from sixteen hours to one hour (Figure 72). 
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Figure 72 Optimized Mukaiyama aldol reactions 
 
We had good reason to believe that the Mukaiyama aldol reaction would yield 
exclusively 2,6-cis-tetrahydropyranone products, based on our Prins reaction model (Figure 64).  
In order to confirm the 2,6-cis- relationship, the relative stereochemistry of the 
tetrahydropyranone ring was established using H,H COSY and  2D NOESY experiments.  
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The H,H-COSY experiment was not absolutely necessary for differentiating the C-2 and C-6 
methine hydrogens. Coupling constant analysis alone could be used to confirm this. The purpose 
of the H,H-COSY was to distinguish normally coupled peaks from the peaks in the NOESY 
spectrum. This comparison revealed a strong cross peak in the NOESY spectrum corresponding 
to the methine hydrogens at C-2 and C-6 (Figure 73). This strong signal, which was also present 
in the NOESY spectrum of the 2,6-cis-THP Prins reaction products, supports the assigned 2,6-
cis-tetrahydropyranone stereochemistry.  
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Figure 73 NOESY results for (93) 
 
In addition to these two model systems (90 and 91), a saturated acetal and a phenyl acetal 
were also evaluated (Figure 74). We found that both of these substrates failed to react under all 
of our conditions. The lack of reactivity of the saturated acetal was not surprising, since there is 
no group to stabilize the oxocarbenium ion intermediate. The failure of the phenyl acetal was not 
expected, but also not surprising considering the lowered reactivity of the anisaldehyde acetal 
(91) compared to the heptenal acetal (90).  
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Figure 74 Failed Cyclization Reactions 
 
Our model systems revealed that the nature of the acetal was a crucial component for 
reactivity. During our study we discovered that only electron rich aromatic or α,β-unsaturated 
acetals were reactive enough toward Ce(NO3)3 to generate the required oxocarbenium ion. We 
also observed a significant solvent dependence for this Mukaiyama aldol reaction. One 
interesting result showed that when methylene chloride was used as solvent, no reaction occurred 
and starting materials were recovered in near quantitative yield. This discovery corresponds to 
our previous result when this reaction was evaluated inside of a SDS micelle. The micelle and 
methylene chloride are both relatively non-polar environments, which do not promote 
oxocarbenium ion formation. Acetonitrile, having a substantially higher dielectric constant, must 
facilitate oxocarbenium ion formation. However, we can not rule out the possibility that the 
solubility of Ce(NO3)3 in methylene chloride compared to acetonitrile may also explain the 
difference in reactivity.  
At this point in the project, we were satisfied with our optimized Mukaiyama aldol 
reaction conditions. Our next challenge was to apply this method, in an asymmetric manner, to 
the synthesis of the complex macrolide bryostatin 1. The following section of this chapter will 
demonstrate the utility of this method in preparing the B ring fragment of Bryostatin 1. 
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 4.5. Enantioselective Preparation of the B Ring of Bryostatin 1 
Our disconnections for the bryostatin 1 B ring (Figure 75) were chosen to allow for the 
construction of the C-14 to C-15 bond (bryostatin numbering) using our Ce(NO3)3 mediated 
Mukaiyama aldol process. Following this aldol reaction, we envisioned that the C-13 ketone 
could be converted to the required α,β-unsaturated methyl ester by utilizing a Horner-Emmons 
reaction. Our planned disconnections show that the tetrahydropyranone ring can be synthesized  
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Figure 75 Retrosynthesis of the bryostatin 1 B ring 
 
in two steps from an appropriate methyl ketone. In order to introduce this ketone, a Wacker 
oxidation117 can be used to regioselctively convert the terminal olefin into the required methyl 
ketone. The enantiomerically enriched 1,3-dioxane ring can be synthesized via an asymmetric 
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 allylation of a propionaldehyde derivative using Brown’s pinene derived chiral allyl borane 
reagent.118 
Our synthesis of the bryostatin1 B ring began with the TIPS ether of 3-hydroxy 
propionaldehyde (94), which was synthesized by a modification of a known procedure for the 
corresponding TBDPS ether.79 The (-)-allyl-B(Ipc)2 reagent was prepared by Brown’s method 
using (+)-α-pinene.119  We found that treatment of the propionaldehyde analog (94) with 
Brown’s allyl borane reagent, followed by an alkaline oxidative workup provided the desired 
homoallylic alcohol (95) in excellent yield (Figure 76). The enantiomeric excess of the allylation 
product (95) was determined by preparing a UV-active benzoate ester (96). The benzoate ester 
chromaphore was required since the enantiomers in question were to be separated using a chiral 
column and a HPLC instrument with a UV detector. A racemic sample, for comparison purposes, 
was prepared exactly as in Figure 76 by using allyl magnesium bromide instead of Brown’s  
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Reagents and conditions: a) (-)-Allyl-B(Ipc)2, Et2O, -78 to 25 oC, then H2O2, NaOH, reflux, 90%. b) BzCl, 
pyridine, CH2Cl2, 2 hr, 85%. c) TBAF, THF, 1 hr, 70%. d) TBAF, THF, 90 min, 92%. 
Figure 76 Asymmetric allylation 
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 reagent. Multiple HPLC experiments were attempted using a Chiracel ODH column, but the 
benzoate ester enantiomers (96) could not be separated. This separation was difficult because the 
Chiracel ODH column is a normal phase HPLC column. The non-polar benzoate ester (96) 
traveled too quickly through the stationary phase and separation could not be achieved. 
This problem was easily remedied by removing the TIPS protecting group using TBAF, 
providing the primary alcohol derivative (97). This time, the new benzoate ester enantiomers 
(97) separated into two resolved peaks using the same chiral HPLC column. Our HPLC 
experiment determined the enantiomeric excess to be 78%. This result is slightly low, but not 
surprising since the difference in size between the methylene group and the aldehyde hydrogen is 
not relatively large for this propionaldehyde derivative (94). The two possible transition states 
for the (-)-allyl-B(Ipc)2 additions are shown in Figure 77. The low enantiomeric excess could be 
the result of the disfavored transition state or it could be due to the quality of the chiral borane 
reagent. 
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Figure 77 Asymmetric allylation transition states 
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 The next step of our synthesis was to address the construction of the cyclic acetal. This 
required the synthesis of the known aldehyde, trans-4,4-dimethylpent-2-enal (100). We were 
able to prepare this aldehyde in one step, from the corresponding allylic alcohol precursor 
(99),120 using a Dess-Martin periodinane oxidation47 (Figure 78). When the chiral 1,3-diol (98) 
was exposed to trans-4,4-dimethylpent-2-enal (100) and catalytic PPTS, under reflux conditions, 
the desired cyclic acetal (101) was formed in excellent yield.  
A Wacker oxidation117 was then employed to selectively oxidize the mono-substituted 
olefin in the presence of the newly introduced di-substituted olefin. We were not concerned with 
the selectivity of the Wacker oxidation for two reasons. First, Wacker oxidations with sterically  
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Reagents and conditions: a) DMPI, NaHCO3, CH2Cl2, 25 oC, 99%. b) Diol 79, PPTS, C6H6, 110 oC, 91%. c) PdCl2, 
CuCl2, Li2CO3, THF, H2O, O2, 25 oC, 79%. d) TBSOTf, Et3N, CH2Cl2, -78 to 25 oC, 63% (84), 20% tri-substituted 
enol ether isomer. e) 4 equiv. Ce(NO3)3, CH3CN, 25 oC; then TBAF, 70%. f) TBSCl, imidazole, CH2Cl2, 25 oC, 
92%. g) trimethylphosphonoacetate, THF, NaHMDS, 0 oC; then (86), 90%, E:Z = 1:1.  
Figure 78 Bryostatin 1 B ring synthesis 
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 encumbered olefins are usually slow.117 This sensitivity arises from steric repulsions between the 
palladium complex and the olefin as the metal coordinates to the olefin’s pi system. Palladium 
coordination with an olefin containing a tert-butyl group is not highly favorable. The second 
reason is that Wacker oxidations exhibit a high degree of regioselectivity, generally oxidizing the 
more electron rich carbon atom in the most electron rich olefin, if the option exists.117 The most 
electron rich carbon atom is preferentially oxidized since it bears more of the positive charge 
during complexation to the electrophilic palladium species. This method provides a convenient 
way to synthesize methyl ketones from terminal olefins in the presence of less reactive olefins. 
However, a significant drawback to the Wacker oxidation is the generation of HCl from 
CuCl2 and PdCl2 during the reaction. When the standard Wacker conditions117 were employed, 
the acetal group (101) was cleaved quantitatively in less than 1 hour. We found that the addition 
of a buffer, such as Li2CO3, could alleviate this problem. However, buffering a Wacker oxidation 
raises the pH and can cause palladium metal to precipitate from the reaction, removing the 
catalyst and preventing oxidation. Conditions were eventually found, utilizing Li2CO3 and 
periodic additions of fresh PdCl2, which minimized both problems associated with high and low 
pH.  
The methyl ketone (102) was then converted to the silyl enol ether using TBSOTf and 
Et3N at low temperature. This gave the desired product (103) in good yield along with a small 
amount of the undesired tri-substituted enol ether. Exposure of this silyl enol ether (103) to 
Ce(NO3)3 in acetonitrile, followed by a TBAF quench, and then an aqueous workup gave the 
tetrahydropyranone product (104) as a single isomer. The formation of a single product is 
consistent with the Zimmerman-Traxler transition state model (Figure 79). We attempted to 
verify the 2,6-cis-stereochemistry in the Mukaiyama aldol adduct (104), but the H,H-COSY 
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Figure 79 Transition state for the Mukaiyama aldol 
 
spectrum did not provide enough information. We found that the C-10, C-12, and C-14 
methylene groups (bryostatin numbering) could not be differentiated. This prevented us from 
positively identifying the C-11 and C-15 methine protons. 
In an attempt to circumvent this problem, the C-9 primary hydroxyl group was protected 
as a TBS ether (105). This conversion produced a downfield shift at the C-9 methine and the C-
10 methylene groups. This caused the C-10 and C-12 methylene signals to separate just enough 
to distinguish two coupling patterns in the 1H NMR. When the TBS ether derivative (105) was 
characterized using an H,H-COSY experiment, each of the protons were positively assigned. The 
2,6-cis stereochemistry was then verified using a 2D NOESY experiment. The NOESY spectrum 
revealed a strong cross peak between the C-11 and C-15 methine protons (Figure 80).  
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Figure 80 NOESY for tetrahydropyranone (105) 
 
98 
 This indicates a syn-relationship at the C-11 and C-15 methine positions. 
In order to complete the B ring of bryostatin 1, the C-13 ketone in the tetrahydropyranone 
substrate (105) needs to be selectively converted to the (Z)-α,β-unsaturated methyl ester (106). 
When the phosphonate derived from trimethylphosphonoacetate and NaHMDS was added to this 
ketone (105), an inseparable 1:1 mixture of E and Z isomers was obtained. Interestingly, the 1H 
NMR resembled a single product, but examination of the 13C NMR spectrum clearly confirmed 
the presence of two isomers. Separation difficulties with similar tetrahydropyran ring systems 
have also been encountered in previous bryostatin syntheses.85, 121-122 The best solution to this 
problem would be to use a chiral phosphonate to improve selectivity. Evans has demonstrated 
that the asymmetric Horner-Emmons method developed by Fuji and coworkers123-124 will give 
the desired selectivity in a related system (Figure 81).85 Fuji’s method utilizes a chiral binol-
derived phosphonate to control the stereochemical outcome of the Horner-Emmons reaction. 
Future work should evaluate if this reagent will give the desired result for this ketone (105). 
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Figure 81 Evans' application of Fuji's binol phosphonate reagent 
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 4.6. Summary 
We have demonstrated that an intramolecular Mukaiyama aldol reaction can be used to 
selectively synthesize chiral 2,6-cis-tetrahydropyranones (Figure 82). The substrates for this 
reaction can be readily prepared, in a convergent manner, from achiral aldehydes and chiral 
diols.  
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Figure 82 A convergent preparation of Mukaiyama aldol precursors 
 
The major advantage of our new method is the especially mild conditions used to 
generate oxocarbenium ions from acetals. These conditions utilize Ce(NO3)3, a commercially 
available, inexpensive, and non-toxic Lewis acid. Additionally, this method is attractive given 
that cyclic acetals are utilized as oxocarbenium ion precursors. This is a particularly important 
feature for complex molecule syntheses, since acetals can be made using very mild 
procedures.125 
 To demonstrate the utility of this method, the C-9 to C-19 fragment, or B ring, of 
bryostatin 1 was synthesized. The 2,6-cis-tetrahydropyranone ring (104) was synthesized in four 
steps (Figure 83), from a known diol (98),126 in an overall yield of 42%. Initial experiments 
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Figure 83 A brief route to the C-9 to C-19 fragment of bryostatin 1 
 
demonstrated that the C-13 ketone could be converted to the required α,β-unsaturated methyl 
ester in high yield, but as an inseparable mixture of diastereomers. The stereoselective 
introduction of this exocyclic ester has previously been addressed by the Evans85, 121 and the 
Hoffmann122 groups, therefore we did not pursued this transformation further.  
One improvement to be addressed in the future is how to increase the enantiomeric 
excess of the 1,3-diol starting materials. For our purpose, a 78% ee was acceptable, but in a total 
synthesis this would not be ideal. Additional boron allylation procedures should be evaluated to 
see if the enantiomeric purity of the starting materials could be improved.  
The Wacker oxidation117 is a superb method for generating methyl ketones from terminal 
olefins. In our case, difficulties were encountered when the pH became too acidic due to the 
presence of the acid labile acetal group. Attempting to buffer the Wacker oxidation with Li2CO3 
causes precipitation of palladium metal, which effectively removes the catalyst from the reaction. 
An interesting experiment would be to replace PdCl2 and CuCl2 with Pd(OAc)2 and Cu(OAc)2, 
since the use of the acetate salts would generate acetic acid in the catalytic cycle instead of HCl. 
Acetic acid (pKa = 4.8) is a substantially weaker acid compared to HCl (pKa = -8.0) and may 
prevent acetal hydrolysis. The amount of palladium needed to achieve good conversions would 
also be reduced if no buffer were added, since this would prevent palladium metal precipitation.  
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 Furthermore, the application of this method for constructing other tetrahydropyran rings, 
with complex substitution patterns, needs to be investigated. We expect that this approach can be 
easily adapted to synthesize similar natural products, such as (+) phorboxazole A or (+) 
dactylolide. The macrolide (+) phorboxazole A127 (Figure 84) contains a persubstituted THP ring 
that can be constructed from a silyl enol ether (107), making it a suitable candidate for this 
Mukaiyama aldol method. 
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Figure 84 C-20 to C-29 fragment of (+) phorboxazole A  
 
 
The required silyl enol ether (107) can be synthesized in high enantiomeric purity by a 
number of asymmetric aldol methods. For example, a chiral oxazolidinone128 and Paterson’s 
boron enolate method129 can be used to create the 1,2-anti-stereochemical relationship. This 
strategy would produce the (+) phorboxazole A fragment in an exceptionally short sequence.  
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 Experimental Procedures 
 
General Procedures. THF and Et2O were dried by distillation over Na/benzophenone ketyl 
under N2. Alternatively, anhydrous, non-stabilized, THF and Et2O were purchased from Aldrich 
in sure-pack™ drums. Using this method, solvents were dried by passing through a cylinder of 
activated Al2O3 immediately before use. Benzene and CH2Cl2 were dried by distillation over 
CaH2. All reagents were used as received unless otherwise noted. Ce(NO3)3 heptahydrate was 
dried under high vacuum at 80 oC for 24 hours, then pulverized using a mortar and pestle. This 
fine white powder was dried for another 12 hours at 80 oC under high vacuum. Column/Flash 
Chromatography was performed using ICN Silitech 32-63 D (60 Å) grade silica gel. Thin layer 
chromatography was performed using plates from EM Science (silica gel 60 F254 / 250 µm 
thickness). NMR experiments were preformed using Bruker 300 and 500 MHz instruments. IR 
spectra were recorded on a Matheson FT-IR. Mass Spectrum were obtained using a VG high 
resolution MS. Chemical shifts (δ) are reported in ppm relative to TMS. All reactions were 
carried out under a nitrogen atmosphere using thoroughly dried glassware unless otherwise 
noted.  
 
Rubottom oxidation of (R)-(-)-Carvone:  O
OH
O
OH
6-Hydroxy-5-isopropenyl-2-methyl-cyclohex-2-enones (31a and 31b) 
TMSCl was purified by distillation over Na2CO3 under a nitrogen atmosphere. m-CPBA was 
purified  by dissolving 77% commercially available m-CPBA in CH2Cl2, then washing the 
organic layer three times with a dibasic sodium phosphate solution adjusted to pH 7.4. The 
organic layer was then dried over MgSO4, filtered, and solvents removed in vacuo. The slightly 
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 yellow crystals were then recrystallized from hexanes and stored in a plastic bottle in a –20 °C 
freezer until use. TLC plates were deactivated prior to use by dipping into a solution 3% Et3N in 
hexanes, then drying. 
To a flask equipped with a Claisen adapter, rubber septum, and N2 adapter was added dry (i-
Pr)2NH (12.35 g, 121.7 mmol) and THF (60 mL). The vessel was cooled to -40 °C and n-BuLi 
(1.6M hexanes, 76.1 mL, 121.7 mmol) was added. The reaction was warmed to 0 °C for 30 
minutes, then cooled to -78 °C and diluted with THF (100 mL). A solution of (R)-(-)-carvone 
(15.0 g, 98.5 mmol) in THF (85 mL) was prepared added by cannula to the LDA solution at -78 
°C. This was stirred at -78 °C for 60 minutes, and then quenched at -78 °C by adding TMSCl 
(21.4 g, 197.1 mmol). The reaction was allowed to warm to ambient temperature and stirred 
there for an additional 60 minutes. TLC analysis (deactivated with Et3N, 15:85 EtOAc:Hexanes) 
showed the silyl enol-ether at Rf = 0.82. The reaction mixture was then concentrated by rotovap. 
Some celite was added and the slurry was taken up in pentanes and filtered through a pad of 
celite. Pentanes were then used to rinse the solids and the solvents were removed by rotovap to 
give the crude TMS enol ether (29) as a viscous yellow oil. The crude silyl enol-ether was placed 
in a dry flask equipped with a claisen adapter, rubber septum, and an addition funnel. CH2Cl2 
(450 mL) and solid NaHCO3 were added and the vessel was cooled to 0 °C. A solution of m-
CPBA (21.0 g, 121.7 mmol) in CH2Cl2 (200 mL) was added drop wise via addition funnel, and 
when complete, the reaction was warmed to ambient temperature and stirred there for 45 
minutes. Then the reaction mixture was filtered through a pad of celite to remove the solids and 
the filtrate was concentrated in vacuo. The resulting green slurry was taken up in pentanes and 
again filtered through celite to remove more solids. Removal of solvents this time afforded a 
yellow oil free of solids. Both diastereomers of the hydroxy ketone (31a) and (31b) as well as 
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 both diastereomers of the desired silyl ether (30a) and (30b) were detected by GC analysis. The 
crude silyl ethers were directly converted to the hydroxy ketone by treatment with HF/MeOH. 
 
 6-Hydroxy-5-isopropenyl-2-methyl-cyclohex-2-enones (31a) and (31b) 
To a stirred solution of (30) and (31) (8.01 g, 33.4 mmol) in MeOH (75 mL) at 25 °C was added 
48% aq. HF (2.17 mL, 62.7 mmol). The reaction was monitored by GC and/or TLC. After 40 
minutes the reaction was complete. The reaction was carefully neutralized by adding solid 
NaHCO3, and then H2O followed by EtOAc (60 mL). The layers were separated and the aqueous 
layer extracted with EtOAc (5x50 mL). The organic layer was dried over MgSO4, filtered, and 
solvents removed in vacuo. This gives a yellow/green oil as the crude products which were 
purified by column chromatography (20:80 EtOAc:Hexanes) to give a 2:1 ratio of 
anti(31b):syn(31a) diastereomers (1.48 g , 27%) and (3.27 g, 59%). Overall yield from (R)-
carvone is 63%. 
6(R)-Hydroxy-5(S)-isopropenyl-2-methyl-cyclohex-2-enone (31a) 
1H NMR (300 MHz, CDCl3) δ 6.65 (t, J = 0.8 Hz, 1H), 4.82 (s, 1H), 4.68 (s, 1H), 4.39 (d, J = 5.8 
Hz, 1H), 3.63 (s, 1H), 3.15 (s, 1H), 2.74-2.47 (m, 3H), 1.80 (s, 3H), 1.66 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 199.8, 144.2, 143.1, 133.8, 113.8, 74.7, 46.9, 29.7, 23.1, 15.3; IR (neat) 3483, 
3055, 2976, 2924, 1674, 1670, 1450, 1360, 1265, 1189, 1134, 1030, 900, 738 cm-1; HRMS (EI) 
m/z calc for C10H14O2 (M)+ 166.0993, found 166.0996; [α]D23  –30.5 o (MeOH, c 1.0). 
6(S)-Hydroxy-5(S)-isopropenyl-2-methyl-cyclohex-2-enone (31b) 
1H NMR (300 MHz, CDCl3) δ 6.77 (t, J = 1.7 Hz, 1H), 4.95-4.96 (m, 2H), 4.17 (d, J = 12.7 Hz, 
1H), 3.80 (s, 1H), 2.74-2.2.67 (m, 1H), 2.49-2.42 (m, 2H), 1.86 (s, 6H); 13C NMR (75 MHz, 
CDCl3) δ 200.7, 145.7, 144.3, 133.2, 113.7, 74.5, 51.2, 30.8, 18.9, 15.4; IR (thin film) 3483, 
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 3056, 2976, 2925, 1674, 1647, 1437, 1373, 1266, 1138, 1045, 898, 734 cm-1; HRMS (EI) m/z 
calc for C10H14O2 (M)+ 166.0993, found 166.0990; [α]D23  -10.5 o (MeOH, c 1.0). 
 
5(S)-Isopropenyl-6(R)-methoxymethoxy-2-methyl-cyclohex-2-enone (32a) 
and 5(S)-Isopropenyl-6(S)-methoxymethoxy-2-methyl-cyclohex-2-enone and (32b) 
O
OMOM
O
OMOM
To a flask equipped with a reflux condenser and N2 adapter were added a mixture of 
diastereomers of (31) (4.75 g, 28.58 mmol), diisopropylethylamine (25 mL), DMAP (100 mg), 
and chloromethyl methylether (5.76 g, 71.44 mmol). The reaction was heated to 40 °C and after 
15 hours was complete. The reaction was cooled to ambient temperature and then quenched with 
NH4Cl(aq. sat.) (10 mL). The mixture was transferred to a separatory funnel using EtOAc (50 mL) 
and an additional amount of aq. sat. NH4Cl (60 mL) was added. The layers were then separated 
and the aqueous layer extracted with EtOAc (5x40 mL). The combined organic layers were the 
washed with dilute HCl(aq.) (25 mL), then with brine (2x50 mL), dried over MgSO4, filtered, and 
solvents removed in vacuo. This gave a yellow oil as the crude products which were then 
purified by column chromatography (15:85 EtOAc: Hexanes, Rf = 0.31 anti (32b), Rf = 0.38 syn 
(32a)) to give the desired compounds (5.05g, 84%) anti (32b) and (901 mg, 15%) syn (32a) as 
slightly yellow oils. 
5(S)-Isopropenyl-6(R)-methoxymethoxy-2-methyl-cyclohex-2-enone (32a) 
1H NMR (300MHz, CDCl3) δ 6.69 (t, J = 2.3 Hz, 1H), 4.89 (s, 1H), 4.80 (s, 1H), 4.67 (d, J = 6.7 
Hz, 1H), 4.65 (d, J = 6.7 Hz, 1H), 4.09 (d, J = 2.2 Hz, 1H), 3.24 (s, 3H), 2.66-2.63 (m, 2H), 2.33-
2.26 (m, 1H), 1.75 (s, 3H), 1.74 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 197.3, 144.8, 143.7, 
133.4, 112.9, 95.5, 76.9, 55.8, 46.6, 27.2, 22.2, 15.8; IR (thin film) 3087, 2925, 2847, 1674, 
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 1641, 1451, 1373, 1152, 1125, 1029, 922, 898, 842 cm-1; LRMS (CI / CH4) m/z calc for 
C12H18O3 (M+H)+ 211, found 211; [α]D23 +55.3 o (MeOH, c 1.0). 
5(S)-Isopropenyl-6(S)-methoxymethoxy-2-methyl-cyclohex-2-enone (32b) 
1H NMR (300 MHz, CDCl3) δ 6.69-6.67 (m, 1H), 4.91 (s, 2H), 4.93 (d, J = 7.1 Hz, 2H), 4.74 (d, 
J = 71. Hz, 1H), 4.18 (d, J = 12.1 Hz, 1H), 3.39 (s, 3H), 2.89-2.83 (m, 1H), 2.53-2.35 (m, 2H), 
1.83 (s, 3H), 1.81 (d, J = 0.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 198.9, 144.2, 143.6, 134.6, 
113.7, 97.0, 78.8, 56.0, 49.5, 30.7, 19.2, 15.6; IR (thin film) 3024, 2955, 2897, 1683, 1647, 1440, 
1381, 1267, 1151, 1076, 1032, 918, 899, 738 cm-1; HRMS (EI) m/z calc for C11H15O2 (M-
CH3O)+ 179.1072, found 179.1070; [α]D23  –110.0 o (MeOH, c 1.0). 
 
5(S)-Isopropenyl-6(R)-methoxymethoxy-2-methyl-cyclohex-2-enone (32a) 
To a flask containing diisopropylamine (1.11 g, 11.0 mmol) and THF (10 mL) was added n-BuLi 
(6.88 mL, 11.0 mmol) at -50 °C. The reaction was warmed to 0 °C and stirred for 30 min under 
N2. Then the LDA solution was cooled to -78 °C and a solution of (32b) (2.1 g, 10.0 mmol) in 
THF (40 mL) was added. The reaction was stirred at -78 °C for 30 minutes and then quenched at 
-78 °C with glacial acetic acid (1.80 g, 30.0 mmol), then warmed to ambient temperature. The 
reaction mixture was poured into a separatory funnel and washed with NaHCO3 (aq. sat.) (2x15 
mL), and then with brine (2x15 mL). The organic layers were dried over MgSO4, filtered, and 
solvents removed in vacuo. This gave the crude products as yellowish oil. The syn and anti 
diastereomers were then separated by column chromatography (15:85 EtOAc:Hexanes, Rf = 0.38 
syn (32a), Rf = 0.31 anti (32b)) to give the desired product (32a) (1.45 g, 69%) and recovered 
starting material (32b) (484 mg, 23%). 
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  2(R)-(1(R,S)-Hydroxy-4-trimethylsilyl-pent-3-enyl)-5(S)-
isopropenyl-6(R)-methoxymethoxy-2(R)-methyl-3(R)-
phenylsulfanyl-cyclohexanone (35 and 36) 
O
O O
PhS
OH
SiMe3
O
O O
PhS
OH
SiMe3
To a flask cooled to 0 °C was added thiophenol (53.7 mg, 0.48 mmol), CH2Cl2 (1.0 mL), and 
then AlMe3 (2M hexanes, 0.48 mL, 0.96 mmol). This solution was then stirred at 0 °C for 35 
minutes then cooled to -50 °C and a solution of (32a) (100 mg, 0.48 mmol) in CH2Cl2 (1.0 mL) 
was added. Stirring was continued for 5 hours at -50 °C. TLC (15:85 EtOAc:Hexanes) can be 
used to monitor the 1,4 addition. After stirring for 5 hours, the reaction was diluted with THF 
(1.0 mL) and a solution of 4-trimethylsilyl-pent-3-enal (34) (170 mg, 0.96 mmol) in THF (1.0 
mL) was added. After stirring for another 5 hours at -50 °C the reaction was diluted with EtOAc 
(5 mL) and quenched with aq. sat. NaK tartrate (3 mL). The mixture was allowed to warm to 25 
°C and stirred until two layers separated from the aluminum emulsion. The aqueous layer 
extracted with EtOAc (3x10 mL). The combined organic layers were then washed with aq. sat. 
NaHCO3 and brine, dried over Na2SO4, filtered, and solvents removed in vacuo. The two 
diastereomers of the product were then purified by column chromatography (15:85 
EtOAc:Hexanes) to give a 2:1 mixture of diastereomers (58.1 mg, 25%). The enone starting 
material (32a) was also recovered (74.2 mg, 74.2%). Major diastereomer (35): 1H NMR (300 
MHz, CDCl3) δ 7.40-7.26 (m, 5H), 5.75-5.78 (m, 1H), 5.01 (s, 1H), 4.81 (s, 1H), 4.66 (s, 2H), 
4.46 (d, J =5.5 Hz, 1H), 4.01-4.04 (m, 1H), 3.58 (dd, J = 4.0, 11.2 Hz, 1H), 3.35 (s, 3H), 2.99 (d, 
J = 4.6 Hz, 1H), 2.39-2.18 (m, 5H), 1.62 (s, 3H), 1.57 (s, 3H), 1.48 (s, 3H), 0.05 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 213.0, 141.4, 138.4, 136.0, 134.7, 132.6, 132.4, 129.4, 127.7, 114.9, 
95.8, 78.0, 75.6, 56.8, 56.1, 49.6, 45.9, 31.4, 30.7, 22.6, 18.7, 14.9, -1.9; IR (thin film) 3437, 
3004, 2954, 1706, 1648, 1618, 1584, 1439, 1247, 1154, 1018, 837, 746, 691 cm-1; HRMS (EI) 
m/z calc for C26H40O4SiS (M)+ 476.2416, found 476.2406. Minor diastereomer (36): 1H NMR 
(300 MHz, CDCl3) δ 7.51-7.42 (m, 5H), 5.89 (t, J = 1.7 Hz, 1H), 4.96 (s, 1H), 4.80 (s, 1H), 4.74-
4.66 (dd, J = 6.9, 19.6 Hz, 2H), 4.48 (d, J = 5.5 Hz, 1H), 4.29-4.26 (m, 1H), 3.87 (dd, J = 4.0, 
10.4 Hz, 1H), 3.36 (s, 3H), 3.01 (d, J = 5.2 Hz, 1H), 2.63-2.50 (m, 1H), 2.41-2.27 (m, 3H), 2.22-
2.17 (m, 1H), 1.71 (s, 3H), 1.56-1.54 (m, 3H), 1.34 (s, 3H), 0.07 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 210.1, 141.6, 138.7, 136.1, 134.4, 132.3, 129.4, 129.2, 127.7, 114.7, 96.2, 79.0, 74.4, 
57.2, 56.1, 50.0, 45.8, 32.2, 30.2, 29.9, 22.7, 17.5, 15.0, -1.9; IR (thin film) 3477, 3002, 2953, 
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 1714, 1439, 1152, 1023, 837, 739 cm-1; HRMS (EI) m/z calc for C26H40O4SiS (M)+ 476.2416, 
found 476.2426. 
 
  
 General procedure for NaBH(OAc)3 directed reduction: 
Syntheses of 2(R)-(1(S)-Hydroxy-4-trimethylsilyl-pent-3-
enyl)-5(S)–isopropenyl-6(R)-methoxymethoxy-2(R)-methyl-
3(R)-phenylsulfanyl-1(R)-cyclohexanol (37) and 2(R)-(1(R)-Hydroxy-4-trimethylsilyl-pent-
3-enyl)-5(S)–isopropenyl-6(R)-methoxymethoxy-2(R)-methyl-3(R)-phenylsulfanyl-1(R)-
cyclohexanol (39). 
OH
O O
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OH
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To a flask containing NaBH4 (129 mg, 3.4 mmol) was added glacial acetic acid (4.0 mL) at 0 °C. 
The mixture stirred until bubbling subsided. A solution of (35 or 36) (160 mg, 0.34 mmol) in 
CH2Cl2 (1.0 mL) was then added and the reaction warmed to 25 °C. After 2.5 hours the reaction 
was quenched using aq. sat. NaHCO3. The reaction was then extracted with Et2O (4x10 mL), and 
then washed with aq. sat. NaHCO3 and brine. The ether layer was then dried over Na2SO4, 
filtered, and solvents removed in vacuo. The product was then purified by column 
chromatography (20:80 EtOAc:Hexanes) to give the desired product as a colorless oil. Diol 
adduct (37) from the major aldol diastereomer: (49.7%) 1H NMR (300 MHz, CDCl3) δ 7.37-7.22 
(m, 5H), 5.82 (t, J = 1.3 Hz, 1H), 5.02 (d, J = 17.0 Hz, 2H), 4.72 (s, 2H), 4.39 (d, J = 9.9 Hz, 
1H), 4.06 (dd, J = 3.0, 9.6 Hz, 1H), 3.80 (dd, J = 5.9, 9.9 Hz, 1H), 3.39 (s, 3H), 3.20-3.24 (m, 
2H), 2.78-2.80 (m, 1H), 2.40-2.45 (m, 2H), 2.00-2.03 (m, 3H), 1.68 (s, 3H), 1.58 (s, 3H), 1.30 (s, 
3H), 0.05 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 142.9, 140.1, 135.4, 131.8, 129.3, 127.2, 114.7, 
96.8, 79.9, 78.1, 71.5, 56.1, 48.0, 46.4, 43.7, 31.6, 30.3, 29.9, 24.4, 15.0, 12.6, -1.9; IR (thin film) 
3448, 3054, 2986, 1422, 1265, 1100, 839, 738, 705 cm-1. Diol adduct (39) from the minor aldol 
diastereomer: (94.2%) 1H NMR (300 MHz, CDCl3) δ 7.43-7.21 (m, 5H), 5.81-5.83 (m, 1H), 5.02 
(s, 1H), 4.98 (s, 1H), 4.69 (s, 2H), 4.33 (d, J = 9.2 Hz, 1H), 4.11 (d, J = 10.4 Hz, 1H), 3.77 (dd, J 
= 5.6, 8.7 Hz, 1H), 3.65 (dd, J = 3.5, 11.2 Hz, 1H), 3.39 (s, 3H), 2.73-2.75 (m, 3H), 2.37-2.41 
(m, 1H), 2.07-2.11 (m, 1H), 1.95-1.99 (m, 2H), 1.72 (s, 3H), 1.58 (s, 3H), 1.12 (s, 3H), 0.06 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 139.7, 136.9, 135.0, 131.3, 129.0, 126.8, 114.2, 96.7, 81.2, 
76.7, 74.8, 69.2, 56.0, 48.0, 47.6, 46.8, 32.0, 30.8, 23.8, 14.9, 11.7, -2.0; IR (thin film) 3465, 
3053, 2955, 1645, 1583, 1481, 1439, 12651214, 1151, 1035, 965, 896, 838, 738, 704 cm-1.  
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 General procedure for cyclic carbonate formation: 
Syntheses of 7(S)-Isopropenyl-8(R)-methoxymethoxy-4(R)-
methyl-5(R)-phenyl sulfanyl-4(S)-(3-trimethylsilyl-but-2-enyl)-
hexahydro-8(R)benzo[1,3]dioxin-2-one (38) and 7(S)-Isopropenyl-8(R)-methoxymethoxy-
4(R)-methyl-5(R)-phenylsulfanyl-4(R)-(3-trimethylsilyl-but-2-enyl)-hexahydro-
8(R)benzo[1,3]dioxin-2-one (40). 
O
O
SPh
H
O
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H
O
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O
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To a dry flask was added (37 or 39) (28.1 mg, 59.1 µmol), pyridine (58.7 mg, 0.71 mmol), and 
CH2Cl2 (1.5 mL). The flask was then cooled to -78 °C and a solution of triphosgene (26.3 mg, 
89.2 µmol) in CH2Cl2 (1.0 mL) was added. The reaction was then warmed to ambient 
temperature. After 3.5 hours the reaction was quenched by adding aq. sat. NH4Cl (1.5 mL). The 
aqueous layer was separated and extracted with EtOAc. The combined organic layers were then 
washed with 1M HCl (aq), then with aq. sat. NaHCO3, then with brine. Then dried over Na2SO4, 
filtered, and solvents removed in vacuo. The products were then purified by column 
chromatography (60:30:10 Et2O:Hexanes:CH2Cl2) to give oils which solidified upon storing at 0 
°C. Carbonate adduct (38) from the major aldol diastereomer: (96.6%) 1H NMR (500 MHz, 
CDCl3) δ 7.38-2.27 (m,5H), 5.89-5.88 (m,1H), 5.06 (d, J = 21.0 Hz, 2H), 4.87 (d, J = 10.5 Hz, 
1H), 4.73 (dd, J = 7.0, 23.9 Hz, 2H), 4.48 (dd, J = 2.5, 10.5 Hz, 1H), 4.01 (q, J = 6.2, 1H), 3.39 
(s, 3H), 3.17 (dd, J = 4.5, 11.7 Hz, 1H), 2.86 (s, 1H), 2.75 (m, 1H), 2.40-2.51 (m, 1H), 2.09-2.02 
(m, 2H), 1.65 (s, 3H), 1.59 (s, 3H), 1.32 (s, 3H), 0.06 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
187.9, 148.5, 142.2, 141.1, 133.4, 131.9, 131.4, 129.6, 128.1, 115.4, 96.7, 88.0, 76.3, 74.4, 56.0, 
46.0, 44.1, 40.5, 31.3, 28.9, 24.4, 15.0, 14.3, 14.0, -2.0; IR (thin film) 3054, 2986, 1750, 1422, 
1265, 1120, 896, 737, 704 cm-1; HRMS (EI) m/z calc for C27H40O5SiS (M)+ 504.2365, found 
504.2383. Carbonate adduct (40) from the minor aldol diastereomer: (58.0%) 1H NMR (500 
MHz, CDCl3) δ 7.40-7.29 (m, 5H), 5.88 (t, J = 5.3 Hz, 1H), 5.05-4.99 (d, J = 28.9 Hz, 2H), 4.71 
(dd, J = 26.4, 7.0 Hz, 2H), 4.58 (d, J = 10.7 Hz, 1H), 4.43 (d, J = 10.4 Hz, 1H), 4.04 (q, J = 6.2 
Hz, 1H), 3.48 (dd, J = 15.6, 6.9 Hz, 1H), 3.39 (s, 3H), 3.10 (dd, J = 12.1, 3.4 Hz, 1H), 2.81 (s, 
1H), 2.39-2.32 (m, 1H), 2.11-2.00 (m, 2H), 1.72 (s, 3H), 1.54 (s, 3H), 1.19 (s, 3H), 0.07 (s, 9H); 
13C NMR (75 MHz, CDCl3) δ 232.9, 149.0, 141.7, 139.7, 133.6, 132.4, 129.4, 128.0, 115.2, 96.6, 
91.8, 80.2, 79.4, 73.4, 55.8, 48.8, 43.4, 41.5, 32.3, 32.0, 29.7, 24.0, 15.1, 8.0, -2.1; IR (thin film) 
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 3054, 2986, 1753, 1470, 1265, 1248, 1215, 1120, 1097, 738, 704 cm-1; HRMS (EI) m/z calc for 
C27H40O5SiS (M)+ 504.2365, found 504.2381. 
 
5(S)-Isopropyl-6(R)-methoxymethoxy-2-methyl-cyclohex-2-enone (52) 
To a Morton style flask equipped with a three way adapter was added freshly prepared 
Wilkinson’s catalyst ((PPh3)3RhCl, 317 mg, 0.34 mmol), dry benzene (40 mL), and 
trifluoroethanol (3 mL). This solution was pump/purged using a H2 filled balloon and a water 
aspirator five times. The catalyst was then stirred under H2 for 20 min, then a solution of (32a) 
(2.82 g, 13.41 mmol) in dry benzene (15 mL) and trifluoroethanol (3 mL) was added to the 
reaction vessel. The Morton flask was pump/purged with H2 several more times and the reaction 
left stirring under 1 atm of H2 at ambient temperature overnight. The reaction mixture was then 
filtered through a pad of SiO2 and the SiO2 washed with EtOAc. Solvents were then removed in 
vacuo and the residue purified by column chromatography (5:30:65 EtOAc: CH2Cl2: Hexanes) to 
give the desired product (2.47 g, 87%) and recovered starting material (286 mg, 10%). The 
product was a slightly yellow oil. 1H NMR (300 MHz, CDCl3) δ 6.71 (t, J = 1.6 Hz, 1H), 4.71 (d, 
J = 6.7 Hz, 1H), 4.57 (d, J = 6.7 Hz, 1H), 4.04 (d, J = 2.3 Hz, 1H), 3.31 (s, 3H), 2.37-2.32 (m, 
2H), 1.91-1.85 (m, 1H), 1.79 (t, J = 1.6 Hz, 3H), 1.66-1.62 (m, 1H), 0.99-0.93 (dd, J = 6.6, 13.4 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 198.3, 145.3, 132.9, 95.4, 77.2, 55.9, 46.8, 28.1, 27.2, 
20.4(6), 20.4(3), 15.7; IR (thin film) 3031, 2985, 1734, 1374, 1266, 1246, 1047, 739, 704 cm-1; 
HRMS (EI) m/z calc for C11H17O2 (M-CH3O)+ 181.1228, found 181.1226; [α]D23 +13.1 o (MeOH, 
c 1.0). 
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 2(S)-(1(S)-Hydroxy-4-iodo-pent-4-enyl)-5(S)-isopropyl-6(R)-methoxymethoxy-
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 2(S)-methyl-3(R)-phenylsulfanyl-cyclohexanone (53 and 54) 
Note: The following procedure was carried out in the absence of light. To a dry flask was added 
CH2Cl2 (3.5 mL) and thiophenol (258 mg, 2.36 mmol). The flask was then cooled to 0 °C and 
AlMe2Cl (1.0M in hexanes, 4.71 mL, 4.71 mmol) added. The mixture was stirred at 0 °C for 60 
minutes, then cooled to -50 °C and a solution of (52) (500 mg, 2.36 mmol) in CH2Cl2 (3.0 mL) 
was added. The progress of the 1,4 addition was monitored by TLC (15:85 EtOAc:Hexanes). 
After stirring for 5 hours at -50 °C, a solution of 4-iodo-pent-4-enal (51) (876 mg, 4.21 mmol) in 
THF (1.5 mL) was added to the reaction flask. After stirring for 2.5 hours at -50 °C, the reaction 
was diluted with EtOAc (15 mL) and slowly quenched using NaK tartrate (aq. sat.) (8 mL). The 
reaction was warmed to ambient temperature and vigorously stirred until the aluminum emulsion 
separated, then diluted with brine (20 mL) and extracted with EtOAc (3x20 mL). The combined 
organic layers were then washed with NaHCO3 (aq. sat.) and brine, then dried over MgSO4, filtered, 
and solvents removed in vacuo. Purification by column chromatography (10:10:80 
EtOAc:Hexanes:CH2Cl2) to separate the enone, aldehyde, and aldol diastereomers, and then 
(60:30:10 Et2O:Hexanes:CH2Cl2) to separate the two aldol diastereomers in a 6:1 ratio, (major 
diastereomer (53), Rf = 0.64 / minor diastereomer (54) Rf = 0.56). The major diastereomer was 
the desired product and isolated as an oil (303 mg, 25%). 1H NMR (300 MHz, CDCl3) δ 7.50-
7.48 (m, 2H), 7.33-7.27 (m, 3H), 6.01 (d, J = 1.3 Hz, 1H), 5.67 (d, J = 1.3 Hz, 1H), 4.62-4.60 (m, 
2H), 4.27 (d, J = 4.0 Hz, 1H), 4.02 (t, J = 9.7 Hz, 1H), 3.88 (dd, J = 9.5, 5.3 Hz, 1H), 3.39 (s, 
3H), 2.62-2.68 (m, 1H), 2.24-2.16 (m, 3H), 2.08-1.99 (m, 1H), 1.85-1.82 (m, 1H), 1.71-1.41 (m, 
3H), 1.40 (s, 3H), 0.97 (d, J = 6.4 Hz, 3H), 0.77 (d, J = 6.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 212.5, 134.6, 132.8, 129.2, 127.6, 125.8, 111.7, 95.3, 79.3, 74.1, 56.1, 50.1, 43.8, 42.7, 31.5, 
29.8, 27.9, 22.6, 21.3, 20.7, 17.6; IR (thin film) 3457, 3010, 2970, 2871, 1699, 1612, 1584, 1473, 
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 1438, 1374, 1149, 1116, 1085, 1002, 915 cm-1; HRMS (EI) m/z calc for C23H33O4SI (M)+ 
532.1144, found 532.1124; [α]D23 +5.3 o (MeOH, c 1.0). 
 
 2(S)-[4-Iodo-1(S)-(2-trimethylsilyl-ethoxymethoxy)-pent-4-enyl]-5(S)-
isopropyl-6(R)-methoxymethoxy-2(S)-methyl-3(R)-phenylsulfanyl-
cyclohexanone (55) 
O
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Note: The following procedure was carried out in the absence of light. To a flask was added 
dimethylaminopyridine (20 mg, cat.), diisopropylethylamine (1.0 mL), and a solution of (53) 
(100.1 mg, 0.188 mmol) in CH2Cl2 (1.0 mL). A reflux condenser was attached and 2-
chloromethoxyethyltrimethylsilane (62.2 mg, 0.413 mmol) was added. The reaction was then 
heated to 40 °C and after 4 hours quenched with NH4Cl (aq. sat.) (6 mL). The reaction mixture was 
then extracted with EtOAc (5x10 mL) and the organic layer washed with dilute HCl (2x5 mL), 
then with brine. The mixture was then dried over MgSO4, filtered, and solvents removed in 
vacuo. The product was then purified by column chromatography (10:90 EtOAc:Hexanes) to 
give the product as a colorless oil (99.8 mg, 80.1%) 1H NMR (300 MHz, CDCl3) δ 7.43-7.22 (m, 
5H), 6.00 (s, 1H), 5.68 (s, 1H), 4.80 (dd, J = 11.0, 7.1 Hz, 2H), 4.64 (d, J = 6.6 Hz, 1H), 4.50 (d, 
J = 6.5 Hz, 1H) 4.41-4.38 (d, J = 9.1 Hz, 1H), 4.12-4.11 (m, 2H), 3.73-3.58 (m, 2H), 3.39 (s, 
3H), 2.68 (t, J = 11.2 Hz, 1H), 2.49 (s, 1H), 2.33 (t, J = 10.6 Hz, 1H), 2.15-2.09 (m, 1H), 2.04-
2.00 (m, 1H), 1.85-1.68 (m, 3H), 1.26 (s, 3H), 1.02-0.91 (m, 5H), 0.76-0.74 (d, J = 6.7 Hz, 3H), 
0.05 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 208.5, 135.2, 132.4, 129.1, 127.3, 125.4, 110.9, 97.4, 
95.8, 80.7, 80.5, 66.3, 58.6, 56.6, 53.2, 43.9, 43.2, 33.1, 27.3, 25.4, 20.7, 20.5, 18.2, 15.2, -1.3; 
IR (thin film) 3054, 2949, 2894, 2069, 2003, 1939, 1741, 1698, 1605, 1580, 1485, 1432, 1380, 
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 1247, 1207, 1089, 1000, 894, 854, 833, 755, 691 cm-1; HRMS (EI) m/z calc for C29H47O5SiSI 
(M)+ 662.1958, found 662.1968; [α]D23  +31.1 o (MeOH, c 1.0). 
 
 3(S)-Isopropyl-4(R)-methoxymethoxy-8a(S)-methyl-5-methylene-1(R)-
phenylsulfanyl-8(S)-(2-trimethylsilyl-ethoxymethoxy)-octahydro-naphthalen-
4a(S)-ol (56) 
SPh OSEM
OH
OMOM
Note: The following procedure was carried out in the absence of light. To a flask was added (55) 
(50 mg, 75 µmol) and THF (3.0 mL). The reaction was cooled to -78 °C and sec-butyl lithium 
(1.07 M in hexanes, 77 µL, 83 µmol) was added. The reaction was stirred at -78 °C and after 100 
minutes quenched at -78 °C with NH4Cl (aq. sat.) (1.5 mL). The reaction was warmed to ambient 
temperature, neutralized with NaHCO3 (aq. sat.) (2.0 mL) and then extracted with EtOAc (3x10 
mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude product was purified by column chromatography (5:20:75 THF:CH2Cl2:Hexanes, Rf = 
0.41) to give a clear oil (29 mg, 72.5%) 1H NMR (300 MHz, CDCl3) δ 7.44-7.19 (m, 5H), 5.26 
(s, 1H), 4.98 (s, 1H), 4.79 (d, J = 7.1 Hz, 1H), 4.65 (d, J = 7.1 Hz, 1H), 4.59 (s, 2H), 4.48-4.39 
(dd, J = 14.4, 2.1 Hz, 1H), 4.03 (d, J = 3.0 Hz, 1H), 3.62-3.54 (m, 3H), 3.38 (s, 3H), 2.37-2.46 
(m, 2H), 2.06-1.97 (m, 2H), 1.77-1.59 (m, 3H), 1.16 (s, 3H), 1.00 (d, J = 6.5 Hz, 3H), 0.94-0.88 
(td, J = 9.3, 3.4 Hz, 4H), 0.85-0.83 (d, J = 6.5 Hz, 3H), -0.02 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 150.9, 138.0, 131.2, 128.9, 126.4, 111.3, 98.7, 93.6, 86.0, 80.2, 74.3, 69.7, 65.6, 56.7, 
51.9, 47.0, 39.5, 30.6, 26.9, 25.0, 21.3, 20.8, 18.2, 13.4, -1.5; IR (thin film) 3484, 3070, 2946, 
2922, 2084, 2019, 1942, 1630, 1580, 1481, 1435, 1383, 1244, 1151, 1098, 1049, 1024, 938, 857, 
830 cm-1; HRMS (EI) m/z calc for C29H48O5SiS (M)+ 536.2991, found 536.2999; [α]D23  –56.2 o 
(MeOH, c 1.0). 
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 6(S)-Isopropyl-5-methoxymethoxy-8a-methyl-4-methylene-8-phenylsulfanyl-
octahydro-naphthalene-1,4a-diol (57) 
To a flask containing (56) (30 mg, 56 µmol) was added a solution of  (1.0 M) potassium 
aminopropyl amide in 1,3-diaminopropane (KAPA) (1.0 mL, 1.0 mmol) at 0 oC under N2. After 
90 min, the reaction was quenched with brine (2 mL) and dilute HCl (aq) (3 mL). This mixture 
was extracted with EtOAc and the organic layer washed with 1 M HCl (aq), then with brine. The 
organic layer was dried over MgSO4, filtered, and concentrated and purified by column 
chromatography (25:75 / EtOAc:Hexane, Rf = 0.25). This gave the diol (57) as a clear oil (17 mg, 
75% yield). 1H NMR (300 MHz, CDCl3) δ 7.41-7.44 (m, 2H), 7.18-7.29 (m, 3H), 5.26 (t, 1H, J = 
1.8 Hz), 4.97 (s, 1H), 4.58 (d, 2H, J = 1.4 Hz), 4.48-4.53 (m, 1H), 4.07 (d, 1H, J = 3.1 Hz), 3.51 
(s, 1H), 3.36 (s, 3H), 2.55-2.65 (m, 1H), 2.44-2.40 (m, 2H), 2.04-2.00 (m, 2H), 1.86-1.83 (m, 
1H), 1.77-1.75 (m, 1H), 1.68-1.64 (m, 3H), 1.09 (s, 3H), 0.98 (d, 3H, J = 6.5 Hz), 0.82 (d, 3H, J 
= 6.5 Hz); 13C NMR (75 MHz, CDCl3) δ 150.9, 137.9, 131.6, 129.2, 126.8, 111.8, 99.1, 86.3, 
78.6, 68.7, 57.0, 52.0, 47.8, 39.8, 31.0, 27.2, 25.1, 21.7, 21.0, 13.7; IR (thin film) 3478, 3048, 
2822, 1584, 1262, 1142, 1095, 1021, 743, 702 cm-1; HRMS (EI) m/z calc for C23H34O4S (M)+ 
406.2178, found 406.2191; [α]D23  –5.3 o (MeOH, c 1.0). 
SPh OH
OH
OMOM
O
OMOM
PhS
OH
SePh
 
2(S)-(1(S)-Hydroxy-4-phenylselanyl-butyl)-5(S)-isopropenyl-6(R)-
methoxymethoxy-2(S)-methyl-3(R)-phenylsulfanyl-cyclohexanone (60 and 61) 
To a flask was added CH2Cl2 (3.0 mL) and thiophenol (182 mg, 1.62 mmol). The flask was then 
cooled to 0 °C and AlMe2Cl (1.0M in hexanes, 3.25 mL, 3.25 mmol) was added and the mixture 
stirred at 0 °C for 45 minutes. Then the reaction flask was cooled to -45 °C and a solution of 
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 (32a) (341 mg, 1.62 mmol) in CH2Cl2 (2.5 mL) was added. The progress of the 1,4 addition was 
monitored by TLC (15:85 EtOAc:Hexanes). After stirring for 4 hours at -50 °C, a solution of 4-
phenylselenobutanal (59) (516 mg, 2.27 mmol) in THF (2.0 mL) was added to the reaction flask. 
After stirring for 2 hours at -45 °C, the reaction was diluted with EtOAc (7 mL) and slowly 
quenched using. NaK tartrate (aq. sat) (2 mL). The reaction was warmed to ambient temperature 
and vigorously stirred until the aluminum emulsion separated, then diluted with brine (10 mL) 
and extracted with EtOAc (4x15 mL). The combined organic layers were then washed with 
NaHCO3 (aq. sat.) and brine, then dried over Na2SO4, filtered, and solvents removed in vacuo. 
Purification by column chromatography (gradient: 5:30:65 EtOAc: CH2Cl2: Hexanes to separate 
the enone and aldehyde, then 50:50 EtOAc:Hexanes to elute aldol adducts) to give recovered 
enone (195 mg, 57%) and aldehyde (424 mg, 82%). The aldol adducts were then separated by 
another column (20:30:50 EtOAc: CH2Cl2: Hexanes) to give the desired product as two 
diastereomers in a 6:1 ratio. Major Diastereomer (60) (Rf = 0.47, 164 mg, 19%) 1H NMR (300 
MHz, CDCl3) δ 7.47-7.38 (m, 4H), 7.33-7.20 (m, 6H), 4.98 (s, 1H), 4.75 (s, 1H), 4.66 (d, J = 0.7 
Hz, 2H), 4.45 (d, J = 5.7 Hz, 1H,), 3.89 (t, J = 10.1 Hz, 1H), 3.50 (dd, J = 11.4, 4.4 Hz, 1H), 3.36 
(s, 3H), 2.98-2.86 (m, 1H), 2.87 (t, J = 6.6 Hz, 2H), 2.18-2.28 (m, 2H), 2.01-2.05 (m, 1H), 1.75-
1.57 (m, 4H), 1.52 (s, 3H), 1.48 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 213.3, 141.4, 134.8, 
133.0, 132.9, 132.8, 132.7, 132.6, 130.9, 129.5, 129.3, 127.9, 126.9, 115.2, 96.1, 78.2, 75.9, 56.9, 
56.2, 49.6, 46.2, 32.2, 31.0, 28.2, 27.6, 22.7, 18.9 ppm ;  IR (thin film) 3506, 3073, 3054, 2943, 
1735, 1704, 1648, 1571, 1438, 1374, 1240, 1027, 922 cm-1; HRMS (EI) m/z calc for 
C28H36O4SSe (M)+ 548.1499, found 548.1498; [α]D23  +4.4 o (MeOH, c 1.0). 
 
116 
 5(S)-Isopropenyl-6(R)-methoxymethoxy-2(S)-(1(S)-methoxymethoxy-4-
phenylselanyl-butyl)-2-methyl-3(R)-phenylsulfanyl-cyclohexanone (62) 
To a flask equipped with a reflux condenser was added (60) (160 mg, 0.29 mmol), CH2Cl2 (2.0 
mL), diisopropylethylamine (1.5 mL), and dimethylaminopyridine (50 mg). Chloromethyl 
methyl ether (74.2 mg, 0.88 mmol) was added and the reaction heated to 40 °C. After stirring for 
20 hours the reaction was quenched by adding NH4Cl (aq. sat.) (4 mL). The mixture was then 
extracted with EtOAc (4x10 mL) and the organic layers were washed with a 50:50 solution of 
brine: 1M HCl(aq) (2x5 mL). The organic layers were then dried over Na2SO4, filtered, and 
solvents removed in vacuo. The resulting yellow residue was purified by column 
chromatography (10:30:60 EtOAc:CH2Cl2:Hexanes) to give the desired product as a slightly 
yellow oil (170 mg, 99%) 1H NMR (300 MHz, CDCl3) δ 7.67-7.48 (m, 2H), 7.49-7.38 (m, 2H), 
7.29-7.25 (m, 6H), 4.94 (d, J = 1.1 Hz, 1H), 4.81 (s, 1H), 4.71 (s, 2H), 4.55 (d, J = 6.8 Hz, 1H), 
4.32 (d, J = 7.2 Hz, 2H), 4.23 (d, J = 3.6 Hz, 1H), 4.08 (t, J = 4.2 Hz, 1H), 3.36 (s, 3H), 3.27 (s, 
3H), 3.00-3.04 (m, 1H), 2.94-2.84 (m, 2H), 2.55-2.58 (m, 1H), 1.99-1.98 (m, 1H), 1.90 (t, J = 4.2 
Hz, 1H), 1.89-1.85 (m, 1H), 1.78 (s, 3H), 1.68-1.61 (m, 2H), 1.29 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 207.6, 142.8, 135.4, 132.2, 131.7, 130.2, 128.9, 126.9, 126.6, 112.8, 99.0, 95.1, 81.4, 
79.1, 58.6, 56.0, 52.6, 43.9, 33.2, 27.9, 27.5, 26.3, 21.9, 15.5 ppm ; IR (thin film) 3057, 2946, 
1710, 1475, 1148, 1089, 1024, 922, 737 cm-1; HRMS (EI) m/z calc for C30H40O5SSe (M)+ 
592.1584 , found 592.1598; [α]D23 +6.7 o (MeOH, c 1.0). 
 
5(S)-Isopropenyl-6(R)-methoxymethoxy-2(R)-(1(S)-methoxymethoxy-but-3-
enyl)-2-methyl-3(R)-phenylsulfanyl-cyclohexanone (63) 
O
OMOM
PhS
OMOM
SePh
O
OMOM
PhS
OMOM
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 To a flask was added (62) (145 mg, 0.245 mmol) and dry CH2Cl2 (3 mL). This solution was then 
cooled to -78 °C and a solution of purified m-CPBA (42.3 mg, 0.245 mmol) in CH2Cl2 (2.0 mL) 
was added slowly. When the addition was complete, the reaction was allowed to slowly warm to 
ambient temperature. After 90 minutes a reflux condenser was attached. Then pyridine (78.2 mg, 
0.98 mmol) and 3,4-dihydro-2H-pyran (618 mg, 7.35 mmol) were added and the reaction heated 
to reflux (oil bath temp 75 °C). After 3 hours, the reaction was cooled to ambient temperature 
and the volatile compounds removed by rotovap. The residue was taken up in EtOAc (20 mL) 
and washed with brine, 10% HCl (aq), and NaHCO3 (aq. sat.). The organic layer was then dried over 
Na2SO4, filtered, and solvents removed in vacuo. The residue was then purified by column 
chromatography (15:85 EtOAc:Hexanes) to give the desired product as a white waxy solid (103 
mg, 97%). 1H NMR (300 MHz, CDCl3) δ 7.39-7.21 (m, 5H), 5.82-5.87 (m, 1H), 5.06 (d, J = 15.2 
Hz, 1H), 5.03 (d, J = 8.2 Hz, 1H), 4.91 (s, 1H), 4.80 (s, 1H), 4.76 (d, J = 7.0 Hz, 1H), 4.65 (d, J = 
7.1 Hz, 1H), 4.57 (d, J = 6.7 Hz, 1H), 4.50-4.51 (m, 1H), 4.47 (d, J = 6.6 Hz, 1H), 4.23 (d, J = 
3.4 Hz, 1H), 4.08 (t, J= 3.6 Hz, 1H), 3.39 (s, 3H), 3.31 (s, 3H), 3.02 (d, J = 11.1 Hz, 1H), 2.61 (t, 
J = 11.4 Hz, 1H), 2.32 (quint, J = 7.8 Hz, 1H), 1.76-1.87 (m, 2H), 1.77 (s, 3H), 1.29 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 207.9, 143.3, 136.2, 135.9, 132.2, 129.3, 127.4, 117.3, 113.2, 98.8, 
95.7, 80.0, 79.6, 58.8, 56.5, 56.4, 53.2, 44.3, 37.7, 26.6, 22.3, 15.8 ppm; IR (thin film) 3076, 
2946, 1704, 1438, 1157, 1018, 909, 733 cm-1; HRMS (EI) m/z calc for C24H34O5S (M)+ 434.2126 
, found 434.2146; [α]D23 +2.7 o (MeOH, c 1.0). 
 
1(R),5(S)-Diisopropenyl-6(R)-methoxymethoxy-2(R)-(1(S)-methoxymethoxy-b
3-enyl)-2-methyl-3(R)-phenylsulfanyl-cyclohexanol (64) 
ut-
OMOM
PhS
OMOM
OH
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 Preparation of 2-propenylmagnesium bromide: To a flask equipped with a reflux condenser was 
added oven dried magnesium turnings (241 mg, 10.0 mmol), iodine (20 mg), and THF (10 mL). 
Then 2-bromopropene (1.20 g, 10.0 mmol) was added drop-wise to the flask. After all of the 
metal had dissolved, the Grignard was stirred for an additional 10 minutes prior to use.  
To a flask was added (63) (60 mg, 0.14 mmol) and THF (2.5 mL). The reaction vessel was 
cooled to –78 °C and 2-propenyl magnesium bromide (1.0M THF, 0.70 mL, 0.70 mmol) was 
added. The reaction was warmed to ambient temperature and after 3 hours quenched by adding 
NaHCO3 (aq. sat.) (1.0 mL). The mixture was then extracted with EtOAc (3x10 mL) and the organic 
layer washed with brine (5 mL). The organic layer was dried over Na2SO4, filtered, and solvents 
removed in vacuo. The product was separated form the starting material by column 
chromatography (5:30:65 EtOAc:CH2Cl2:Hexanes) to give the starting material (63) (45 mg, 
75%) as a waxy solid and the product (64) as a slightly yellow oil (13.2 mg, 20%). 1H NMR (300 
MHz, CDCl3) δ 7.51 (d, J = 7.1 Hz, 2H), 7.25-7.29 (m, 3H), 5.82-5.89 (m, 1H), 5.11 (s, 2H), 
5.09 (s, 1H), 5.02 (s, 2H), 4.94 (s, 1H), 4.77 (d, J = 7.9 Hz, 2H), 4.71 (d, J = 6.9 Hz, 1H), 4.54 
(d, J = 7.0 Hz, 1H), 4.67 (d, J = 0.9 Hz, 2H), 4.18 (d, J = 7.1 Hz, 1H), 4.10 (dd, J = 11.9, 4.2 Hz, 
1H), 4.00 (dd, J = 7.0, 4.3 Hz, 1H), 3.37 (s, 3H), 3.33 (s, 3H), 2.89-2.92 (m, 1H), 2.78-2.81 (m, 
2H), 2.21 (dt, J = 14.6, 3.6 Hz, 1H), 2.01-2.04 (m, 2H), 1.94 (s, 3H), 1.76 (s, 3H), 1.23 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 148.6, 146.3, 138.6, 135.8, 132.7, 129.6, 127.2, 116.0, 113.9, 98.5, 
96.2, 85.4, 83.7, 78.7, 56.8, 56.5, 50.0, 48.7, 42.2, 38.3, 32.6, 24.3, 23.3, 17.5 ppm ; IR (thin 
film) 3556, 3069, 2923, 1636, 1442, 1153, 1093, 1034, 911, 745, 689 cm-1; HRMS (EI) m/z calc 
for C27H40O5S (M)+ 476.2596, found 476.2613; [α]D23  –3.3 o (MeOH, c 1.0). 
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 3(S)-Isopropenyl-4(R),8(S)-bis-methoxymethoxy-5,8a(S)-dimethyl-1(R)-
phenylsulfanyl-1,3,4,7,8,8a-hexahydro-2H-naphthalen-4a(S)-ol (65) 
OMOM
OH
OMOM
PhS
Note: Grubbs 2nd generation catalyst was prepared according to the literature procedure starting 
from bis(tricyclohexylphosphine)methylidene ruthenium dichloride and 1,3-dimesityl-4,5-
dihydroimidazolium chloride. 
To a flask equipped with a greased reflux condenser was added (64) (12.0 mg, 25 µmol) and 
CH2Cl2 (0.63 mL). Then Grubbs 2nd generation catalyst (0.6 mg, 2.5 mole%) was added and the 
reaction heated to reflux. After stirring for 15 minutes at reflux the reaction was cooled to 
ambient temperature and filtered through a plug of silica gel to remove most of the catalyst. The 
plug was washed with 50:50 EtOAc:Hexanes to elute product. Solvents were then removed in 
vacuo to give a brown oily residue (10.9mg, 94% yield). 1H NMR (300 MHz, CDCl3) δ 7.25-
7.38 (m, 4H), 7.15-7.17 (m, 1H), 5.42 (t, J = 1.5 Hz, 1H), 4.90 (s, 1H), 4.87 (s, 1H), 4.83 (d, J = 
5.0 Hz, 1H), 4.76 (d, J =  3.7 Hz, 2H), 4.70 (d, J = 5.0 Hz, 1H), 4.34 (dd, J = 9.3, 6.7 Hz, 1H), 
3.87 (d, J = 5.7 Hz, 1H), 3.78 (s, 1H), 3.77 (d, J = 4.8 Hz, 1H), 3.42 (s, 3H), 3.34 (s, 3H), 3.05 
(ddd, J = 10.3, 5.5, 2.64 Hz, 1H), 2.78 (td, J = 13.5, 6.5 Hz, 1H), 2.49-2.54 (m, 1H), 2.02-2.13 
(m, 1H), 1.62-1.66 (m, 1H), 1.84 (s, 3H), 1.80 (s, 3H), 1.29 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 145.9, 137.6, 137.5, 129.4, 128.9, 125.4, 124.4, 116.1, 114.1, 111.3, 98.1, 97.2, 79.7, 78.6, 
76.9, 57.3, 55.8, 48.6, 43.8, 41.5, 31.6, 31.4, 22.7, 20.0, 14.3 ppm ; IR (thin film) 3521, 3061, 
2919, 1640, 1584, 1434, 1141, 1101, 1038, 911, 737 cm-1; HRMS (EI) m/z calc for C25H36O5S 
(M)+ 448.2283 , found 448.2267; [α]D23  –6.3 o (MeOH, c 1.0). H,H-COSY and 1D NOE are 
consistent with proposed structure.  
 
120 
 6(S)-Isopropenyl-1(S),5(R)-bis-methoxymethyl-4,8a(S)-dimethyl-8-
phenylsulfanyl-1,5,6,8a-tetrahydro-2H-naphthalen-4a(S)-ol (66)-(67) 
A solution of (65) (50 mg, 0.11 mol) in CH2Cl2 (5 mL) was cooled to –78 oC under N2. A 
solution on purified m-CPBA (20 mg, 0.12 mmol) in CH2Cl2 (1.0 mL) was added dropwise and 
the reaction stirred for 40 min before warming to 25 oC for 30 min. Pyridine (87mg, 1.10 mmol) 
was added followed by TFAA (116 mg, 0.55 mmol) to the crude sulfoxide (66) and the mixture 
stirred for 5 hrs. The reaction was quenched with NaHCO3 (aq. sat.) (2 mL) and then diluted with 
EtOAc. The organic layer was separated and washed with 1 M HCl (aq.), dried over Na2SO4, 
concentrated, and purified by prep. TLC (15:85 / EtOAc:Hexane, Rf = 0.25). This gave the vinyl 
sulfide (67) as a clear oil. (43 mg, 87% yield) 1H NMR (300 MHz, CDCl3) δ7.53-7.56 (m, 2H), 
7.26-7.33 (m, 3H), 5.46-5.47 (m, 1H), 4.98 (d, J = 2.7 Hz, 1H), 4.90 (d, J = 6.9 Hz, 1H), 4.76 (d, 
J = 6.9 Hz, 1H), 4.73 (d, J = 5.0 Hz, 1H), 4.71 (s, 2H), 4.66 (d, J = 5.0 Hz, 1H), 4.36 (dd, J = 
14.6, 7.6 Hz, 1H), 4.03 (d, J = 8.8 Hz, 1H), 3.41 (dd, J = 8.8, 2.7 Hz, 1H), 3.38 (s, 3H), 3.36 (s, 
3H), 2.78-2.84 (m, 1H), 2.16-2.25 (m, 1H), 1.87 (s, 3H), 1.58 (s, 3H), 1.17 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 146.8, 143.3, 136.3, 135.8, 134.6, 129.1, 127.8, 127.4, 124.9, 115.2, 98.5, 98.2, 
77.3, 76.8, 57.5, 56.2, 49.2, 48.6, 31.9, 21.6, 21.4, 15.7  ppm ; IR (thin film) 3514, 3063, 2935, 
1634, 1440, 1373, 1152, 1096, 1030, 902, 737, 646 cm-1; HRMS (EI) m/z calc for C25H34O5S 
(M)+ 446.2126, found 446.2143; [α]D23  –2.7 o (MeOH, c 1.0). 
 
2,6(R),10,10-Tetramethyl-7(R)-phenylsulfanyl-11(S)-oxa-9(R)-tricyclo[7.2.1.01,6] 
dodec-2-ene-5(S),12(R)-diol (68) 
OH
O
PhS
OH
OMOM
OH
PhS
OMOM
To a solution of (65) (10.0 mg, 22 µmol) in THF (0.5 mL) at 25 °C was added a solution of 
trifluoromethanesulfonic acid (4.35 mg, 29 µmol) in THF (1.0 mL). The reaction was stirred for 
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 25 minutes and then quenched by adding solid NaHCO3 (20 mg). The reaction was concentrated 
to half volume then purified by preparatory TLC (20:30:50 / EtOAc:CH2Cl2:Hexanes, Rf = 0.29) 
This gave the desired product as a white residue (2.5 mg, 30% yield). 1H NMR (300 MHz, 
CDCl3) δ 7.51-7.54 (m, 2H), 7.27-7.36 (m, 3H), 5.64 (d, J = 5.6 Hz, 1H), 4.63 (s, 1H), 4.28 (dd, 
J = 9.6, 5.9 Hz, 1H), 4.14 (s, 1H), 3.67 (dd, J = 11.7, 6.8 Hz, 1H), 2.31-2.35 (m, 1H), 2.14-2.17 
(m, 1H), 2.06-2.07 (m, 2H), 2.05 (s, 3H), 1.99-2.03 (m, 1H), 1.97-1.98 (m, 1H), 1.51 (s, 3H), 
1.17 (s, 3H), 1.15 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 133.2, 132.7, 132.1, 129.3, 128.1, 
127.9, 91.5, 82.3, 80.7, 73.5, 52.6, 51.0, 47.9, 35.9, 31.1, 29.4, 24.1, 22.8, 12.3; IR (thin film) 
3534, 3053, 1617, 1421, 1106, 908, 733  cm-1; HRMS (EI) m/z calc for C21H28O3S (M)+ 
360.1759, found 360.1753; [α]D23  –8.5 o (MeOH, c 1.0); H,H-COSY and 1D NOE experiments 
are consistent with proposed structure. 
 
Acetic acid 12(R)-hydroxy-2(R),6(S),10,10-tetramethyl-7(R)-phenysufanyl-11(S)-
oxa-tricyclo [7.2.1.01,6]dodec-2-en-5(S)-yl ester (69) 
OAc
O
PhS
OH
To a solution of (68) (12.0 mg, 32 µmol) in CH2Cl2 (1.0 mL) was added triethylamine ( 6.5 mg, 
64 µmol), DMAP ( 1mg), and finally Ac2O ( 3.3 mg, 32 µmol) in CH2Cl2 (0.15 mL) at 25 oC 
under N2. After 2.5 hrs the reaction was concentrated and purified by prep. TLC. (15:30:55 / 
EtOAc:CH2Cl2:Hexane, Rf = 0.31). This gave the desired product (7.2 mg, 56 % yield). 1H NMR 
(300 MHz, CD2Cl2) δ 7.41-7.44 (m, 2H), 7.22-7.30 (m, 2H), 5.62-5.67 (m, 2H), 4.58 (s, 1H), 
3.77 (dd, J = 11.3, 6.3 Hz, 1H), 2.14-2.18 (m, 2H), 2.04 (s, 3H), 2.02 (dd, J = 5.2, 3.4 Hz, 3H), 
1.90-1.92 (m, 2H), 1.81-1.84 (m, 1H), 1.62 (s, 1H), 1.51 (s, 3H), 1.24 (s, 3H), 1.19 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 171.6, 134.6, 133.2, 132.3, 128.9, 127.0, 92.3, 91.3, 82.4, 80.7, 73.2, 
51.1, 48.8, 48.1, 36.0, 29.5, 29.0, 24.3, 22.7, 22.2, 13.7; IR (thin film) 3435, 3053, 1722, 1265, 
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 733 cm-1; HRMS (EI) m/z calc for C23H30O4S (M)+ 402.1864, found 402.1868; [α]D23  -4.3 o 
(MeOH, c 1.0). 
 
Acetic acid 5(S)-12(R)-hydroxy-2(R),6(S),10,10-tetramethyl-7(R)-phenylsulfanyl-
11(S)-oxa-tricyclo[7.2.1.01,6]dodec-5(S)-yl ester (70)  
OAc
O
PhS
OH
A solution of (69) (16.8 mg, 42 µmol) was dissolved in CH2Cl2 (2.0 mL). The mixture was 
flushed with H2 and [Ir(cod)py(PCy3)]PF6 (3.4 mg, 4.2 µmol) was added by dissolving in CH2Cl2 
(0.4 mL) and adding by syringe pump over a 45 min period. This addition was made once more 
to total 20 mol% catalyst. After a total of 3 hrs, the reaction was concentrated and purified by 
prep. TLC (25:75 / EtOAc:Hexane, Rf = 0.35) to give recovered starting material (69) (7.6 mg, 
45% recovery) and desired product (70) (5.5 mg, 33% yield), both waxy solids. ). 1H NMR (300 
MHz, CDCl3) δ 7.44-7.45 (m, 2H), 7.20-7.27 (m, 3H), 5.49 (dd, J = 12.0, 3.6 Hz, 1H), 4.37 (s, 
1H), 3.60-3.63 (m, 1H), 2.18-2.21 (m, 2H), 2.03-2.07 (m, 1H), 2.03 (s, 3H), 1.86-1.89 (m, 2H), 
1.69-1.74 (m, 3H), 1.53-1.57 (m, 4H), 1.26 (s, 3H), 1.18 (d, J = 7.5 Hz, 3H), 1.11 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 171.5, 134.8, 133.1, 128.9, 127.3, 116.5, 95.9, 93.4, 78.1, 78.0, 71.2, 
50.6, 35.5, 34.1, 30.7, 29.8, 26.8, 24.3, 23.9, 22.3, 17.9, 13.3 ppm; IR (thin film) 3498, 3057, 
1731, 1260, 1028 cm-1; HRMS (EI) m/z calc for C23H32O4S (M)+ 404.2021, found 404.2027; 
[α]D23  –3.6 o (MeOH, c 1.0); H,H-COSY and 1D NOE experiments are consistent with proposed 
structure. 
 
4(S)-Isopropenyl-3(R)-methoxymethoxy-1(R)-methyl-7-oxa-bicyclo[4.1.0]heptan-
2-one (71) 
O
O O
O
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 A solution of (32a) (1.58 g, 7.52 mmol) and K2CO3 (2.08 g, 15.04 mmol) in THF (22.5 mL) and 
H2O (7.5 mL) was cooled to 0 oC. H2O2 (30% aq.) (4.26 mL, 37.60 mmol) was added slowly by 
syringe. After stirring for 2 hrs another addition of H2O2 (30% aq.) (4.26 mL, 37.60 mmol) was 
made and the reaction allowed to warm to 25 oC. After 17 hrs, the reaction was cooled back to 0 
oC and a final addition of H2O2 (30% aq.) (4.26 mL, 37.60 mmol) was made. The reaction was 
allowed to warm to 25 oC and after a total reaction time of 37 hrs poured into brine (60 mL) and 
extracted with EtOAc. The combined organic layers were washed with Na2S2O3 (aq.sat.) and then 
with brine. The organic layer was dried over MgSO4, filtered, concentrated, and purified by 
column chromatography (50:50 / Ether:Hexane, Rf = 0.50). This gave the desired compound as a 
clear oil (1.31 g, 77% yield). 1H NMR (300 MHz, CDCl3) δ 4.93 (s, 1H), 4.77 (s, 1H), 4.65 (d, J 
= 6.7 Hz, 1H), 4.61 (d, J = 6.7 Hz, 1H), 4.40 (d, J = 3.8 Hz, 1H), 3.48 (t, J = 2.3 Hz, 1H), 3.35 (s, 
3H), 2.76-2.78 (m, 1H), 2.29-2.34 (m, 2H), 1.78 (s, 3H), 1.45 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 202.3, 143.9, 112.7, 95.3, 75.7, 62.8, 59.3, 55.8, 43.3, 25.9, 22.5, 15.1; IR (thin film) 
1721, 1148, 922 cm-1; HRMS (EI): m/z calc for C11H15O4 (M-CH3)+ 211.0970, found 211.0968; 
[α]D23 +2.7 o (MeOH, c 1.0).  
 
 4(S)-Isopropenyl-3(R)-methoxymethoxy-1(S)-methyl-2(R)-(1-methylene-4-
triisopropylsilyly-butyl)-7-oxa-bicyclo[4.1.0]heptan-2(R)-ol (73) 
O O
OTIPS
OH
O
A solution of (71) (1.03 g, 4.55 mmol) in THF (14 mL) was cooled to -78 oC under N2. In a 
separate flask, (4-Bromopent-4-enyloxy)-triisopropylsilane (72) (2.08 g, 6.47 mmol) was 
dissolved in THF (16 mL) and cooled to -78 oC under N2. Then t-butyl lithium (7.61 mL, 12.94 
mmol) was added to the solution of (72) and the resulting yellow solution stirred for 10 min. The 
vinyl lithium reagent was then added by syringe to the epoxy ketone (71) solution at -78 oC. 
124 
 After 45 min, the reaction was quenched by pouring into a solution of brine (25 mL) and 1 M 
HCl (aq) (20 mL). This mixture was extracted with EtOAc and the organic layers dried over 
MgSO4, filtered, concentrated, and purified by column chromatography (10:90 / EtOAc:Hexane, 
Rf = 0.30). This gave separable diastereomers as a 12:1 (β:α) ratio in favor of the desired 
diastereomer (1.23 g, 58% yield). 1H NMR (300 MHz, CDCl3) δ 5.42 (s, 1H), 5.08 (s, 1H), 4.88 
(d, J = 0.8 Hz, 1H), 4.78 (s, 1H), 4.64 (d, J = 6.4 Hz, 1H), 4.56 (d, J = 6.4 Hz, 1H), 3.83 (d, J = 
1.7 Hz, 1H), 3.75 (t, J = 6.4 Hz, 2H), 3.59 (s, 1H), 3.38 (s, 3H), 3.05 (t, J = 2.1 Hz, 1H), 2.40 
(dd, J = 10.7, 6.4 Hz, 1H), 2.34 (t, J = 20.4 Hz, 2H), 2.20 (td, J = 14.4, 2.2 Hz, 1H), 1.92 (ddd, J 
= 14.4, 4.5, 1.9 Hz, 1H), 1.80 (s, 3H), 1.78-1.83 (m, 2H), 1.39 (s, 3H), 0.96-1.10 (m, 21H); 13C 
NMR (75 MHz, CDCl3) δ 149.4, 145.5, 111.9, 111.8, 98.3, 78.8, 74.5, 63.3, 61.2, 59.3, 56.3, 
37.9, 31.9, 28.2, 24.9, 22.8, 20.3, 18.0, 11.9; IR (thin film) 3508, 1639, 1465, 1378, 1152, 1107, 
912, 887, 784, 733 cm-1; HRMS (EI): m/z calc for C23H41SiO5 (M-C3H7)+ 425.2723, found 
425.2724; [α]D23  –26.2 o (MeOH, c 1.0).  
 
2(R)-(4-Hydroxy-1-methylene-butyl)-4(S)-isopropenyl-3(R)-methoxymethoxy-
1(S)-methyl-7-oxa-bicyclo[4.1.0]heptan-2-ol (75) 
O O
OH
OH
O
 To a solution of (73) (705 mg, 1.50 mmol) in THF (20 mL) was added TBAF hydrate (511 mg, 
1.96 mmol) at 25 oC. After 2.5 hrs, the reaction was concentrated and purified by column 
chromatography (75:25 / EtOAc:Hexane, Rf = 0.50). This gave the desired diol as a clear oil (437 
mg, 93% yield). 1H NMR (300 MHz, CDCl3) δ 5.43 (s, 1H), 5.03 (s, 1H), 4.83 (s, 1H), 4.72 (s, 
1H), 4.59 (d, J = 6.4 Hz, 1H), 4.50 (d, J = 6.4 Hz, 1H), 3.75 (d, J = 1.4 Hz, 1H), 3.58-3.63 (m, 
2H), 3.32 (s, 3H), 3.00 (t, J = 1.9 Hz, 1H), 2.35 (dd, J = 6.5, 4.1 Hz, 1H), 2.24 (t, J = 7.4 Hz, 
2H), 2.15 (td, J = 10.8, 2.2 Hz, 1H), 1.84 (ddd, J = 14.4, 1.9, 1.8 Hz, 1H), 1.75 (s, 3H), 1.72-1.74 
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 (m, 1H), 1.34 (s, 3H), 1.18-1.22 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 148.4, 145.2, 112.7, 
111.8, 98.2, 78.5, 74.5, 61.6, 60.2, 59.1, 56.8, 37.6, 31.5, 27.2, 24.6, 22.6, 20.8; IR (thin film) 
3452, 1147, 917 cm-1; HRMS (EI): m/z calc for C16H24O4 (M-CH4O)+ 280.1674, found 
280.1677; [α]D23  –57.8 o (MeOH, c 1.0).  
 
1(R)-(4-Hydroxy-1-methylene-butyl)-5(S)-isopropenyl-6(R)-m
2(R,S)-methyl-cyclohexane-1(R),3(R)-diol (76) 
ethoxymethoxy-
O O
OH
OH
HO
To a solution of (75) (437 mg, 1.40 mmol) in THF (17 mL) was added 1,4-cyclohexadiene (1.12 
g, 14.0 mmol), collidine hydrochloride (883 mg, 5.60 mmol), Mn powder (246 mg, 4.48 mmol) 
and titanocene dichloride (70 mg, 0.28 mmol) at 25 oC under N2. After stirring for 23 hrs, the 
reaction was poured into a flask containing 1 M HCl (aq). The mixture was extracted with EtOAc 
and the organic layer washed with 1 M HCl(aq) then dried over MgSO4, filtered, concentrated, 
and purified by column chromatography (85:15 / EtOAc:Hexane, note: the starting material (75) 
and product (76) have exactly the same Rf = 0.50). This gave the desired product as a clear oil 
(352 mg, 80% yield). 1H NMR (300 MHz, CDCl3) δ 5.99 (s, 1H), 5.28 (s, 1H), 5.18 (s, 1H), 4.83 
(s, 1H), 4.71 (s, 1H), 4.66 (d, J = 6.3 Hz, 1H), 4.50 (d, J = 6.3 Hz, 1H), 3.97 (dd, J = 3.6 Hz, 1H), 
3.67 (s, 1H), 3.56-3.68 (m, 3H), 3.38 (s, 3H), 2.57 (d, J = 1.2 Hz, 1H), 2.09-2.27 (m, 2H), 2.07 
(td, J = 13.4, 3.7 Hz, 1H), 1.95 (q, J = 3.4 Hz, 1H), 1.77-1.81 (m, 2H), 1.73 (s, 3H), 1.51-1.54 
(m, 1H), 1.10 (d, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 147.1, 145.6, 116.9, 111.4, 98.9, 
81.5, 79.5, 69.9, 60.9, 56.4, 42.7, 38.6, 32.9, 31.6, 27.5, 22.3, 11.7; IR (thin film) 3421, 1434 cm-
1; HRMS (EI): m/z calc for C17H30O5 (M)+ 314.2093, found 314.2092; [α]D23  –42.1 o (MeOH, c 
1.0).  
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 3(S)-Isopropenyl-2(R)-methoxymethoxy-6(R,S)-methyl-1(R)-(1-methylene-
4-triethylsilyly-butyl)-5(R)-triethylsilyl-cyclohexanol (77) 
To a solution of (76) (342 mg, 1.09 mmol) in CH2Cl2 (10 mL) was added pyridine (342 mg, 4.35 
mmol), DMAP (13 mg, 0.11 mmol), and then TESCl (341 mg, 2.29 mmol) at 25 oC under N2. 
After 20 hrs, the reaction was quenched by adding brine (10 mL) and 1 M HCl (aq). This mixture 
was extracted with CH2Cl2 and the organic layer dried over MgSO4, filtered, concentrated, and 
purified by column chromatography (15:85 / Ether:Hexane, Rf = 0.33). This gave the desired 
product as a clear oil (326 mg, 55% yield). 1H NMR (300 MHz, CDCl3) δ 6.01 (s, 1H), 5.11 (s, 
1H), 4.83 (s, 1H), 4.69 (s, 1H), 4.67 (d, J = 6.4 Hz, 1H), 4.53 (d, J = 6.4 Hz, 1H), 3.98 (dd, J = 
6.6, 3.3 Hz, 1H), 3.65 (t, J = 6.7 Hz, 3H), 3.39 (s, 3H), 3.02 (s, 1H), 2.61 (d, J = 12.4 Hz, 1H), 
1.99-2.21 (m, 3H), 1.77-1.84 (m, 3H), 1.75 (s, 3H), 1.45 (d, J = 14.3 Hz, 1H), 1.03 (d, J = 7.3 
Hz, 3H), 0.96 (t, J = 6.5 Hz, 9H), 0.94 (t, J = 7.7 Hz, 9H), 0.61 (q, J = 7.9 Hz, 6H), 0.59 (q, J = 
6.7 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 147.1, 146.4, 115.8, 111.0, 98.9, 81.4, 79.6, 70.7, 
62.9, 56.4, 43.8, 38.5, 32.7, 32.2, 28.9, 22.4, 12.2, 6.8, 6.7, 4.9, 4.4; IR (thin film) 3544, 1644, 
1096 cm-1; HRMS (EI): m/z calc for C17H28O3 (M)+ 542.3822, found 542.3821; [α]D23  –25.4 o 
(MeOH, c 1.0).  
 
8(R)-Methoxymethoxy-4(R,S),7,7-trimethyl-5(R)-(1-methylene-4-
triethylsilyly-butyl)-3(R)-triethylsilyly-6(R)-oxa-bicyclo[3.2.1]octane (78) 
O O
OTES
OH
TESO
O
O
O
OTES
OTES
To a solution of (77) (256 mg, 0.47 mmol) in CH2Cl2 (7 mL) was added pyridine (150 mg, 1.90 
mmol) and added I2 (240 mg, 0.94 mmol) at 25 oC, in the dark, under N2. After stirring for 22 hrs 
the reaction was quenched with sodium bisulfite (aq.sat.) and extracted with CH2Cl2. The organic 
layers were washed with 1 M HCl (aq), dried over MgSO4, filtered, and concentrated. The crude 
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 diastereomeric alkyl iodides were dissolved in toluene (3 mL) and AIBN (10 mg, 0.06 mmol) 
was added followed by Bu3SnH (112 mg, 0.39 mmol). The mixture was immersed into a 
preheated oil bath (120 oC) and refluxed for 40 min. The mixture was cooled to 25 oC and ether, 
saturated with H2O, (4 mL) was added followed by DBU (61 mg, 0.40 mmol). Bu3SnOH was 
precipitated by stirring for 10 min. This slurry was filtered through a plug of cotton, sand, and 
MgSO4. The plug was washed with ether and the combined organic layers concentrated and 
purified by column chromatography (9:91 / EtOAc:Hexane, Rf = 0.40). This gave the desired 
product as a clear oil (141 mg, 55% yield, 2 steps). 1H NMR (300 MHz, CDCl3) δ 5.05 (s, 1H), 
4.84 (s, 1H), 4.77 (d, J = 7.1 Hz, 1H), 4.62 (d, J = 7.1 Hz, 1H), 4.43 (dt, J = 13.7, 6.9 Hz, 1H), 
4.14 (s, 1H), 3.64 (t, J = 6.7 Hz, 2H), 3.41 (s, 1H), 3.38 (s, 3H), 2.10-2.21 (m, 3H), 1.90-1.94 (m, 
1H), 1.67-1.72 (m, 2H), 1.47 (s, 3H), 1.37 (s, 3H), 1.19-1.30 (m, 1H), 0.96 (t, J = 6.6 Hz, 9H), 
0.95 (t, J = 6.6 Hz, 9H), 0.90 (d, J = 7.2 Hz, 3H), 0.61 (q, J = 6.6 Hz, 6H), 0.56 (q, J = 6.6 Hz, 
6H); 13C NMR (75 MHz, CDCl3) δ 147.1, 111.5, 96.6, 92.8, 83.1, 81.8, 67.4, 63.0, 56.2, 46.9, 
45.6, 34.6, 31.9, 30.6, 28.9, 28.7, 24.5, 24.0, 19.1, 16.6, 15.1, 13.5, 11.6, 10.6, 9.6, 6.4, 5.3, 5.0, 
4.8; IR (thin film) 1685, 1091,  cm-1; HRMS (EI): m/z calc for C17H28O3 (M)+ 542.3822, found 
542.3826; [α]D23  –18.4o (MeOH, c 1.0).  
 
5(R)-(4-Hydroxy-1-methylene-butyl)-8(R)-methoxymethoxy-4(R,S),7,7-
trimethyl-6(R)-oxa-bicyclo[3.2.1]octan-3(R)-ol (79) O
O
O
OH
OH
To a solution of (78) (137 mg, 0.25 mmol) in THF (4 mL) was added TBAF hydrate (165 mg, 
0.63 mmol). After 1 hr, the reaction was concentrated and purified by column chromatography 
(5:20:75 / MeOH:CH2Cl2:EtOAc, Rf =0.5). This gave the desired products as a clear oil (72.9 
mg, 92% yield). 1H NMR (300 MHz, CDCl3) δ major diastereomer: 5.15 (s, 1H), 4.83 (s, 1H), 
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 4.74 (d, J = 6.9 Hz, 1H), 4.64 (d, J = 6.9 Hz, 1H), 4.51 (dt, J = 11.4, 6.9 Hz, 1H), 4.15 (s, 1H), 
3.61-3.65 (m, 3H), 3.41 (s, 3H), 2.10-2.27 (m, 3H), 1.62-1.76 (m, 4H), 1.49 (s, 3H), 1.41 (s, 3H), 
0.94 (d, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ major diastereomer: 145.7, 113.4, 96.4, 
93.2, 82.6, 71.2, 66.9, 61.6, 56.4, 46.8, 43.9, 32.3, 29.9, 27.9, 24.5, 17.5, 11.2; IR (thin film) 
3396, 1629 cm-1; HRMS (EI): m/z calc for C17H30O5 (M)+ 314.2093, found 314.2079; [α]D23  –7.1 
o (MeOH, c 1.0).  
 
4-(8(R)-Methoxymethoxy-4(S),7,7-trimethyl-3-oxo-6(R)-oxa-bicyclo[3.2.1]oct-
5(R)-yl)-pent-4-enal (80) 
To a solution of (79) (49 mg, 0.16 mmol) in CH2Cl2 (5.5 mL) was added NaHCO3 (50 mg) and 
then DMPI (159 mg, 0.38 mmol). After 2 hrs, the reaction was quenched by adding Na2S2O3 
(aq.sat) and NaHCO3 (aq.sat). The mixture was stirred for 15 min, then extracted with CH2Cl2, dried 
over MgSO4, filtered, concentrated, and purified by column chromatography (50:50 / 
EtOAc:Hexane, Rf = 0.35). This gave the desired product as a clear oil (38.4 mg, 80% yield). 1H 
NMR (300 MHz, CD2Cl2) δ 9.74 (t, J = 1.6 Hz, 1H), 5.06 (s, 1H), 4.79 (s, 1H), 4.76 (d, J = 6.9 
Hz, 1H), 4.69 (d, J = 6.9 Hz, 1H), 4.43 (s, 1H), 3.40 (s, 3H), 2.61-2.65 (m, 4H), 2.50-2.58 (m, 
2H), 2.36-2.47 (m, 2H), 1.41 (s, 3H), 1.19 (s, 3H), 1.02 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, 
CD2Cl2) δ 212.7, 202.4, 144.1, 113.5, 96.9, 91.3, 82.9, 82.8, 56.9, 56.7, 46.8, 43.2, 43.1, 29.6, 
26.9, 25.6, 16.3; IR (thin film) 1721, 1644, 1460 cm-1; HRMS (EI): m/z calc for C17H26O5 (M)+ 
310.1780, found 310.1794; [α]D23  –11.4 o (MeOH, c 1.0).  
 
5(S)-Hydroxy-12(R)-methoxymethoxy-6(S),10,10-trimethyl-2-methylene-11(S)-o
tricyclo[7.2.1.01,6]dodecan-7-one (81) 
O
O
O
O
O
O
OH
O
O
O
xa-
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 To a solution of (80) (4.4 mg, 14 µmol) in CH2Cl2 (0.5 mL) was added DBU (3 mg, 18 µmol) 
and the reaction stirred for 5 hrs at 25 oC under N2. The reaction was then concentrated to ~0.1 
mL and purified by column chromatography (50:50 / EtOAc:Hexane, Rf = 0.52). This gave the 
desired product as a waxy solid (3.1 mg, 71% yield). 1H NMR (300 MHz, CD2Cl2) δ 5.24 (s, 
1H), 5.09 (dd, J = 2.8, 1.1 Hz, 1H), 4.95 (unresolved dd, J = 1.9 Hz, 1H), 4.73 (d, J = 6.9 Hz, 
1H), 4.63 (d, J = 6.9 Hz, 1H), 3.99 (d, J = 2.9 Hz, 1H), 3.36 (s, 3H), 2.68 (dd, J = 18.5, 3.0 Hz, 
1H), 2.50 (dd, J = 18.5, 3.9 Hz, 1H), 2.39 (t, J = 3.2 Hz, 2H), 2.17-2.21 (m, 1H), 1.91 (d, J = 3.9 
Hz, 1H), 1.82 (tdd, J = 14.1, 4.6, 1.6 Hz, 1H), 1.65 (dquint, J = 14.1, 2.5 Hz, 1H), 1.43 (s, 3H), 
1.15 (s, 3H), 0.98 (s, 3H); 13C NMR (75 MHz, CD2Cl2) δ 215.7, 144.6, 110.6, 96.3, 89.7, 83.7, 
82.4, 76.4, 60.9, 56.2, 46.5, 46.1, 31.4, 29.9, 28.9, 26.9, 18.6; IR (thin film) 3421, 1701, 1649 
cm-1; HRMS (EI): m/z calc for C17H26O5 (M)+ 310.1780, found 310.1769; [α]D23 +42.2 o (MeOH, 
c 1.0).  
 
5(R)-Hydroxy-12(R)-methoxymethoxy-6(S),10,10-trimethyl-2-methylene-11(S)-o
tricyclo[7.2.1.01,6]dodecan-7-one (82) 
xa-
O
OH
O
O
O
To a solution of (80) (38.4 mg, 0.12 mmol) in CH2Cl2 (3.5 mL) was added DBU (24.5 mg, 0.16 
mmol) and the reaction stirred for 6 hrs. Then an additional amount of DBU (24.5 mg, 0.16 
mmol) was added and the reaction stirred for a total of 24 hrs at 25 oC under N2. The reaction 
was then concentrated to ~0.2 mL and purified by column chromatography (50:50 / 
EtOAc:Hexane, Rf = 0.5 and 0.25) This gave (82) as a waxy solid (25.8 mg, 67% yield) and (81) 
as a minor product (8.8 mg, 23% yield). 1H NMR (300 MHz, CD2Cl2) δ 5.15 (dd, J = 2.6, 1.3 
Hz, 1H), 4.96 (t, J = 2.1 Hz, 1H), 4.75 (d, J = 7.0 Hz, 1H), 4.61 (d, J = 7.0 Hz, 1H), 4.42 (s, 1H), 
3.85 (ddd, J = 12.4, 4.9, 1.1 Hz, 1H), 3.36 (s, 3H), 2.67 (td, J = 19.2, 2.9 Hz, 2H), 2.62 (dd, J = 
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 19.0, 3.9 Hz, 1H), 2.46 (t, J = 3.2 Hz, 1H), 2.32 (ddd, J = 13.9, 4.7 Hz, 1H), 1.99-2.05 (m, 1H), 
1.83-1.85 (m, 1H), 1.43-1.45 (m, 1H), 1.44 (s, 3H), 1.19 (s, 3H), 1.00 (s, 3H); 13C NMR (75 
MHz, CD2Cl2) δ 216.9, 142.9, 111.6, 96.2, 89.6, 83.4, 82.7, 71.1, 61.8, 56.5, 46.2, 44.1, 29.8, 
29.4, 29.2, 26.8, 11.4; IR (thin film) 3457, 1696, 1649 cm-1; HRMS (EI): m/z calc for C17H26O5 
(M)+ 310.1780, found 310.1780; [α]D23  +8.6 o (MeOH, c 1.0). 
 
 5-(2,2-Dimethyl-1,1-diphenyl-propoxy)-3-hydroxypentanoic acid 
methoxymethylamide (84) 
O HO O
N
O
To a stirring solution of N-Methoxy-N-methyl-acetamide (83) (5.18 g, 50.24 mmol) in THF (50 
mL) at -78 oC, under N2, was added LDA (1.0 M THF, 50.24 mL, 50.24 mmol). After stirring for 
100 min., 3-(tert-butyldiphenylsilyl)-hydroxy propionaldehyde (7.89 g, 41.87 mmol) in THF (15 
mL) was added at -78 oC to the orange enolate solution. After stirring for 2.5 hrs. at -78 oC, the 
reaction was warmed to 30 oC for 30 min., then quenched by adding 1% HCl (aq.) (55 mL). The 
organic layer was separated and the aqueous layer extracted with ethyl acetate (5x60 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated 
by rotovapor to give clear oil. The product was purified by passing through a plug of silica gel 
using EtOAc to elute (17.13 g, 41.22 mmole, 98 % yield). 1H NMR (300 MHz, CDCl3) δ 7.67-
7.70 (m, 4H), 7.39-7.42 (m, 6H), 4.33-4.35 (m, 1H), 3.87-3.91 (m, 1H), 3.88 (dd, J = 9.1, 15.4 
Hz, 2H), 3.68 (s, 3H), 3.21 (s, 3H), 2.61-2.67 (m, 2H), 1.79-1.84 (m, 2H), 1.07 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 173.5, 135.5, 133.5, 133.4, 129.6, 127.7, 66.4, 61.5, 61.2, 38.7, 31.9, 26.8, 
19.1; IR (thin film) 3467, 3062, 3042, 1639, 1107 cm-1; HRMS (EI): m/z calc for C19H24SiNO4 
(M-C4H9)+ 358.1474, found 358.1465. 
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  2-(2-Hex-1-en-[1,3]dioxan-4)-N-methoxy-N-methyl-acetamide (85) HO HO O
N
O
The TBDPS ether (84) (17.13g, 41.22 mmol) was the dissolved in THF (70 mL) and TBAF 
hydrate (11.52 g, 41.22 mmol) was added. The mixture was stirred at 25 oC for 60 min., then 
concentrated by rotovapor to a volume ~15 mL. The crude brown oil was loaded onto a plug of 
silica gel and washed with 10% ethyl acetate in hexane, then eluted with 15% methanol in ethyl 
acetate. This gave the semi-purified diol as clear oil with trace solids (5.59g, 31.54 mmol, 77%). 
1H NMR (300 MHz, CDCl3) δ 4.32 (ddt, J = 8.9, 3.6 Hz, 1H), 3.87 (t, J = 5.8 Hz, 2H), 3.71 (s, 
3H), 3.21 (s, 3H), 2.51-2.71 (m, 2H), 1.68-1.82 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 172.9, 
66.5, 60.9, 59.7, 38.3, 38.0, 31.4; IR (thin film) 3411, 1644 cm-1; Could not obtain a satisfactory 
HRMS on this diol. Both EI and CI (CH4) were experiments tried. 
 
N-Methoxy-2-[2-(4-methoxyphenyl)-[1,3]dioxan-4-yl]-N-methylacetamide (86) 
To a solution of (85) (1.0 g, 5.64 mmol) in benzene (54 mL) was added 4-
anisaldehyde diethylacetal (1.16 g, 5.50 mmol) and PPTS (100 mg, cat. H+). A short 
path distillation head was attached and the mixture heated to 110 oC for 70 min to remove 
ethanol. After cooling to 25 oC, the brown residue was purified by flash column chromatography 
(70% ethyl acetate: hexane) to give the product as a pale yellow oil (1.15 g, 3.91 mmol, 71%). 
1H NMR (300 MHz, CD2Cl2) δ 7.38 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 5.49 (s, 1H), 
4.34-4.37 (m, 1H), 4.20 (dd, J = 11.4, 4.9 Hz, 1H), 3.96 (td, J = 11.9, 2.8 Hz, 1H), 3.77 (s, 3H), 
3.67 (s, 3H), 3.15 (s, 3H), 2.90 (dd, J = 15.7, 6.9 Hz, 1H), 2.52 (dd, J = 15.8, 5.8 Hz, 1H), 1.80 
(ddd, J = 25.0, 12.9, 5.0 Hz, 1H), 1.63-1.68 (m, 1H); 13C NMR (75 MHz, CD2Cl2) δ 171.4, 
160.2, 131.8, 127.7, 113.7, 101.4, 74.1, 67.1, 61.6, 55.5, 38.6, 32.1, 31.6; IR (thin film) 3052, 
O O O
N
O
O
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 1726, 1654, 1245, 1102 cm-1; HRMS (EI): m/z calc for C15H21NO5 (M)+ 295.1419, found 
295.1415. 
 
1-[2-(4-Methoxyphenyl)-[1,3]dioxan-4-yl]-propan-2-one (88) 
To a solution of (86) (1.00 g, 3.39 mmol) in THF (60 mL) at -78 oC under N2 was added 
MeLi (1.4M Ether, 6.10 mL, 8.48 mmol). After stirring for 1 hr. aqueous saturated NH4Cl (20 
mL) was added followed by hexane (24 mL) and CH2Cl2 (12 mL) and the reaction was warmed 
to 25 oC. The organic layer was separated and the aqueous layer extracted with methylene 
chloride (3x10 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated by rotovapor. The crude yellow oil was then purified by flash column 
chromatography (70% diethyl ether: pentane) to give the desired product as colorless oil (823 
mg, 97%). 1H NMR (300 MHz, CD2Cl2) δ 7.36 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 
5.47 (s, 1H), 4.28-4.31 (m, 1H), 4.20 (ddd, J = 11.5, 4.9, 1.3 Hz, 1H), 3.95 (td, J = 12.0, 2.7 Hz, 
1H), 3.78 (s, 3H), 2.80 (dd, J = 16.3, 7.4 Hz, 1H), 2.55 (dd, J = 16.3, 5.2 Hz, 1H), 2.16 (s, 3H), 
1.45 (ddd, J = 23.5, 12.2, 5.0 Hz, 1H), 1.54-1.59 (m, 1H); 13C NMR (75 MHz, CD2Cl2) δ 206.3, 
160.4, 131.9, 127.8, 113.9, 101.5, 73.7, 67.2, 55.7, 50.0, 31.6, 31.1; IR (thin film) 3062, 1706, 
1614, 1522, 1096 cm-1; HRMS (EI): m/z calc for C14H18O4 (M-H)+ 249.1127, found 249.1138.  
O O O
O
 
tert-Butyl-{1-[2-(4-methoxyphenyl)-[1,3]dioxan-4-ylmethyl]-vinyloxy-
dimethylsilane (90) 
O O O
Si
O
The ketone (88) (500 mg, 1.99 mmol) and Et3N (2.01 g, 19.90 mmol) were dissolved in CH2Cl2 
(15 mL), then cooled to –78 oC under N2. TBSOTf (528 mg, 2.00 mmol) was added and after 10 
min the reaction was slowly warmed to 25 oC. After 2.5 hrs, the mixture was poured into 
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 NaHCO3 (aq. sat.) (10 mL). The organic layer was separated and the aqueous layer extracted with 
CH2Cl2. The combined organic layers were dried over MgSO4, filtered, concentrated, and 
purified by column chromatography (4:94:2 / Ether:Hexane:Et3N, Rf =0.33) This gave the 
desired kinetic silyl enolether (90) as a pale yellow oil (406 mg, 56% yield) The thermodynamic 
enol ether (90b) was isolated in 19% yield. 1H NMR (300 MHz, CD2Cl2) δ 7.36 (d, J = 6.9 Hz, 
2H), 6.86 (d, J = 6.7 Hz, 2H), 5.43 (s, 1H), 4.19 (ddd, J = 11.4, 4.9, 1.2 Hz, 1H), 4.14 (s, 1H), 
4.12 (d, J = 0.6 Hz, 1H), 4.05-4.09 (m, 1H), 3.90 (td, J = 11.9, 2.7 Hz, 1H), 3.78 (s, 3H), 2.46 
(dd, J = 13.9, 6.8 Hz, 1H), 2.19 (dd, J = 13.9, 6.8 Hz, 1H), 1.68-1.74 (m, 1H), 1.55-1.60 (m, 1H), 
0.95 (s, 9H), 0.18 (s, 6H); 13C NMR (75 MHz, CD2Cl2) δ 160.3, 155.9, 132.1, 127.8, 113.7, 
101.5, 92.3, 75.0, 67.4, 55.6, 43.9, 31.5, 25.9, 18.4, -4.5, -4.6; IR (thin film) 1618, 1516, 1250, 
1107, 1020 cm-1; HRMS (EI): m/z calc for C20H32SiO4 (M)+ 364.2070, found 364.2077. 
 
2-(2-Hydroxyethyl)-6-(4-methoxyphenyl)-tetrahydropyran-4-one (92) 
To a flask containing dry Ce(NO3)3 (1.07 g, 3.29 mmol) was added CH3CN (8 mL). 
This slurry was stirred at 25 oC under N2 for 10 min, then a solution of (90) (300 mg, 
0.82 mmol) in CH3CN (4 mL) was added and the solids slowly began to dissolve. After 80 min, 
TBAF hydrate (230 mg, 0.82 mmol) was added and the mixture stirred for 60 min. The mixture 
was then poured into NaHCO3 (aq. sat.) (20 mL) and slowly neutralized by adding 1 M HCl. The 
biphasic mixture was concentrated by rotovapor to remove most of the CH3CN and the 
remaining solution was extracted with EtOAc. The organic layers were dried over MgSO4, 
filtered, concentrated, and purified by column chromatography (100 % Ether). This gave the 
desired product as a clear oil (166 mg, 81%).  1H NMR (300 MHz, CD2Cl2) δ 7.28 (d, J = 8.8 
Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 4.61 (dd, J = 9.9, 4.5 Hz, 1H), 3.93-3.99 (m, 1H), 3.78 (s, 3H), 
O
O
HO
O
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 3.75-3.76 (m, 2H), 2.56 (d, J = 7.2 Hz, 1H), 2.54 (s, 1H), 2.43 (d, J = 5.0 Hz, 1H), 2.41 (s, 1H), 
2.20 (t, J = 4.9 Hz, 1H), 1.67-1.94 (m, 2H); 13C NMR (75 MHz, CD2Cl2) δ 206.4, 159.9, 133.4, 
127.5, 114.3, 79.0, 76.7, 60.4, 55.7, 49.7, 47.9, 39.1; IR (thin film) 3442, 1716, 1511, 1250 cm-1; 
HRMS (EI): m/z calc for C20H32SiO4 (M)+ 250.1205, found 250.1216.  
 
 2-(2-Hex-1-en-[1,3]dioxan-4)-N-methoxy-N-methyl-acetamide (87) 
To a solution of (85) (3.0 g, 17.23 mmol) in benzene (160 mL) was added (E)-2-
heptenal diethylacetal (3.06 g, 16.71 mmol) and PPTS (300 mg, cat. H+). A short path 
distillation head was attached and the mixture heated to 110 oC for 70 min to remove ethanol. 
After cooling to 25 oC, the brown residue was purified by flash column chromatography (75% 
ethyl acetate: hexane) to give the product as a pale yellow oil (3.46 g, 12.75 mmol, 74%). 1H 
NMR (300 MHz, CDCl3) δ 5.83 (dt, J = 15.6, 6.7 Hz, 1H), 5.40 (dd, J =15.6, 5.1 Hz, 1H), 4.92 
(d, J = 3.4 Hz, 1H), 4.09-4.19 (m, 1H), 4.07 (dd, J = 11.3, 4.7 Hz, 1H), 3.79 (td, J = 11.3, 3.0 Hz, 
1H), 3.61 (s, 3H), 3.12 (s, 3H), 2.84 (dd, J = 15.7, 6.2 Hz, 1H), 2.45 (dd, J = 15.7, 6.3 Hz, 1H), 
1.98 (dd, J = 13.2, 7.6 Hz, 2H), 1.58-1.65 (m, 2H), 1.21-1.32 (m, 4H), 0.82 (t, J = 6.8 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 171.0, 135.6, 126.6, 100.7, 73.1, 66.2, 61.1, 38.0, 31.7, 31.5, 31.0, 
30.5, 21.9, 13.7; IR (thin film) 1665, 1475, 1419, 1383, 1116 cm-1; HRMS (EI): m/z calc for 
C14H25NO4 (M)+ 271.1783, found 271.1773.                         
O O O
N
O
     
 1-(2-Hex-1-en-[1,3]dioxan-4)-propan-2-one (89) 
To a solution of (87) (1.05 g, 3.87 mmol) in THF (60 mL) at -78 oC under N2 was added 
MeLi (1.4M Ether, 6.91 mL, 9.68 mmol). After stirring for 1 hr. aqueous saturated NH4Cl (20 
mL) was added followed by hexane (24 mL) and CH2Cl2 (12 mL) and the reaction was warmed 
O O O
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 to 25 oC. The organic layer was separated and the aqueous layer extracted with methylene 
chloride (3x10 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated by rotovapor. The crude yellow oil was then purified by flash column 
chromatography (70% diethyl ether: pentane) to give the desired product as colorless oil (697 
mg, 89%). 1H NMR (300 MHz, CDCl3) δ 5.38 (dt, J = 14.3, 6.7 Hz, 1H), 5.41 (dd, J = 15.7, 3.5 
Hz, 1H), 4.90 (d, J = 4.9 Hz, 1H), 4.04-4.12 (m, 2H), 3.78 (t, J = 11.9 Hz, 1H), 2.76 (d, J = 16.4, 
6.8 Hz, 1H), 2.46 (dd, J = 16.4, 5.6 Hz, 1H), 2.13 (s, 3H), 2.00 (dd, J = 13.4, 6.5 Hz, 2H), 1.61 
(qd, J = 12.2, 4.9 Hz, 2H), 1.48 (d, J = 13.1 Hz, 1H), 1.22-1.34 (m, 4H), 0.82 (t, J = 6.6 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 205.9, 135.6, 126.7, 100.7, 72.6, 66.2, 49.4, 31.5, 31.0, 30.8, 30.6, 
22.0, 13.6; IR (thin film) 1716, 1419, 1363, 1132 cm-1; HRMS (EI): m/z calc for C13H22O3 (M)+ 
225.1490, found 225.1493.  
 
 tert-Butyl-[1-(2-hex-1-en-[1,3]dioxan-4-methyl)-vinyloxy]-dimethylsilane (91) 
 To a solution of (89) (300 mg, 1.33 mmol) in CH2Cl2 (10 mL) was added Et3N (1.34 
g, 13.26 mmol) under N2. The reaction flask was cooled to -78 oC and tert-butyldimethylsilyl 
triflate (357 mg, 1.35 mmol) was added. The reaction was stirred for 10 min. at -78 oC, then 
warmed to 25 oC and stirred for 1 hour, monitoring by TLC. The reaction was quenched by 
adding aqueous saturated sodium bicarbonate (8 mL) and the CH2Cl2 layer was separated. The 
aqueous layer was extracted with ethyl acetate (3x15 mL). The combined organic layers were 
washed with brine, dried over MgSO4, filtered, and concentrated by rotovapor. The crude brown 
oil was purified by column flash chromatography (5:93:2 diethyl ether: hexane: triethylamine) to 
give the desired product (91) as colorless oil (227 mg, 50%). The undesired thermodynamic enol 
(91b) ether was the major byproduct (20%). 1H NMR (300 MHz, CD2Cl2) δ 5.85 (dt, J = 15.6, 
O O O
Si
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 6.8 Hz, 1H), 5.45 (ddt, J = 15.6, 5.1, 1.5 Hz, 1H), 4.88 (d, J = 5.1 Hz, 1H), 4.09 (d, J = 2.4 Hz, 
2H), 4.06 (dd, J = 5.0, 1.4 Hz, 2H), 3.83-3.88 (m, 1H), 3.74 (td, J = 11.7, 2.9 Hz, 1H), 2.36 (dd, J 
= 13.9, 6.7 Hz, 1H), 2.12 (dd, J = 13.9, 6.7 Hz, 1H), 2.04 (dd, J = 13.1, 6.7 Hz, 2H), 1.55-1.56 
(m, 1H), 1.50 (qd, J = 11.8, 1.5 Hz, 2H), 1.32-1.36 (m, 4H), 0.94 (s, 9H), 0.87-0.91 (m, 3H), 
0.17 (s, 6H); 13C NMR (75 MHz, CD2Cl2) δ 156.1, 135.5, 128.0, 101.5, 92.3, 74.8, 67.0, 44.0, 
32.2, 31.7, 31.5, 26.1, 22.8, 18.5, 14.1, -4.4, -4.5; IR (thin film) 1654, 1634, 1132, 1009, 963 cm-
1; HRMS (EI): m/z calc for C19H36SiO3 (M)+ 339.2355, found 339.2359.  
 
2-Hex-1-en-6-(2-hydroxy-ethyl)-tetrahydro-pyran-4-one (93) 
To a flask containing dry Ce(NO3)3 (1.73g, 5.30 mmol) was added CH3CN (8 mL). 
This slurry was stirred at 25 oC under N2 for 10 min, then a solution of (91) (300 mg, 
1.33 mmol) in CH3CN (4 mL) was added and the solids slowly began to dissolve. After 80 min, 
TBAF hydrate (307 mg, 1.18 mmol) was added and the mixture stirred for 60 min. The mixture 
was then poured into NaHCO3 (aq. sat.) (20 mL) and slowly neutralized by adding 1 M HCl. The 
biphasic mixture was concentrated by rotovapor to remove most of the CH3CN and the 
remaining solution was extracted with EtOAc. The organic layers were dried over MgSO4, 
filtered, concentrated, and purified by column chromatography (100 % Ether). This gave the 
desired product as a clear oil (248 mg, 93%). 1H NMR (300 MHz, CD2Cl2) δ 5.71 (dtd, J = 15.4, 
6.7, 0.9 Hz, 1H), 5.49 (ddt, J = 14.1, 6.2, 1.3 Hz, 1H), 4.07 (dd, J = 13.8, 6.7 Hz, 1H), 3.82-3.86 
(m, 2H), 3.72-3.76 (m, 1H), 2.32 (t, J = 7.3 Hz, 5H), 2.03 (dd, J = 13.2, 6.5 Hz, 2H), 1.76-1.87 
(m, 2H), 1.30-1.39 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CD2Cl2) δ 206.4, 
133.9, 129.5, 78.1, 76.6, 60.6, 48.2, 48.0, 38.9, 32.3, 31.5, 22.6, 14.1; IR (thin film) 3437, 1721, 
1065 cm-1; HRMS (EI): m/z calc for C13H22O3 (M)+ 226.1568, found 226.1565.  
O
O
HO
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(S)-1-Triisopropylsilylyhex-5-en-3-ol (95) 
O OH
TIPS
(-)Ipc2B-allyl was prepared according to the procedure of Brown, H.C. JACS  1983, 105, 2092. 
A flask containing the (-)Ipc2B-allyl reagent (9.79g, 30.0 mmol) in ether (75 mL) was cooled to  
-78 oC under N2. Then a solution of 3-(triisopropylsilyl)-hydroxy propanal (94) (6.21g, 26.9 
mmol) in ether (20 mL) was added dropwise and stirred for 1 hr. The mixture was then warmed 
to 25 oC over 1 hr, and stirred for 95 min before carefully quenching with 3 N NaOH (22 mL). 
Then H2O2 (30% aq, 10.2 mL, 90 mmol) was slowly added. After bubbling subsided the reaction 
refluxed for 45 min, then cooled to 25 oC and diluted with H2O (50 mL). The mixture was 
extracted with EtOAc, the organic layer washed with H2O, then with brine. The organic layer 
was dried over MgSO4, filtered, concentrated, and product purified by column chromatography 
(15:85 / EtOAc:Hexane, Rf = 0.40). This gave the desired product (95) as a clear oil (6.59 g, 90% 
yield). 1H NMR (300 MHz, CDCl3) δ 5.87 (ddt, J = 10.0, 9.9, 2.9 Hz, 1H), 5.10 (d, J = 10.8 Hz, 
1H), 5.04 (d, J = 1.6 Hz, 1H), 3.95 (qt, J = 10.0, 5.3 Hz, 2H), 3.89 (t, J = 6.3 Hz, 1H), 3.50 ( br s, 
1H), 2.24 (dt, J = 14.1, 7.9 Hz, 2H), 1.68 (dd, J = 5.6, 5.0 Hz, 2H), 1.05 (d, J = 4.7 Hz, 21H); 13C 
NMR (75 MHz, CDCl3) δ 135, 117, 71, 63, 42, 38, 18, 12; IR (thin film) 3457, 1101, 1000 cm-1; 
HRMS (EI): m/z calc for C12H28SiO2 (M-C3H4)+ 231.1780, found 231.1784; [α]D23 +7.7º (CHCl3, 
c 1.0). 
 
(S)-Benzoic acid 1-(2-triisopropylsilyly-ethyl)-but-3-enyl ester (96) O OBzTIPS
The secondary alcohol (95) (500 mg, 1.83 mmol) was dissolved in CH2Cl2 (15 mL) at 25 oC 
under N2. Next Et3N (371 mg, 3.67 mmol) was added followed by DMAP (10 mg) and BzCl 
(245 mg, 1.74 mmol). The mixture was heated to reflux and after stirring for 24 hrs cooled to 25 
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 oC. The mixture was poured into NaHCO3 (aq. sat.) (20 mL) and extracted with CH2Cl2. The 
combined organic layers were dried over MgSO4, filtered, concentrated, and purified by column 
chromatography (10:90 Ether:Hexane, R f= 0.25). This gave the desired product (96) as a clear 
oil (644 mg, 98% yield). 1H NMR (300 MHz, CDCl3) δ 8.05 (dd, J = 5.0 Hz, 2H), 7.53-7.58 (m, 
1H), 7.41-7.46 (m, 1H), 5.82-5.87 (m, 1H), 5.34 (dt, J = 12.7, 6.0 Hz, 1H), 5.13 (d, J = 15.4 Hz, 
1H), 5.07 (d, J = 0.9 Hz, 1H), 3.82 (t, J = 6.7 Hz, 2H), 2.50-2.56 (m, 2H), 2.00 (ddd, J = 7.6, 5.7, 
2.3 Hz, 2H), 1.05 (s, 21H); 13C NMR (75 MHz, CDCl3) δ 166, 134, 133, 131, 130.7, 129.5, 128, 
118, 72, 60, 39, 37, 10, 12; IR (thin film) 3078, 3032, 1721, 1270, 1107 cm-1; HRMS (EI): m/z 
calc for C19H29SiO3 (M-C3H7)+ 333.1885, found 333.1891; [α]D23 +19.1º (CHCl3, c 1.0). 
 
(S)-Benzoic acid 1-(2-hydroxyethyl)-but-3-enyl ester (97) OH OBz
The TIPS ether (96) (177 mg, 0.47 mmol) was dissolved in CH2Cl2 (3 mL). Then TBAF hydrate 
(160 mg, 0.61 mmol) was added and after stirring at 25 oC for 10 hrs the mixture was 
concentrated. The resulting oil was purified by column chromatography (25:75 / EtOAc:Hexane, 
Rf = 0.30). This gave the desired product (97) as a clear oil (72 mg, 70% yield). Chiral HPLC 
(Chiracel ODH, flow rate 0.4 mL/min, 10:90 iPrOH:Hexane) shows (97) to have an % ee of 
78%. This is consistent with Browns’ results using the (Ipc)2B-allyl reagent with sterically 
undemanding aldehydes. 1H NMR (300 MHz, CDCl3) δ 8.02-8.05 (m, 2H), 7.53-7.55 (m, 1H), 
7.41-7.46 (m, 2H), 5.79-5.86 (m, 1H), 5.16 (ddd, J = 14.2, 2.15, 1.02 Hz, 1H), 5.12 (t, J = 1.0 
Hz, 1H), 4.53-4.58 (m, 1H), 4.43-4.43 (m, 1H), 3.85 (ddt, J = 7.4, 3.7, 2.6 Hz, 1H), 2.36 (s, 1H), 
2.31-2.13 (m, 2H), 2.00-2.04 (m, 1H), 1.88-1.92 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 167, 
134, 133, 130.1, 129.5, 128, 118, 68, 62, 42, 36; IR (thin film) 3452, 1721, 1271 cm-1; HRMS 
(EI): m/z calc for C13H17O3 (M+H)+ 221.1177, found 221.1184; [α]D23 +15.9º (CHCl3, c 1.0). 
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 (S)-Hex-5-ene-1,3-diol (98) OH OH
 The TIPS ether (95) (3.0 g, 11.01 mmol) was dissolved in THF (100 mL) and TBAF hydrate 
(3.17 g, 12.11 mmol) was added in one portion at 25 oC. After 90 min, the mixture was 
concentrated and purified by column chromatography (100 % EtOAc, Rf = 0.33) This gave the 
known diol (98) (Hosokawa, T. Chem. Lett. 1989, 2001) as a clear oil (1.18 g, 92% yield) 1H 
NMR (300 MHz, CDCl3) δ 5.81 (qt, J = 10.0, 7.6, 6.7 Hz, 1H), 5.18 (d, J = 2.0 Hz, 1H), 5.15 (d, 
J = 14.0 Hz, 1H), 3.84-3.93 (m, 3H), 2.25-2.32 (m, 4H), 1.72 (dt, J = 4.8, 2.6 Hz, 2H); 13C NMR 
(75 MHz, CDCl3) δ 134, 118, 70, 61, 42, 38; IR (thin film) 3365, 1055 cm-1; [α]D23 +11.6º 
(CHCl3, c 1.0).  
 
 (S)-4-Allyl-2-(3,3-dimethylbut-1-enyl)-[1,3]dioxane (101) 
 The diol (98) (1.08 g, 9.32 mmol) was dissolved in benzene (55 mL) and 4,4-Dimethyl-
pent-2-enal (100) (983 mg, 8.76 mmol) was added followed by PPTS (128 mg). A reflux 
condenser and dean stark trap filled with molecular sieves was attached and the reaction heated 
to 110 oC under N2 for 2.5 hrs. The reaction was then cooled to 25 oC and Et3N  (0.2 mL) was 
added. The reaction was concentrated and purified by column chromatography (5:30:65 / 
EtOAc:CH2Cl2:Hexane, Rf = 0.40). This gave the desired product (101) as a clear oil (1.38 g, 
91% yield). 1H NMR (300 MHz, CDCl3) δ 5.86 (dd, J = 16.0, 0.8 Hz, 1H), 5.80 (qt, J = 13.0, 
7.3, 2.8 Hz, 1H), 5.40 (dd, J = 16.0, 5.1 Hz, 1H), 5.10 (d, J = 13.5 Hz, 1H), 5.05 (d, J = 5.0 Hz, 
1H), 4.91 (d, J = 5.1 Hz, 1H), 4.12 (dd, J = 11.4, 4.9 Hz, 1H), 3.80 (dd, J = 12.2, 2.6 Hz, 1H), 
3.62-3.68 (m, 1H), 2.30 (dquint, J = 17.8, 11.3 Hz, 2H), 1.66 (qd, J = 12.8, 7.8 Hz, 1H), 1.43 (d, 
J = 13.3 Hz, 1H), 0.99 (s, 9H,); 13C NMR (75 MHz, CDCl3) δ 146, 134, 122, 117, 101, 75, 66, 
O O
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 40, 33, 31, 29; IR (thin film) 1111, 1101, 1000 cm-1; HRMS (EI): m/z calc for C13H22O2 (M)+ 
209.1541, found 209.1547; [α]D23 +3.9º (CHCl3, c 1.0). 
 
(S)-1-[2-(3,3-Dimethylbut-1-enyl)-[1,3]dioxan-4-yl]-propan-2-one (102) 
The terminal olefin (101) (1.0 g, 4.80 mmol) was dissolved in THF (25 mL), and H2O 
(4 mL). Li2CO3 (3.55 g, 48.0 mmol) was added followed by CuCl2 (320 mg, 2.40 mmol) and 
PdCl2 (143mg, 0.80 mmol). The reaction mixture was stirred vigorously under 1 atm of O2 for 1 
hour, then another addition of PdCl2 (143 mg, 0.80 mmol) was made. After stirring for another 1 
hour under O2, a third and final addition of PdCl2 (143 mg, 0.80 mmol) was made. After 3 hrs 
total, the mixture was diluted with ether and filtered through a plug of celite. Additional ether 
was added and the mixture washed with brine, dried over MgSO4, filtered, concentrated, and 
purified by column chromatography (20:80 / EtOAc:Hexane, Rf = 0.25). This gave the desired 
product (102) as a clear oil (685 mg, 84% yield). 1H NMR (300 MHz, CDCl3) δ 5.90 (dd, J = 
16.0, 0.8 Hz, 1H), 5.39 (dd, J = 16.0, 5.0 Hz, 1H), 4.95 (d, J = 5.0 Hz, 1H), 4.13-4.17 (m, 1H), 
3.84 (td, J = 11.2, 2.7 Hz, 1H), 2.84 (q, J = 6.7 Hz, 1H), 2.57 (q, J = 6.7 Hz, 1H), 2.20 (s, 3H), 
1.70 (qd, J = 11.4, 4.2 Hz, 1H), 1.54 (dq, J = 13.2, 1.5 Hz, 1H), 1.02 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 206, 146, 122, 101, 72, 66, 60, 49, 30, 29, 28; IR (thin film) 1716, 1142, 1081 cm-1; 
HRMS (EI): m/z calc for C13H22O3 (M-H)+ 225.1490, found 225.1493; [α]D23 +4.1º (CHCl3, c 
1.0). 
O O O
 
(S)-tert-Butyl-{1-[2-(3,3-dimethylbut-1-enyl)-[1,3]dioxan-4-ylmethyl]-vinyloxy}-
dimethylsilane (103) O O OTBS
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  The methyl ketone (102) (575 mg, 2.54 mmol) and Et3N (2.57 g, 25.40 mmol) were dissolved in 
CH2Cl2 (18 mL), then cooled to -78 oC under N2. TBSOTf (698 mg, 2.64 mmol) was added and 
after 10 min the reaction was slowly warmed to 25 oC. After 2.5 hrs, the mixture was poured into 
NaHCO3 (aq. sat.) (10 mL). The organic layer was separated and the aqueous layer extracted with 
CH2Cl2. The combined organic layers were dried over MgSO4, filtered, concentrated, and 
purified by column chromatography (4:94:2 / Ether:Hexane:Et3N, Rf = 0.33) This gave the 
desired kinetic silyl enol ether (103) as a pale yellow oil (542 mg, 63% yield). 1H NMR (300 
MHz, CD2Cl2) δ 5.85 (dd, J = 16.0, 0.9 Hz, 1H), 5.35 (d, J = 5.1 Hz, 1H), 4.88 (dd, J = 5.1, 0.8 
Hz, 1H), 4.10 (s, 1H), 4.08 (d, J = 0.8 Hz, 1H), 4.06 (dd, J = 5.0, 1.4 Hz, 1H), 3.88-3.92 (m, 1H), 
3.74 (td, J = 11.8, 2.9 Hz, 1H), 2.38 (q, J = 6.7 Hz, 1H), 2.15 (q, J = 6.7 Hz, 1H), 1.60 (qd, J = 
13.3, 5.0 Hz, 1H), 1.49 (dq, J = 13.3, 2.7 Hz, 1H), 1.00 (s, 9H), 0.93 (s, 9H), 0.17 (s, 6H); 13C 
NMR (75 MHz, CD2Cl2) δ 156, 146, 123, 102, 92, 75, 67, 44, 33, 32, 30, 26, 18, -4.4, -4.6; IR 
(thin film) 1148, 1019 cm-1; HRMS (EI): m/z calc for C19H36SiO3 (M)+ 340.2433, found 
340.2431; [α]D23 +2.0º (CHCl3, c 1.0). 
 
 2-(3,3-Dimethylbut-1-enyl)- 6(S)-(2(R)-hydroxyethyl)-tetrahydropyran-4-one 
(104) O
OH
O
To a flask containing dry Ce(NO3)3 (1.50 g, 4.72 mmol) was added CH3CN (8 mL). This slurry 
was stirred at 25 oC under N2 for 10 min, then a solution of (103) (400 mg, 1.18 mmol) in 
CH3CN (4 mL) was added and the solids slowly began to dissolve. After 80 min, TBAF hydrate 
(307 mg, 1.18 mmol) was added and the mixture stirred for 60 min. The mixture was then poured 
into NaHCO3 (aq. sat.) (20 mL) and slowly neutralized by adding 1 M HCl. The biphasic mixture 
was concentrated by rotovapor to remove most of the CH3CN and the remaining solution was 
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 extracted with EtOAc. The organic layers were dried over MgSO4, filtered, concentrated, and 
purified by column chromatography (100 % Ether, Rf = 0.45). This gave the desired product 
(104) as a clear oil (182 mg, 69% yield). 1H NMR (300 MHz, CD2Cl2) δ 5.71 (dd, J = 15.8, 1.0 
Hz, 1H), 5.40 (dd, J = 15.8, 6.2 Hz, 1H), 4.08 (q, J = 6.8 Hz, 1H), 3.83-3.86 (m, 1H), 3.75 (t, J = 
5.4 Hz, 2H), 2.32 (t, J = 6.8 Hz, 4H), 1.73-1.87 (m, 3H), 1.00 (s, 9H); 13C NMR (75 MHz, 
CD2Cl2) δ 206, 144, 125, 78, 77, 61, 48.3, 48.0, 39, 33, 29; IR (thin film) 3432, 1726 cm-1; 
HRMS (EI): m/z calc for C13H22O3 (M)+ 226.1568, found 226.1573; [α]D23 +24.7º (CHCl3, c 1.0). 
 
 2-(R)-[2-(tert-butyldimethylsilyl)-ethyl]-6-(S)-(3,3-dimethyl-but-1-enyl)-
tetrahydropyran-4-one (105) O
OTBS
O
The primary alcohol (104) (50.0 mg, 0.22 mmol) was dissolved in CH2Cl2 (1 ml) at 25 oC under 
N2. Imidazole (30 mg, 0.44 mmol) was added followed by TBSCl (35 mg, 0.44 mmol). The 
reaction was stirred for 2 hrs, then quenched by adding H2O (1 mL). The organic layer was 
separated and the aqueous layer extracted with CH2Cl2. The combined organic layers were dried 
over MgSO4, filtered, concentrated, and purified by column chromatography (25:75 / 
Ether:Hexane, Rf = 0.45). This gave the desired product (105) as a clear oil (69mg, 92% yield). 
1H NMR (300 MHz, CD2Cl2) δ 5.74 (dd, J = 15.7 0.4 Hz, 1H), 5.40 (dd, J = 15.7, 6.2 Hz, 1H), 
4.02 (qd, J = 6.2, 1.0 Hz, 1H), 3.75-3.81 (m, 1H), 3.71 (ddt, J = 18.1, 5.0 Hz, 2H), 2.25-2.32 (m, 
4H), 1.69-1.79 (m, 2H), 1.00 (s, 9H), 0.88 (s, 9H), 0.03 (s, 6H); 13C NMR (75 MHz, CD2Cl2) δ 
207, 144, 125, 78, 74, 59, 49, 48, 40, 33, 30, 26, 19, -5.2, -5.3; IR (thin film) 1716, 1260, 1086 
cm-1; HRMS (EI): m/z calc for C18H33SiO3 (M-CH3)+ 325.2198, found 325.2203; [α]D23 +29.0º 
(CHCl3, c 1.0). 
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